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Abstract
Introduction
Cun-ently, traditional phannacological techniques are being increasingly complimented 
by applying parallel transgenic approaches employing the use of functional laiock-out, 
over-expressed and site-directed mutagenesis models of individual proteins in order to 
determine their functional role or distribution within cells and tissues.
Recent advances have provided individual functional knockout models of the three a i- 
AR subtypes (aiA-KO, am-KO and am-KO). All three have been implicated as having 
a role in the maintenance of blood pressure, as a result of studies of the phenotypes of 
the individual KO models. However, of the three ai-ARs, only the aio  and aie-AR 
have been reported to be involved in vasoconstriction of the mouse aorta. As such, the 
aiD-AR is reported to be the major adrenergic vasoconstrictor with a minor role for aiB- 
ARs.
The data presented in this thesis is the result of a detailed pharmacological study, aided 
by the use of transgenic mice of the ai-ARs involved in the functional responses of the 
mouse aorta.
Chapter 1. Contractile responses o f the mouse aorta: Effect o f age and aj- 
AR knockout
In Chapter 1 the functional alterations o f contractile (KCl: single challenge; adrenergic 
and serotonergic responses done by cumulative concentration response curves 
[CCRCs]) and relaxant responses (acetylcholine-induced; single challenge) as a result of 
increasing age were tested by studying adult male mice at two age points: 4-momth-old 
mice and 16-month-old mice.
As a whole, no significant alterations in function as a result of increased age were 
observed in the strains studied.
Since both aiB-KO and am-KO possibly had different genetic backgrounds it was 
essential to ensure that varied genetic background did not have a significant effect on 
functional responses. The control strains for each KO, a^ -W T  (wild-type) and am-WT 
were compared and no differences were observed at either age point. Therefore for 
further experiments either strain of WT mice were used as control mice.
The aiB-KO was not significantly different from its WT at either age point, but this was 
complicated by the apparent compensation by am-ARs. The aio-KO had 33-fold and 
44-fold reduced potency and 19% and 23% reduced maximum for phenylephrine (PE) 
induced contractile responses compared to its WT at 4m and 16m age point 
respectively.
5-Hydroxytryptamine (5-HT) and 125mM KCl contractile responses and acetylcholine 
(ACh) induced relaxations were unaltered by age.
Thus, this data confirmed that the am-AR was the adrenergic vasoconstrictor with little 
or no role for aiB-ARs and the phenotypic differences the am-KO exhibited were 
unaffected by age.
Chapter 2. Subtyping the aj-AR mediated contractile responses in mouse 
aorta.
The adrenergic responses of the WT and am-KO have previously been subtyped 
pharmacologically and the am-AR has been indicated as the adrenergic vasoconstrictor 
with the aiB"AR playing a minor role in the WT. The PE response of the am-KO was 
subtyped in this chapter.
The pKb values for prazosin (non-selective ai-A R antagonist) and 5-methylurapidil (5- 
MU; aiA-AR selective) were 9.3 and 7.7 respectively. The pKg for prazosin confirmed 
the response was ai-AR mediated whilst the relatively low pKfi for 5-MU indicated that 
the am-AR was responsible for contraction in the am-KO aorta rather than aiA-AR.
The use of the selective aiA-AR agonist confirmed this. The order of potency of both 
PE and A61603 in the mouse strains was am-KO > WT > am-KO. In fact, it was not 
possible to establish a pECso value for A61603 in the am-KO as A61603 has little or no
II
efficacy at am-ARs. However, this data also demonstrated the significant potency of 
A61603 at am-ARs contrary to previous reports.
To compliment the pharmacological study, the adrenergic response of the aortae of 
double-AR KO, the am-aio-KO was tested. PE and A-61603 failed to cause contractile 
responses, whilst serotonergic responses remained unaltered. Therefore, there were no 
contractile functional ai-ARs in the am-aio-KO aortae. This confirmed that either am- 
ARs or aiD-ARs are the adrenergic vasoconstrictors in the mouse aorta
An attempt was then made, using a receptor protection protocol, to isolate the minor 
aiB-AR response in WT mouse aorta. lOjaM chloroethylclonidine (CEC: non-selective 
ai-A R alkylating agent) completely ablated the adrenergic (PE) response and 
incubation with lOnM BMY 7378 (am-AR competitive antagonist) prior to lOpM CEC 
treatment could not protect any of the response.
However, IpM CEC reduced the maximal response by 50% but the entire response was 
protected by pre-incubation with lOnM BMY 7378 but not by lOnM 5-MU. These 
results indicated that there was little or no role for am-AR in the WT mouse aorta and 
confirmed the lack of aiA-AR role in functional responses. However in the am-KO the 
response was due to am-AR activation which could be due to am-AR up-regulation in 
the absence of functional am-ARs in the mouse aorta.
Chapter 3. Adrenergic and serotonergic synergy in the mouse aorta
The synergistic interaction between am-AR mediated contractions and 5-HT2a 
mediated contractions in the mouse aorta is shown in Chapter 3. 30nM PE and 5-HT 
synergistically amplified the serotonergic and adrenergic responses respectively in WT 
aortae. This was observed as sensitivity increases in the CCRC of PE and 5-HT curves.
However this was complicated by the finding that the 5-HT response is partially am - 
AR mediated. Both lOnM prazosin and lOnM BMY 7378 decreased the sensitivity to 5- 
HT in WT aortae but no decrease in sensitivity was observed in am-KO as a result of 
lOnM or lOOnM prazosin treatment. Thus, the serotonergic response in the WT aorta is 
partially ai-AR mediated and the two systems can synergistically interact.
Ill
However, the serotonergic responses of the WT and am-KO were not significantly 
different. Use of ritanserin (5-HT2a receptor insurmountable antagonist) and BRL 
54443 (5-HT2A agonist) confmned that 5-HTia receptors appeared to be compensating 
for the lack of functional am-ARs in the am-KO aortae.
Chapter 4. The effect o f L-NAME on contractile responses in the mouse 
aorta
lOOpM L-NAME (nitric oxide synthase blocker) treatment increased the maximal 
response to KCl in all three strains (WT, am-KO and am-KO). Serotonergic responses 
exhibited increased sensitivity but no increase in maxima as a result of L-NAME 
treatment.
The adrenergic responses of all tlrree strains exhibited an increased maximum after L- 
NAME treatment. L-NAME treatment resulted in an increased PE sensitivity in the WT 
and am-KO but not in the am-KO. This indicated that the am-AR is also involved in 
nitric oxide (NO) release, probably from endothelial cells, as well as being the major 
adrenergic vasoconstrictor.
The involvement of a 2-ARs in the PE response was also tested. Rauwolscine (a 2-AR 
antagonist) had no effect on the PE-induced response in WT aortae.
Conclusions
Thus, the am-AR is the sole adrenergic vasoconstrictor in the WT aorta. Knocking out 
the functional am-AR results in an am-AR-mediated response that is probably the 
result of compensatory mechanisms leading to an upregulation of the am-AR.
The am-AR can synergistically interact with the serotonergic response as well as being 
involved in partially mediating the response to 5-HT. The am-AR is also involved in 
NO release and hence vasodilatation as well as being a vasoconstrictor.
Thus the am-AR has a complex but crucial role in modulating tone of the mouse aorta.
IV
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General Introduction
General Introduction
Adrenoceptors
Adrenoceptors mediate the responses of the endogenous catecholamines: the 
sympathetic neurotransmitter, norepinephrine (NE: noradrenaline) and the circulating 
hoiTuone, epinepluine (adrenaline). In 1896, Oliver & Schafer observed that extracts of 
adrenal glands could effect a pressor response (Rang et a l, 1999) and from this initial 
observation, the study of adrenaline and its involvement in the cardiovascular system 
began.
Over a century later and the role of adrenoceptors has been uncovered in such organ 
systems of the body as the brain, spinal cord, lungs, liver, kidneys and many more, 
along with the heart and the vasculature. The effects of the adrenal extracts Oliver & 
Schafer observed, we now Icnow, was due to the presence of epinephrine and its activity 
at receptors termed adrenoceptors. It is also now known that norepineplirine is the 
endogenous neurotransmitter which elicits its response via action at adrenoceptors.
Currently, nomenclature describes nine distinct subtypes of adrenoceptors (Alexander et 
a l, 2004), namely three ai-A R subtypes (aiA, am  & am), tliree az-AR subtypes (azA, 
azB & azc) and three p-AR subtypes (pi, Pz & P3). So how did we go from Oliver & 
Schafer’s original observations to the current climate with 9 distinct subtypes mediating 
the responses of NE and epinepluine? Following is a brief history of the discovery and 
classification of ARs, in particular the ai-A R subtypes as this is the focus of this thesis. 
However, preceding this is a note on nomenclature throughout the thesis.
Note on nomenclature
Tluoughout the thesis the individual AR subtypes will be indicated with uppercase 
letters such as aiA, am  and am  or alternatively, with lower case letters i.e. au , a ^  and 
aid. It is customary to use upper case letters for native receptor subtypes within tissues 
or cells. The lowercase letters are used for cloned receptors, i.e. those receptors that are 
not native to those tissues or cells, and have been artificially introduced. Therefore, 
throughout the thesis this nomenclature has been applied.
History o f  adrenoceptors subtypes: a-AR and /3-AR subtypes
In 1913, Dale obseived blood pressure responses to epinephrine after treatment with a 
crude ergot alkaloid substance (Rang et a l, 1999). The response went from a 
vasoconstrictor response to vasodilatation response once the tissue had been exposed to 
the ergot extracts. This was the first indication of the multiple receptor action of 
epinephrine.
In 1948, Ahlquist postulated the existence of two distinct populations of ARs, alpha (a) 
and beta (p). His conclusions were based on the effects of the endogenous agonists, 
epinephrine (Epi), NE and a synthetic derivative of epinepMne, isoprenaline (Iso).
Ahlquist (1948) reported administration of NE in vivo, in dogs, cats and rabbits, resulted 
in an elevation of mean arterial pressui'e (MAP), whilst isoprenaline administration 
caused a decrease in MAP. Epinepluine administration though, resulted in a biphasic 
response, an initial increase in MAP followed by a decrease below baseline before 
returning to normal.
This indicated to Ahlquist (1948) the existence of two distinct populations of receptors, 
the NE-sensitive receptors (a) and the isoprenaline-sensitive receptors (p), whilst 
epinepluine appeared to have efficacy at both. Due to the activity of epinephrine at both 
a and p adrenoceptors, he concluded that epinephrine was the endogenous sympathetic 
neurotransmitter, but further research later found the neurotransmitter was 
norepinepluine.
Ahlquist (1948) described two observed orders of agonist potency dependent on 
whether the agents resulted in pressor responses or depressor responses. The order of 
potency for vasoconstrictor responses was NE > Epi > Iso for activity at what Alilquist 
(1948) called a-adrenotropic receptors (adrenoceptors). Conversely, the order of agonist 
potency for vasorelaxant responses at p-adrenoceptors was Iso > Epi > NE. However 
this division was only the Erst of more family divisions to come.
a-AR subtypes: further division into a r  cind Œ2-AR subtypes
In 1957, Brown and Gillespie reported dibenamine treatment increased sympathetic 
outflow from nerve stimulation in cat spleens. In Starke’s (1972) study of adrenergic 
and cholinergic transmission in the rabbit heart, he introduced the concept of a-ARs 
having a negative feedback action on the release of noradrenaline from sympathetic 
neurons. His conclusions were based on the observations that oxymetazoline and 
naphazoline could decrease NE overflow but phenyleplirine caused an increase in the 
force of contraction of the heart indicating the a-ARs resulting in negative feedback of 
NE release were different from those a-ARs on the cardiac cells enhancing contractility.
Then Langer (1974) reviewed the evidence for the existence of pre- and post-junctional 
a-ARs, which he also argued were non-identical. His evidence for this was based on a 
previous report by Dubocovich & Langer (1974) where the authors reported 
phenoxybenzamine treatment resulted in an increase in sympathetic outflow at a 30-fold 
higher concentration than was required to block post-junctional a-receptors. Therefore 
he postulated the subdivision of a-ARs by their anatomical location and suggested 
dividing a-ARs into a i and a% for postjunctional and prejunctional respectively.
This division was an oversimplification, as Berthelsen & Pettinger (1977) reported az- 
ARs can be involved post-synaptically, reporting a role for az-AR activation in renin 
releases from kidneys and melanocyte dispersion in frog skin. They suggested the 
subtype division should be due to pharmacological properties and not anatomical 
location as previously suggested.
The ai/az division was pharmacologically conflrrned by Timmermans & Van Zwieten 
(1980), when they established that ai-ARs and az-ARs had different selective 
antagonists. In a study performed in pithed rats they reported that the prazosin blockade 
of pressor responses by various agonists had the following order;
phenylephrine > clonidine »  B-HT 933 
In contrast yohimbine blockade had the following order:
B-HT 933 > clonidine > phenyleplnine
Timmermans & Van Zweiten (1980) had phannaco logic ally confinned the two 
subtypes, the prazosin sensitive ai-ARs and the yohimbine sensitive az-ARs.
Subdivision o f aj-ARs
In McGrath’s (1982) review of the apparent heterogeneous distribution of ai-ARs he 
suggested a subdivision of the ai-ARs into two separate subtypes. His conclusion was 
based on the activity of phenylethanolamine and non-phenylethanolamine agonists in 
various tissues but in particular, the rabbit basilar artery and rat annococygeus.
He reported phenylethanolamines resulted in biphasic responses in these tissues and 
suggested the subdivision of the phenylethanolamine-sensitive a ] A-ARs and the 
phenylethanolamine-insensitive am-ARs. He proposed the first phase of the curve was 
due to aiA-ARs and the second phase due to am-ARs. The actions of non- 
phenylethanolamines further pointed to a difference in the pharmacology of the aiA and 
aiB-ARs. Non-phenylethanolamines had little efficacy at am-ARs but were good 
agonists at ai a-A R s.
McGrath (1982) was not alone in suggesting the subdivision of ai-AR into two 
subtypes. Hoick et a l  (1983) had noted the differential blockade of verapamil, the 
calcium entry blocker, in rabbit pulmonary artery. They reported that verapamil and 
prazosin were better antagonists at blocking clonidine-induced responses than 
methoxarnine-induced responses, postulating the existence of two receptors. However, 
their data also hinted that the dependence of extracellular calcium for the two postulated 
receptors may be different.
However, this subdivision was somewhat resisted mainly due to the lack of suitably 
selective antagonists. It wasn’t until M oitow  and Creese (1986) performed a binding 
study of rat brain that the division was confirmed. They reported [^HJprazosin and 
[^H]WB4101 dissociation curves were biphasic. [^H]WB4101 had a 37-fold difference 
between Khigh (a;A-AR) and Kjow (am-AR) dissociation constants.
They reported the following antagonist potencies:
aiA-AR: WB4101 > prazosin > phento lamine
aiB“AR: prazosin > WB4101 > phentolamine
Thus, WB4101 was confirmed as an aiA-AR selective antagonist and could be used to 
establish which ai-A R subtypes are involved in functional responses. Unlike WB4101, 
prazosin could not differentiate between aiA-AR or am-ARs.
Han et al. (1987) then further strengthened this hypothesis by reporting that the 
alkylating agent chloroethylclonidine (CEC) could differentiate between sites with high 
and low affinity for WB4Î01. Low affinity sites for WB4101 were preferentially 
alkylated by CEC, thus CEC alkylation was am-AR selective.
Gross et al. (1988) then reported the urapidil analogue, 5-methylurapidil (5-MU) had 
affinity for aia-ARs over am-ARs by performing binding studies in rat hippocampus, 
vas deferens, heart, liver and spleen. Thus aia-ARs could be defined by their sensitivity 
to 5-MU and WB4101, whilst am-ARs could be defined by their sensitivity to CEC 
alkylation.
ajH and an-ARs subdivision
Around the time when McGrath (1982) suggested a subdivision of ai-ARs into aiA and 
am-ARs, Medgett & Langer (1984) observed that ai-ARs appeared to have two 
different populations based on their varying affinity of prazosin. In their study of the rat 
tail artery, Medgett & Langer (1984) noted an apparent ddnk in the Schild p lo f  of 
prazosin blockade. They reviewed the literature and noted that in general two distinct 
affinities for prazosin tended to be reported, a population with prazosin affinity with a 
pKe value >9.36 and a second population with pKs values of 8.80.
Medgett and Langer’s (1984) findings added weight for McGrath’s (1982) call to 
subdivide the ai-ARs. Flavahan and Vanhoutte (1986) reviewed the literature, 
providing additional evidence for the postulated heterogeneity of the ai-AR responses 
but they suggested the two receptors had differential affinity for prazosin. Thus
Flavahan & Vanhoutte (1986) introduced the subtypes ai h (high affinity for prazosin) 
and aiL (low affinity for prazosin) into the nomenclature.
Contrast this with the binding study done by Mon'ow & Creese (1986) who reported 
prazosin could not distinguish between subtypes, but the response can be subtyped by 
WB4101 sensitivity. It is noteworthy that the thi'ee cunent ai-AR subtypes, aiA, am, 
and am-ARs all have high affinity for prazosin i.e. they are all am-ARs.
Muramatsu et a l (1990) then added to the increasing complexity of ai-AR subtypes. In 
their extensive study of various vessels from dogs, rabbits, guinea-pigs and rats they 
found the vessels broadly fell into thi'ee categories based on their variation of antagonist 
affinity.
Group II (dog carotid artery and rat thoracic aorta) had high affinity for prazosin (pAz = 
9.5) which was more potent than both WB4101 and HV723. They associated this with 
am-ARs, previously described by Flavahan & Vanhoutte (1986). The am-AR was 
associated with group III (rabbit mesenteric artery, thoracic aorta, carotid artery and 
guinea-pig thoracic aorta). This gi'oup had pAz values for prazosin, HV723 and 
WB4101 ranging from 8-9 but no distinct order of potency was noted.
Group I (dog mesenteric artery, vein and saphenous vein) had affinity for HV723 and 
WB4101 over prazosin. The affinities in this group did not fit the above two groups as 
they had a low affinity for prazosin (pAz = approx 8 .6) and these tissue were unusually 
insensitive to yohimbine (pAz values < approx 6 .0) compared to the other two groups. 
Muramatsu et a l (1990) tenned this group am-
Although the evidence pointed to ami/L/N subtypes, no evidence from cloned studies had 
been provided to support this subdivision. It is now believed that the am-AR may be a 
splice variant of the am-AR of which four variants are believed to exist (Chang et a l,
1998). Therefore the am/UN-AR subtypes have fallen into relative disuse.
Cloning studies o f  aj-AR subtypes
aib-AR: The a^-A R  was the first to be cloned. Cotecchia et al. (1988) cloned a
1545-base pair fragment of DNA that coded for the 515 amino-acid hamster 
aib-AR. As no other ai-A R had been cloned at the time, Cotecchia et al. 
(1988) compared the protein sequence with otz, Pi and pz-ARs. The most 
conserved regions were in the transmembrane regions of the receptors with 
42-45% conservation with the other ARs.
They highlighted seven distinct hydrophobic regions of approximately 20 to 
25 amino acids that they associated with the seven transmembrane regions 
GPCRs have (see section on Murine ai-ARs). They also reported threonines 
and serines present in the third cytoplasmic loop as possible 
phosphorylation sites hy protein kinase C.
Pharmacological studies revealed the cloned receptor had a high affinity for 
prazosin and low affinity for WB4101, consistent with the functional am - 
AR.
aia-AR: The a  % a-AR was then cloned by Schwimi et al. (1990) but was provisionally
temied the aic-AR as this protein could not be detected in tissues which had 
been shown to have am-AR mediated responses such as, rat vas deferens 
and hippocampus (Gross et a l, 1988). The cloned bovine aic-AR (466 
amino-acids: Schwinn et a l,  1990) was reported to have 72% sequence 
homology with the a^-A R  (previously cloned by Cotecchia et a l, 1988: 
discussed earlier). Tlrreonine and serine residues in the third intracellular 
loop indicated possible phosphorylation sites by protein kinases.
The phannacology though was consistent with the am-AR: high affinity for 
WB4101 and phentolamine (Morrow & Creese, 1986). Later Schwimi et a l 
(1991) reported the novel am-AR antagonist, 5-MU (Gross et a l, 1988), 
could discriminate between am and am, having affinity for am (Schwinn et 
a l, 1991).
aid-AR: The rat am-AR was the last AR to be cloned (Perez et a l, 1991). The gene
was a 1680 base pair fragment encoding 560 amino-acids. The am-AR had 
72% and 64% homology with hamster am-ARs and bovine am-ARs 
respectively.
However, pharmacological findings indicated the novel am-AR had 
significantly lower affinity for 5-MU than native am-ARs in tissue studies 
as well as being susceptible to CEC alkylation. They concluded the am-AR 
was a new subtype distinct from the am-AR that had been 
pharaiacologically identified.
At the same time Lomansay et a l (1991) cloned a receptor from rat cortex 
which they termed the am-AR but it was identical to the cloned am-AR.
We had gone from having only two pharmacological subtypes to four cloned subtypes 
with apparently distinct phannacology. The nomenclature was eventually cleared up by 
the International Union of Phannacology (Byland et a l, 1994) when the am and am- 
ARs were accepted as a novel am-AR, the am-AR became the original am-AR, whilst 
the cloned am-AR remained as the pharmacologically distinct am-AR.
Current subtype selective agonists
Selective agents for the individual ai-AR subtypes are becoming increasingly available 
but the pharmacology remains complex. Following is some of the ligands that have 
been used in this project for ai-AR subtyping studies.
Norepinephrine (NE) is the endogenous agonist for a-ARs. Ahlquist (1948) showed that 
NE has greater affinity for a-ARs over p-ARs. In 1995 Knepper et al. perfonned a 
binding study and reported that NE has partial affinity for am-ARs over am and am- 
ARs (22-fold and 15-fold respectively). However NE has efficacy at az-ARs as well as 
partial efficacy at p-ARs. Using NE as the agonist, a host of blockers would have been 
required in order to isolate the ai-AR mediated response i.e. propranolol to block p, 
rauwolscine for az-ARs, cocaine for uptake-1 and corticosterone for uptake-2. 
Therefore NE has not heen used in the present study.
Phenylephrine (PE), an ai-A R agonist with full efficacy, had slight affinity for am-ARs 
over aia and am-ARs (6-fold and 8-fold affinity respectively: Knepper et a i, 1995). 
Therefore, it is essentially a non-subtype selective ai-AR selective full agonist and was 
therefore the agonist of choice for the study reported in this thesis, as the focus was the 
a]-AR subtypes.
The R-enantiomer of A61603 is a currently accepted full agonist with selectivity for 
a  1 A-ARs (Knepper et a l, 1995). R-A61603 had 163-fold and 58-fold affinity for cloned 
a ]a-ARs over am and am-ARs respectively. They also demonstrated this selectivity by 
perfonning binding studies using specific tissues from the rat (am - vas deferens; aie- 
spleen; am - aorta).
Furthermore, the racemate mix of A61603 was shown to have no efficacy at hamster 
am-ARs as it could not raise IP3 levels to a quantifiable level but increased IP3 levels 
132-fold 3.5-fold in cells transfected with bovine am-ARs and rat am-ARs respectively. 
However, R-A61603 was reported to have affinity for az-ARs but the authors made no 
indication of which az-AR subtype was involved or whether A61603 had efficacy at az- 
ARs. R-A61603 was used in Chapter 2 to compliment antagonist studies done using PE 
as the agonist, in order to detennine functional roles for specific ai-A R subtypes.
Current subtype selective antagonists
Phentolamine is a classical a-AR selective antagonist that has affinity for both a i and 
az-ARs. Mon'ow & Creese (1986) demonstrated that phentolamine could be used to 
discriminate between am  and am-ARs but more selective antagonists are now available 
for sub typing. Unlike phentolamine which is a reversible antagonist, 
phenoxybenzamine, another a-selective antagonist is insunnountable. However, both 
phentolamine and phenoxybenzamine, remain useful tools in establishing a-AR 
selectivity of ligands, but have not been used in this study.
Prazosin is the most commonly used a%-AR selective antagonist for determining the 
extent of ai-AR involvement. Prazosin camiot discriminate between ai-A R subtypes, 
but has potency at all tlnee subtypes in the nanomolar range. It has been used in this 
project to ensure responses were ai-A R mediated.
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5-methylurapidil is an am-AR selective antagonist with approximately 50-fold 
selectivity for cloned am-ARs over am and am-ARs (see Table 2-A), Gross et al. 
(1988) was the first to show the selectivity of 5-MU at am-ARs but this was pre-1994 
when only two ai-ARs had been pharmacologically profiled in native tissues. Schwinn 
et al. (1994) later confirmed that 5-MU had affinity for am-AR over am  and am-ARs.
No suitable am-AR antagonist is cuinently available (Alexander et a l, 2004). 
Chloroethylclonidine (CEC), an ineversible alkylating agent which was postulated to be 
an am-AR selective antagonist (Han et a l, 1987; Perez et al. 1994). However more 
recent data, particularly from cellular studies, has indicated that this apparent selectivity 
is due to heterogeneous distribution of ai-A R subtypes at the cellular level.
Hirasawa et a l (1997) suggested that CEC preferentially alkylates the receptors 
presented on the cellular membrane irrespective of ai-A R subtype. The authors 
postulated that the am-ARs are present on the membrane whilst the am  or aip-ARs 
tend to be intracellular. However CEC can still be used as an iineversible ai-AR 
alkylating agent.
Other am-AR selective antagonists that have been postulated include cyclazosin 
(Giardina et a l, 1996) and L765,314 (Patane et a l  1998). However, both agents have 
been used by colleagues who have been unable to reproduce the selectivity reported by 
the initial authors.
Therefore there currently is no suitable am-AR selective antagonist. However, after 
personal correspondence with Dr. Michael T. Piascik (University of Kentucky, 
Lexington, Kentucky, USA) and Prof. James E. Faber (University of North Carolina, 
Chapel Hill, North Carolina, USA), it was decided that the best approach to isolate the 
am-AR mediated response would be a receptor protection protocol (See Chapter 2 for 
greater detail).
The hypothesis was, by pre-incubating with selective am  and am-ARs selective 
antagonists, the am-AR could be alkylated by CEC treatment. The antagonists could 
then be washed out and the response remaining should be a response minus the role of 
am-ARs. This approach has been applied in Chapter 2.
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For the study of am-ARs the most commonly used antagonist is BMY 7378 (Saussy et 
al., 1994). In a later study Goetz et al. (1995) reported selectivity of 126-fold and 110- 
fold for aid-ARs over aia and an,-ARs respectively. Therefore BMY has been used in 
this study for the isolation of the role of am-ARs.
The mouse aorta
Murine models are being increasingly used in adrenoceptor pharmacology due to the 
availability of knockout models of each individual ai-AR subtypes. However, such 
studies only highlight the cuirent lack of background physiological studies done in 
mice. Recently, Russell & Watts (2000), performed a study of the vascular reactivity of 
the mouse thoracic aorta.
They used the C57 Black 6J strain of mice, as this strain is commonly used for the 
breeding of genetically manipulated models. Using helical strips of aorta they tested 
various vasoactive agonists and highlighted the high potency and efficacy of NE, PE 
and 5-HT. They also reported endothelium-dependent ACh-induced relaxation.
Other interesting notes included the low efficacy U K l4,304 (az-AR selective agonist) 
and angiotensin II. There was a distinct lack of P-AR-mediated relaxation and no 
relaxation to histamine or adenosine which Russell & Watts (2000) noted was different 
to the effect of these agents in the rat aorta. Comparison of mouse and rat aortae 
revealed that the mouse aorta had little response to angiotensin II and endothelin, whilst 
in the rat aorta they both exhibited high efficacy and relatively high potency. Thus the 
mouse aorta exhibits distinct physiological responses indicating background work on 
the mouse was essential.
Interestingly, the 5-HT was equipotent to PE in the mouse aorta, whilst 5-HT has been 
shown to he less potent than PE in the rat aorta (Christ & Jean-Jacques, 1991). McKune 
& Watts (2001) then subtypes the serotonergic response of the mouse aorta. 5-H T za  
receptor activation was reported to be responsible for the 5-HT induced response.
The adrenoceptor response of the mouse aorta (albino ddY strain) has been subtyped 
pharmacologically (Yamamoto & Koike, 2001) using ai-AR subtype selective 
antagonists. They reported pAz values of 9.7, 9.6, 7.5 and 8.4 for prazosin, WB4101, 5-
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MU and BMY 7378 respectively and that the NE-response was sensitive to CEC 
alkylation. BMY 7378 was significantly more potent than 5-MU, indicating the am-AR 
was the major adrenergic vasoconstrictor. This was later confirmed by studies done in 
transgenic mice but is discussed later.
Adrenoceptor responses in other murine vessels
Yamamoto & Koike (2001a) also perfonned a study of ai-AR subtype of the abdominal 
aorta and mesenteric arteries. They suggested the adrenergic responses in the upper 
region of the abdominal aorta were am-AR mediated whilst in the lower region were 
a  1 a-A R  mediated.
However they could not detennine the ai-AR subtype involved in vasoconstriction of 
the superior mesenteric artery as both BMY 7378 and 5-MU exhibited low affinity, 
whilst prazosin and WB4101 had high affinity. Thus, they concluded it was non-am 
(tissue was not BMY sensitive), non-aiA (tissue was not 5-MU sensitive), non-am 
(tissue had high affinity for WB4101) and non-am (tissue had high affinity for 
prazosin). Their suggestion was that it may have been a functional phenotype of the 
am-AR, akin to the am-AR being a splice variant of the aiA-AR.
Daly et a l (2002) performed a study of four different vascular preparations (aorta, 
carotid artery, U‘-order mesenteric artery & tail artery) from mice. They also used 
transgenic models but the data provided on the effect of ai-A R subtype selective 
antagonists in the WT alone indicated that the aorta and carotid artery adrenergic 
responses are primarily am-AR mediated whilst the ai-AR responses of the mesenteric 
and caudal arteries were due to mainly a i A-AR activation.
Thus, it appears that in large conductance arteries in the mouse the adrenergic responses 
tend to be am-AR mediated whilst the aiA-AR seems to be responsible for the 
adrenergic responses of smaller resistance arteries such as the mesenteric arteries or the 
tail artery.
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Murine aj-ARs
The mouse (Mus musculus: Domestic mouse) genome consists of 40 chi'omosomes. 
Detailed information on individual proteins can be accessed on the SWISS-PROT© 
database by entering the appropriate protein code.
All ARs ai'e metabotropic receptors belonging to a class of proteins known as G- 
protein-coupled receptors (GPCRs). GPCRs are single polypeptides chain proteins with 
seven a-helical regions that span across the cellular membrane. As such, GPCRs have 
an extracellular N-tenninus, an intracellular C-terminus, with tlnee intracellular and 
three extracellular loops. The 3'^ intracellular loop is extended and is believed to be 
involved in the interaction of the GPCR with its appropriate G-protein (Rang et a l
1999).
All three ai-AR subtypes are coupled to the Gq/n subset of G-proteins and increase 
inositol trisphosphate (IP3) production. As a result, they raise intracellular calcium and 
can recruit voltage-gated calcium channels.
Following is a brief description of the three murine ai-AR subtypes. The amino-acid 
sequences are also shown with the seven transmembrane regions (potential) underlined 
and the extended third intracellular loops shown in bold.
a  1 a-AR: The gene for the a  1 A-AR is located on chromosome 14. It is now Icnown that
splice variants of the a  1 A-AR now exist of which four- distinct variants have 
been identified (aiA-i, aiA-2, aiA-3 & aiA-4; Chang et a l, 1998). For this 
study the aiA-i variant is considered as the sole aiA-AR in the mouse 
although this may not be the case. The murine aiA-AR is 466 amino-acids 
long (protein code: P97718; accession number: GI 20141255).
001 mvllsenase gsncthppaq vniskaillg vilqqliifq vlqnilvils vachrhlhsv
061 thyyivnlav adllltstvl pfsaifeilq ywafqrvfcn iwaavdvlcc tasimqlcii
121 sidryiqvsy plryptivtq rrqvrallcv walslvisiq plfqwrqqap edeticqine
181 epqyvlfsal qsfyvpltii Ivmycrvyvv a k r e s r g l k s  g l k t d k s d s e  q y t l r i h r k n
241 v p a e g s g v s s  a k n k t h f s v r  l l k f s r e k k a  a k t l q i v v q c  fvlcwlpffl vnipigsffpn
301 fkppetvfki vfwlgylnsc inpiiypcss qefkkafqnv Iriqclrrrq sskhalqytl
361 hppsqaveeq hrqmvripvq sgetfykisk tdgvcewkff ssmpqqsari tmpkdqsact
421 tarvrsksfl qvcccvgsst prpeenhqvp tikihtislg enqeev
14
aiB-AR: The gene for the am-AR is located on cliromosome 11. The murine am-AR
is 514 amino-acids long (protein code: P97717; accession number: GI 
3023234).
001 ranpdldtghn 
0 61 gnilvilsva 
121 aavdvlccta
tsapahwgel
cnrhlrtptn
silslcaisi
181 ]Lgwkepapnd 
241 it ik em sn sk e l
301 mfilcwlpff
dkecgvteep
t l r i h s k n f h
ialplgslf3
kdanftgpnq tssnstlpql dvtraisvgc Igafilfaiv 
yfivnlaiad lllsftdlpf satlevlgyw vlqrifcdiw 
dryigvrysl qyptlvtrrk ailallsvwv Istvisiqpl 
fyalfsslgs fyiplavilv mycrvyxvak
361 ilgcqcrggr 
421 aspspgylgr 
481 tegdasnggc
rrrrrrrlga
gtqppvelca
dtttdlangq
e d t l s s t k a k  g h n p r s s i a v
t1kppdavfk vvfwlgyfns 
caytyrpwtr ggslersqsr 
fpewkpgall slpeppgrrg 
pgfksnmpla pghf
k l f k f s r e k k
clnpiiypcs 
kdslddsgsc 
rldsgplftf
r t t k n l e a g v
aaktlgivvg 
skefkrafmr 
msgsqrtlps 
kllgepespg
aiD-AR: The gene for the am-AR is located on clnomosome 2. The murine am-AR
is 562 amino-acids long (protein code: P97714; accession number: GI 
3121722).
001 mtfrdilsvt 
061 qsstaeagaa 
121 Iqtvtnyfiv 
181 Ictisvdryv 
241 qiteevqyai
fegprassst
asgevnqsaa
nlavadllls
ggsgaqqqaq 
vgglvvsaqg 
aavlpfsatm
qvrhslkypa 
fssvcsfyip
imterkaaai
mavivvmycr
301  h c r g a a t s a k
361 vlplqslfpq 
421 rlwpslrppl 
481 slrlrewrll 
541 aeavicqaye
g n p g t q s s k g
Ikpsegvfkv
h t l r s s l s v r
ifwlqyfnsc
asldrrpalr
qplqrpttql
pqdlsnlret
Icpqpahrtp
rakvsslshk
di
tvgpeqpavq gvpgatgqsa vvqtgsgedn 
vqvgvflaaf iltavagnll vilsvacnrh 
evlqfwpfgr tfcdvwaavd vlcctasils 
vsvqpllgwk epvppderfc 
s l e a g i k r e p  g k a s e v v l r i  
aktlaivvqv fvlcwfpfff 
refkraflrl Ircqcrrrrr 
rpglrrhaqq aqfqlrpska 
tacalrseve avslnvpqdq
lallwavalv
v y v v a r s t t r
l l k f s r e k k a
vnpliypcss
rqspsphctp
frsgqarrae
Generation o f ai~AR subtype knockout mice
The first ai-AR subtype knockout (KO) mouse created was the am-KO, reported by 
Cavalli et at. (1997). Using gene targeting vectors, Cavalli et a l (1997) removed exon 1 
o f the am-AR gene. The disrupted gene was then electroporated into embryonic stem 
cells from the 129 mouse strain before microinjection into C57/Black/6J blastocytes. 
From this, homozygous progeny were obtained by further breeding with C57/B1/6J 
mice. Using this approach, the mice produced had a mixed genetic background, part 
129/Sv and part C57/B1/6J. Therefore, Cavalli et a l (1997) obtained both wild-type 
(WT) and KO homozygous progeny to ensure a genetically matched control strain of 
mice with which to make a comparison.
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The aiD-KO and «ia-KO mice were created in 2002 by Tanoue et a l (2002) and 
Rokosh & Simpson (2002) respectively. Tanoue et a l (2002) took an almost identical 
approach to Cavalli et a l (1997) creating the am-KO by targeted gene disruption before 
using the 129/Sv stem cells microinjected into C57/B1/6J blastocytes and bred the 
progeny with C57/B1/6J mice. Using heterozygous progeny, several generations of 
breeding were done to ensure homozygous strains of WT and am-KO mice were 
obtained. Thus both the am-KO and am-KO had mixed 129/Sv/C57/Bl/6J genetic 
backgrounds but it is unknown the extent of the genetic mixing and therefore the 
respective WT control strains were obtained in order to make appropriate comparisons.
Rokosh and Simpson (2002) created the aiA-KO using a similar approach but 
additionally, they inserted the Escherechia coli fi-galactosidase gene, LacZ. Having 
created the homozygous KO mice also using 129Sv stem cells but breeding mice on 
both C57/B1/6J and FVB/N mice they went on to localise the expression of the R- 
galactosidase protein in the vasculature and demonstrate the heterogeneous expression 
of a] A-ARs within blood vessels.
Disrupted gene expression in aj-AR KO mice
In all tliree KO’s created, only exon 1 was removed. For all thi'ee ai-A R subtypes, exon 
1 codes for the first five transmembrane spanning domains. The promoters for protein 
expression were unaffected and as such, some unanswered questions about the disrupted 
proteins expression remain.
Does the cell produce the disrupted AR? This question must be tackled at two levels, 
transcription and translation. Cavalli et at. (1997), Tanoue et al. (2002) and Rokosh & 
Simpson (2002) all perfonned RT-PGR of isolated RNA from mouse tissues, therefore 
the genes must have heen transcribed for the RNA products to be present.
Rokosh & Simpson (2002) clearly demonstrated the disrupted gene was expressed 
tlnough to protein level, i.e. translation had also occuned. No evidence for the 
translation of the disrupted am  and am-AR RNA products into proteins is currently 
available. Therefore, it is cuiTcntly unknown how far the production of these disnipted 
receptors proceeds, although if the findings of Rokosh & Simpson (2002) are consistent 
across the board then it may be fair to make this assumption.
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What happens to the protein products of these mutant genes? Although Rokosh & 
Simpson (2002) demonstrated protein expression, they were unable to comment on the 
cellular location of the protein, as their protocol did not have the resolution to do so. 
Therefore, assuming the protein products for all three mutant genes are present, it is 
unknown whether or not the cells detect this mutant gene, and initiate the degradation of 
the protein or whether these gene products actually are transported to the cellular 
membrane, bearing in mind that the protein code for transmembrane regions 6 and 7 of 
the receptors were still present.
What can be confinned though is that all three mutant gene products have lost the 
functional response associated with that native ai-AR subtype. Therefore these KO are 
functional Icnockouts and not complete gene KOs as their name suggests.
Phenot)’pes resulting from aj~AR subtype KO
aiA “KO: Rokosh and Simpson (2002) reported aiA-AR mice were moderately 
hypotensive (approx 10% reduction in systolic and mean arterial pressure; 
MAP), had significantly reduced pressor responses to both phenylephrine 
and A61603 and a decreased baroreceptor reflex. They also demonstrated a 
reduction in the number of [^H]-prazosin binding sites in brains, hearts and 
kidneys isolated from aiA-KO mice compared with WT mice.
Furthermore, by insertion of the p-galactosidase gene in place of exon 1 of 
the a  1 A-AR in the aiA-KO, Rokosh & Simpson (2002) were able to study 
the expression of the mutant gene throughout the arterial tree. They reported 
a distinct lack of {3-galactosidase staining in the thoracic aorta and 
abdominal aorta with clear staining in celiac artery, mesenteric artery and 
both left and right renal artery branches. They concluded the aiA-AR is 
involved in homeostatic control of blood pressure in mice whilst there was 
no significant aiA-AR expression in the mouse aorta.
aiB"KO: aiB-KO mice exhibited a lessened number of ai-ARs binding sites in the 
cerebral cortex, cerebellum, kidneys, liver & hearts compared to WT 
(Cavalli et a l, 1997). Although the am-KO mice were noimotensive, they
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had significantly reduced pressor responses compared to WT mice. In aortic 
ring segments they reported a decrease in PE potency, therefore, they 
implicated the am-AR as having a role in blood pressure maintenance and 
also suggested the am-AR is the major adrenergic vasoconstrictor in the 
mouse aorta.
However, Daly et a l (2002) perfonned a comprehensive pharmacological 
study of four blood vessels from the mouse aorta, namely the aorta, carotid 
arteries, mesenteric arteries (1®^ order branch of superior mesenteric artery) 
and caudal (tail) arteries. They reported that the lack of functional am-ARs 
did not adversely affect vascular contractility in any of the arteries studied, 
with Daly et a l (2002) suggesting that the am-AR ""confuses the 
pharmacology^ of the WT rather than play a major role in vasoconstriction. 
However they did not completely rule out a role in vasoconstriction for the 
am-AR, suggesting instead that it has a minor role in contractile responses 
of all four vascular preparations studied.
Vecchione et a l (2002) then attempted to make the am-KO mice and their 
WT controls hypertensive by chronic administiation of NE, PE and 
angiotensin II to selected mice over a number of days using osmotic pumps. 
PE infusion did not induce hypertension in either WT or am-KO whilst 
angiotensin II induced hypertension in both. However, NE treatment only 
resulted in hypertension in WT mice whilst am-KO mice remained 
normotensive.
Although PE treatment did not result in hypertension Vecchione and 
colleagues (2002) reported that in WT mice, PE-infusion resulted in inward 
eutrophic vascular remodelling, where vascular wall thickness remains 
unaltered whilst lumen diameter decreases. This can be obseiwed as a 
significant increase in media: lumen ratio and Vecchione et a l (2002) 
reported a 45% increase in media: lumen ratio in WT mice, whilst the am- 
KO did not exhibit any significant vascular remodelling. Thus, the am-KO 
has been implicated in the induction of hypertension by raised 
catecholamine levels, and also has a role in vascular remodelling.
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a iD “KO: Compared to the WT, the am-KO mouse had significantly less total ai-AR 
protein binding (reduced B^ax values) in whole brain and cerebral cortex, 
whilst no binding was detected in aorta (Tanoue et a l, 2002). However, 
binding studies indicated no loss of ai-AR population in heart and kidney 
tissues. am-KO mice were also moderately hypotensive and had reduced 
pressor responses to NE and PE. Aortae isolated from am-KO mice were 
significantly less sensitive than WT to PE and NE and not susceptible to 
blockade with lOOnM BMY 7378, whilst the pAz for BMY 7378 was 8 .6 . 
Thus, they concluded that the am-AR is involved in blood pressure 
maintenance and the am-AR is the major vasoconstrictor in the mouse 
aorta.
Tanoue et a l (2002a) then perfonned a study of salt-induced hypertension 
in subtotal neplnectomised WT and am-KO mice. Of the 15 mice from each 
group used in the study, by day 35 following subtotal neplnectomy and 1% 
saline loading, only 8 o f the WT mice had survived, whilst only 1 fatality 
was recorded in the am-KO strain of mice. Furthermore, am-KO mice were 
less susceptible to the onset of salt-induced hypertension, and Tanoue et a l 
(2002a) suggested this may be due, in part at least, to the reduced ai-AR 
induced vascular reactivity.
Thus, each of the ai-A R subtypes has been implicated in the pathophysiology of 
hypertension. The use of these transgenic mice has suggested that all thi'ee ai-ARs play 
a critical role in hypertension but they may have distinct roles in its pathogenesis. The 
individual roles for each of the subtypes in vasoconstriction could help elucidate 
important functional differences.
Therefore the mouse aorta has been chosen as the vascular preparation in this study in 
an attempt to focus particularly on the role of the am-AR in vasoconstriction.
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Aims of Study
20
Aims of Study
Chapter 1
1. Establish if there were any significant age-related changes in vascular 
contractility or relaxant responses in WT aortae.
2. Ensure that there were no significant strain-related differences in the contractile 
or relaxant responses between the two WT strains.
3. Confinn that the am-AR is the major adrenergic vasoconstrictor in the mouse 
aorta with little role for am-ARs.
4. Ensure that no age-related changes in the phenotypes in the am-KO or am-KO 
(such as compensatory up-regulation) occuined.
Chapter 2
1. Establish that the PE-induced response in am-KO aortae is ai-AR mediated and 
subtype this response using
a. Selective antagonists (prazosin, 5-MU)
b. Selective agonists (A61603)
2. Test the adrenergic response of the double am-am-KO mouse aorta
3. Isolate the minor role of the am-AR in mediating the contractile response of WT 
aortae, using a receptor protection protocol.
21
Chapter 3
1. Demonstrate synergy between the adrenergic and serotonergic vasoconstrictor 
systems in the mouse aorta.
2. Demonstrate that 5-HT responses in the mouse aorta are prazosin-sensitive and 
establish which ai-AR subtype is responsible for this
3. Establish 5-HT receptor subtype responsible for the serotonergic responses of 
both WT and am-KO aoitae.
Chapter 4
1. Investigate the role of aio-ARs in NO-dependent vasodilatation by testing the 
effect of L-NAME on KCl, adrenergic and serotonergic responses on WT aiB- 
KO and aio-KO.
2. Test the involvement of ai-ARs in PE-induced vasoconstrictor responses.
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General Methods
Colony Maintenance
Breeding pairs of 129/Sv/C57B1/6J control wild-type mice (WT) and mice lacking 
functional am-ARs (aiB-KO) were kindly supplied by Professor Susanna Cotecchia 
(University of Lausamie, Lausanne, Switzerland). Breeding pairs of 129/Sv/C57BL/6J 
control wild-type mice (WT) and mice lacking functional aio-ARs (ato^KO) mice were 
kindly supplied by Professor Gozoh Tsujimoto (National Children’s Medical Research 
Center, Tokyo, Japan). The generation and background of am-KO mice, aio-KO mice 
and their appropriate genetically-matched control WT counteiparts have previously 
been described in detail (Cavalli et al., 1997; Tanoue et ah, 2002 respectively). aiB-otm- 
KO mice were created by cross breeding aie-KO and aio-KO mice (see below for more 
details). All mice were bred in the University of Glasgow, maintained on a 12:12-hour 
light/dark schedule at 22-25°C with 45-65% humidity and fed ad-libitum on a standard 
rodent diet and tap water.
The aiB-ociD-KO was created by cross-breeding homozygous ais-KO with homozygous 
aiD-KO. Since the genes for the aie-AR (Clmomosome 11) and aiD-AR (Chiomosome 
2) are located on separate chi'omosomes, the genetic makeup of future generations is 
predicted by Mendelian genetics.
Thus, the first generation (Fi) was heterozygous for WT alleles and both aie-KO and 
aiD-KO mutant alleles and Fi mice were genotyped, in order to confirm a heterozygous 
population. Fi were then interbred and the second generation (F2) was genotyped. F2 
mice that were homozygous for both mutant œib-AR and aio-AR alleles were selected 
and interbred, thus a population of am-aiD-KO mice were created. These mice should 
therefore only express aiA-ARs. It was not deemed necessary to obtain a control strain 
of mice that were homozygous for the both the native aiB and am-ARs (Chapter 1).
The primers used for genotyping were those primers used by Cavalli et a l (1997) and 
Tanoue et al. (2002) who created the am-KO and am-KO mice respectively. This work 
was not done myself and is therefore not shown. However tissue was isolated from 
these mice and use for experiments presented herein.
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Vessel isolation
4-month-old mice of weights 25-40g (4m, all chapters) or 16-month-old adult male 
mice of weights 35-50g (16m, Chapter 1 only) control (am-WT or am-WT), am-KO, 
am-KO or am-ocm-KO mice were euthanased by exposure to an increasing 
concentration of CO2. Skin on the ventral surface of the thoracic cavity was carefully 
incised, the ribcage was removed and the heart and lungs were exposed. The aortic arch 
was located and cut in order to free the aorta from the heart. The thoracic aorta, from the 
aortic arch to the diaplrragm was then excised directly into ice cold physiological saline 
solution (PSS).
The aorta was cleared of fat and connective tissue by dissection in an agar-filled Petri 
dish with the aid of a dissection stereomicroscope (Zeiss). The remains of the aortic 
arch and the first 2mm of descending aorta were removed and discarded. Four 
consecutive rings of 2mm in length were then cut and the remainder of the aorta 
discarded. No attempt was made to denude the vessels of endothelium.
Myograph mounting
The technique used for studying the vessels was small vessel wire myography, an 
extensively used and reliable in vitro teclmique used for phannacological and 
physiological studies of small blood vessels. This method was originally described by 
Mulvany & Halpem (1977) and has been used for functional studies of blood vessels 
with passive lumen diameters as small as 100pm.
In brief, a 40pm diameter stainless-steel wire was carefully passed through the lumen 
and attached by screws to a mounting head, fixed to a force transducer. A second 40pm 
stainless-steel wire was then passed tlirough the lumen and attached by screws to a 
mounting head which is fixed to an adjustable micrometer (Fig. I-l). The micrometer 
can be manually adjusted in order to apply circumferential tension to the vessel and the 
transducer measures the force (tension) generated by this stretching. Once a suitable 
tension has been set, any alterations in tone as a result of vascular activity can be 
measured as a change in isometric force.
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2x 40pm wires passed 
through the lumen of 
the vessel
Head attached 
to a force 
transducer
Head attached 
to a 
micrometer
2mm ring of 
aorta
Fig I-l. The mounting heads o f  a myograph bath. The vessel 
sits between the two ‘jaw s’ o f  the mounting heads and the 
screws are used to secure the 40pm wires.
Aortic rings were randomised and mounted on a 4-channel wire myograph (Danish 
Myo-Technologies) in PSS at 37°C bubbled with 95% O2 /5% CO2 gas mixture. 
Previously, colleagues had construeted passive-active length-tension curves in order to 
determine the optimal tension for contractile responses and tension equivalent to 
l.Ogram (9.8ImN) was found to be suitable for the mouse aorta (data not shown). 20 
minutes (min.) after vessels were mounted, 1 .Ograms of passive circumferential tension 
was applied by graduated increments of 0.33g, 3 min. apart. After a further 20 min. the 
tone was readjusted to 1 .Og.
Myograph mounted vessels
Tissues were allowed 40 min. to equilibrate before any agonist challenges were made. A 
‘wake-up’ protocol was then performed. Tissue viability was tested by replacing the 
PSS solution with a high KCl (125mM) PSS solution for 10 min. to allow contractions 
to reach plateau and then washed out with normal PSS. In the high KCl solution, NaCl 
was replaced by the molar equivalent of KCl (see Solution Used section).
After a further 20 min., adrenergic contractile responses were assessed by a single 
challenge to lOpM phenylephrine (PE) and 3pM acetylcholine (ACh) was added a few
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minutes prior to washout in order to determine endothelial function. Serotonergic 
responses (where appropriate) were assessed by a single challenge to IpM 5-HT. 
Cumulative concentration response curves (CCRCs) to the appropriate agonists were
then constructed using half-log step increments (i.e. InM, 3nM, lOnM etc). Agonist
concentrations were added at 3 min. intervals. Detail of the appropriate protocols used 
in each chapter are given in the following pages.
Protocol used: Chapter 1
A CCRC to PE was constmcted (lnM-30pM for am-WT, am-KO and am-WT; lOnM- 
300pM for aiD-KO). Following a washout and equilibration period, a CCRC to 5-HT 
was constructed (lnM-3pM, all strains).
Protocol used: Chapter 2
A second challenge to PE was made (lOpM for WT & am-KO; lOOpM for am-KO and 
ocm-ocm-KO). In the experiments using antagonists in the am-KO (see below), the PE 
CCRCs were normalised using this response as the maximum.
Initial experiments to establish the sustainability of the PE responses of am-KO aortae 
were performed by constmcting a CCRC to PE (100nM-300pM) and then after washout 
a second CCRC to PE was constructed (lOOnM-lmM)
The effects of InM, lOnM & lOOnM prazosin and InM, lOnM , lOOnM & IpM 5-MU 
on the PE-induced contractile responses of the am-KO aorta were tested in order to 
establish pKe values for prazosin and 5-MU (see below). These experiments were done 
by incubating the agonist before constructing the first CCRC due to the loss of response 
on the second curve (see Chapter 2-Results, Figure 2-1, Table 2-1 and Chapter 2- 
Discussion).
A61603 responses in WT, am-KO and am-KO aortae were tested by constructing 
CCRCs (lnM-300pM) both in the absence and presence of 3nM or 30nM prazosin. For 
consistency across strains the effect of prazosin was tested on the initial CCRC. Where 
appropriate, a pKg value for prazosin was estimated. The am-WT, am-KO and am-
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KO PE response curves from the previous chapter were used for comparison of the 
A61603 responses.
The aiB-otiD-KO was studied by constructing CCRCs to PE (100iiM-3inM), A61603 
(lnM-30pM) or 5-HT (lnM-3pM). Responses were compai’ed with the a^-W T  data 
from the previous chapter.
The isolation of am-ARs and aiA-ARs in the WT response was attempted by using a 
receptor protection protocol (all data from this protocol was pooled). After the initial 
agonist testing procedure, selected tissues were incubated with either lOnM BMY 7378 
or lOnM 5-MU. 30min. later, IpM or lOpM chloroethylclonidine (CEC) was added to 
baths, both with and without BMY 7378 or 5-MU present.
Following a further 30 min. incubation, CEC was washed out by repeated washes at 5 
min. intervals over a 15 min. period. In baths where BMY 7378 or 5MU was already 
present, the CEC was washed using PSS with the BMY 7378 or 5-MU added at the 
appropriate concentration. Finally, all agonists were removed by repeated washing with 
normal PSS at 5 min. intervals over a 15 min. period. Following this CCRCs to PE were 
constructed (InM-SOpM). This protocol is shown in diagrammatic form in Figure 1-2.
30 min. 30 min. , 15 min.. 15 min.. ---------------- h— ----h ►
Wake Up
luM /lQ uM C E C
lOiiM BMY 7378/ 5~MeU
125iiiM KPSS
lO^M PE & 3fiM ACh
lO^IVIPE
PTT/
Wash with Krebs 
+ lOnM BMY 
7378/ 5-MeU 
every 5 min. 
•CEC removed
PE CCRC 
(lnM-30pM)
Wash with normal 
Krebs every 5 min.
•BMY 7378/ 5- 
MU removed
Figure 1-2. Diagrammatic representation of the receptor protection protocol 
used.
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Three distinct experiments were perfonned using the receptor protection protocol.
i. The effect of lOpM CEC and the protective effect of lOnM BMY 7378 on lOpM 
CEC treated tissues.
ii. The effect of IpM CEC and the protective effect of lOnM BMY 7378 on IpM 
CEC treated tissues.
iii. The effect of IpM CEC and the protective effect of lOnM 5-MU on IpM CEC 
treated tissues.
For each protocol four treatments were considered.
A. Control: no antagonist exposure.
B. BMY 7378/ 5-MU post-removal control: BMY 7378/ 5-MU incubated and 
washed away to ensure blockade with these antagonists was reversible.
C. CEC treated post-removal: CEC treatment alone with no other antagonists 
present.
D. CEC treated, BMY 7378/ 5-MU protected post-removal: CEC treatment in baths 
where BMY 7378 or 5-MU was present in order to protect the aio-AR and the 
aiA-AR response respectively.
Protocol used: Chapter 3
Synergy studies were conducted in the WT by constmcting CCRCs to PE (liiM-30pM) 
and then constmcting a second PE CCRC in either control aortic rings or 5-HT treated 
rings (either lOnM or 30nM). Similarly 5-HT CCRCs (lnM-3pM) were constructed, 
then second CCRCs in the absence and presence of lOnM or 30nM PE were 
constmcted. Synergist doses were added 10-minutes prior to the constmction of the 
CCRC. Where the synergist treatment resulted in a contractile response, the magnitude 
o f the CCRC was measured from this elevated baseline
The ai-AR-mediated actions of 5-HT (InM to 3pM) in the WT were examined by 
testing 5-HT sensitivity to InM, lOnM & lOOnM prazosin and BMY 7378. 5-HT 
responses in the aio-KO were tested against prazosin (control, +liiM  prazosin, +lGnM 
prazosin & +lCOnM prazosin). For consistency, antagonist effects were tested on the 
first CCRC as initial experiments in the aio-KO showed a tendency for desensitisation, 
when a second CCRC to 5-HT was constmcted (data not shown).
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Serotonergic responses were subtyped by constructing CCRCs to 5-HT (InM to 3pM) 
and BRL 54443, 5-HT2a receptor agonist (InM  to 30pM). The effects of a selective 
concentration of ritanserin (lOnM; 5-HT2a receptor antagonist) on the 5-HT and BRL 
54443 responses were investigated in both the WT and the aio-KO. The effects of 
lOnM ritanserin on lOpM PE and lOOnM U46619 responses were also tested, in order 
to confirm selectivity of blockade.
Protocol used: Chapter 4
In this set of experiments lOOpM Nm-nitro-L-arginine methyl ester (L-NAME) was 
added to randomly selected baths for a further 40 min. before any agonist challenges 
were made (prior to the ‘wake-up’ protocol. Tissue viability was then tested as before 
(KCl, PE, ACh and 5-HT responses in the absence and presence of lOOpM L-NAME).
CCRCs were then constructed for either PE (lnM-30pM for WT and aie-KO; lOOnM- 
300pM for aiD-KO) or 5-HT (liiM-3pM) in the absence and presence of lOOpM L- 
NAME.
The involvement of (%2-ARs in the PE mediated response was investigated by testing the 
effects of 30nM rauwolscine on the PE response in both L-NAME treated and non­
treated WT aortae (PE curves: lnM-30pM).
Equilibration periods
A 30 min. equilibration period was allowed between single agonist challenges or 
successive CCRCs. With the exception of the receptor protection protocol (See previous 
Chapter 2 section and Chapter 2- Introduction), antagonists were allowed 40 min. 
incubation before the CCRCs were constmcted. Washouts using PSS were repeated 
every 5 min. until the initial baseline was re-established. Responses recorded were the 
isometric forces generated by the tissues and were expressed in grams.
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Data recording, graphing and statistics
Responses were recorded either mechanically on a Linseis L6514-11 4-channel pen 
recorder or digitally via an ADI Powerlab 4/20 analogue-digital converter linked to a 
PC mnning the data capture software, Charf^’^ . Calibration of the equipment, using a 
1.0 gram force, was done regularly and little change in sensitivity of the equipment was 
observed.
Using Graphpad Prism, data from replicate experiments were grouped and the mean, 
standard deviation, standard en*or of the mean (S.E.M.) and 95% confidence intervals 
for responses at individual x-values were calculated. For nonnalised data, data was first 
normalised and then statistical operations were performed. Graphs were then 
constructed using the mean values and with the S.E.M values used to add in the error 
bars.
Graphpad Prism was also used in order to mathematically fit sigmoidal-curves to the 
mean data using non-linear regression. The equation for the fit is shown in Fig 1-3.
Y = Bottom + (Top-Bottom)
1
Fig 1-3. The ‘four parameter logistic equation’ used by Graphpad Prism 
in order to perfomi a nonlinear regression, where X is the logarithm of 
the concentration of drug and Y is the response which starts at the bottom 
and rises to the top in a sigmoidal shape.
The non-linear regression returns EC50 values, Hill slopes and the errors of estimation 
for both. However only the Hill slopes were recorded, but not used for statistical 
analysis. The error values generated by this method were the error of the estimation of 
fit of the non-linear regression and not necessarily the geometric mean of the data 
spread. Therefore the Hill slopes were not statistically compared. However, it was 
deemed appropriate to calculate the geometric mean of the EC50 values of individual 
curves so that statistical analysis could be reliably perfomied.
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pECso values were estimated by first normalising responses (y) of individual curves to 
their own maximum and expressing them as a percentage of maximum. pECso’s could 
then be calculated for individual experiments by returning the solution for the equation 
shown in figure 1-4. The equation describes a straight line intercept equation using the % 
and y  values both immediately below (xj, y /) and immediately above (x2 , y 2) the y  = 
50%.
pECSO  = _ ( £ i ( Z iz Z ) ± i lT z Z l l )  
(Tz -Ti)
Fig 1-4. The straight line equation used to calculate pECso values, hi 
order to calculate the pECso, Y was substituted with ’50’ and the pEQo 
was returned on solving the equation. Where pEQg values are shown, Y 
was replaced in the equation with ‘25’.
Individual values for the maximal responses (Emax) and the pECso or pEC%5 values were 
grouped and entered into Graphpad Prism. Statistical comparisons were done using 
either Student’s t-test (unpaired) or a one-way-ANOVA with Bonferroni’s multiple 
comparisons test. CCRCs were compared using a two-way-ANOVA with a Bonferroni 
post-test. A ‘p ’ value less than 0.05 was taken to be statistically significant. Where no 
statistical significance was obseiwed, it is clearly stated.
Graphs are shown throughout with the Y-axis units in grams, percentage of the 
maximum response (nonnalised to own cuiwe maximum; % max) or percentage of the 
wake-up maximum (normalised to maximum response of single agonist challenge 
during wake-up protocol; % wake-up max) where appropriate. Tables tliroughout 
display the mean ± S.E.M except where Hill slopes are shown, in which case the mean 
is shown with the 95% confidence interval shown in parenthesis. The number (total 
number of animals) for each set of experiments is also given throughout.
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Solutions used
PSS composition (in mM): 119 NaCl, 4.7 KCl, 1.2 MgS04 .H20 , 1.2 KÏÏ2PO4, 24.9 
NaHCOs, 2.5 CaCB, and 11.1 glucose.
125mM K^ PSS composition (in mM): 125 KCl, 1.2 MgS04 .H20 , 1.2 KH2PO4, 24.9 
NaHCOs, 2.5 CaCB, and 11.1 glucose.
Drugs used
All dmgs used were of analytical grade and purchased from SIGMA"^^ (unless 
otherwise stated). The following stock solutions were made from crystalline form using 
de-ionised H2O (unless otherwise stated). All further dilutions were made in de-ionised 
H2O.
Agonists:
• 5-HT, 5-hydroxytryptamine (3-[2-Aminoethyl]-5-hydroxyindole): lOmM
. A61603 (N-[5-(4,5-Dihydro-lH-imidazol~2~yl)-2-hydroxy-5,6,7,8-
tetrahydronaphthalen~l-yl]^^^hanesulfonamide)- purchased from TOCRIS™: 
lOOmM
• ACh {Acetylcholine): lOmWL
BRL 54443 (3-(l-Methylpiperidin-4-yl)-^E-indol-5-ol): lOmM
• PE, phenylephrine {(R)-(-)-l-(3-Hydroxyphenyl)-2-methylaminoethanol)\ lOOinM
• U46619 (9,11-Dideoxy-l 1 a, 9a-epoxymethanoprostaglandin F 2a)~ purchased from 
CALBIOCHEMT'^: liquid fonn made to linM in ethanol
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Antagonists:
5-MU, 5-methylurapidil {5-Methyl-6[[3-[4-(2-methoxyphenyl)-l-piperazinyl]~
propyl]amino]-1,3-dimethyluracil)'. lOOpM
BMY 7378 {8-[2~[4-(2-Methoxyphenyl)-l-piperazinyl]ethyl]-8-
azaspiro[4,5]decane- 7,9-dione) : ImM
• CEC, chloroethylclonidine {2-[2,6-Dichloro(N-(3-chloroethyl-N-methyl)~4- 
aminomethyl]phenylimino-2-imidazolidine) : lOOmM
L-NAME, (Na-Nitro-L-arginine methyl ester): lOOmM
• Prazosin (J-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2- 
furanylcarbonyl)piperazine): ImM
. Rauwolscine {17a-Hydroxy~20a-yohimban-16l3-carboxylic acid methyl ester): 
lOOpM
Ritanserin (6-[2-[4-(bis(4-Fluorophenyl)methylene]-1 -piperidinyl]ethyl]-7- 
methyl-5H-thiazolo[3,2-a]pyrimidin-5-one): ImM in dimethylsulfoxide
Note: Due to the photosensitive nature of BRL 54443, care was taken during 
preparation and use to minimise exposure to light.
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Chapter 1. Contractile responses of the mouse 
aorta: Effect of age and ai-AR knockout.
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Introduction- Chapter 1
Cardiovascular studies in mice
Murine models are increasingly being used in cardiovascular studies, primarily due to 
the numerous functional knockouts, over-expresse and transgenic mice that are now 
available. Recently, Russell & Watts (2000) published an extensive agonist profile of 
the “Vascular reactivity of the isolated thoracic aorta of the C57/BL/6J mouse.” Perhaps 
suiprisingly, such a study had previously not been performed and a useful reference of 
the specific activity of the mouse aorta to various vasoactive agents was provided. Both 
NE and phenylephrine (PE) were shown to be potent agonists, indicating that the mouse 
aorta had a significant apA R  mediated contractile response, hi addition, it was 
observed that the aorta exhibited both a high degree of sensitivity and a substantial 
contractile response to 5-HT.
arAdrenoceptors in the mouse aorta
Yamamoto & Koike (2001), pharmacologically characterised the adrenergic response of 
the mouse aorta, and suggested that the aio-AR is the major vasoconstrictor and the 
aiB-AR has a minor vasoconstrictor role. The use of genetically altered mice has 
confirmed this, as Tanoue et a l (2000) demonstrated the am-KO mouse aorta was 
approximately 50-fold and 40-fold less sensitive than the WT for NE and PE 
respectively. The ability o f BMY 7378 (aio-AR selective antagonist) to competitively 
block the NE response in WT aorta was absent in the am-KO aorta.
Cavalli et a l (1997) used the am-KO mouse and observed a significantly reduced 
contraction in the mouse aorta, to about 75% of that observed in the WT, and suggested 
that the am-AR plays an important role in contraction of the aorta. However, Daly et al 
(2002) performed a detailed pharmacological study of four arteries from WT and am- 
KO mice, namely the aorta, carotid artery, caudal (tail) artery and, 1st-order mesenteric 
artery. The authors concluded there that there was no significant role for the am-AR in 
contractile responses as none of the four arteries studied had significantly reduced 
responses to PE. Some of the data provided in this chapter was included in the 
publication by Daly et a l (2002).
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The use of transgenic mice has proved extremely useful in subtyping responses but 
detailed pharmacological analysis is still required. It is unknown if and what 
compensatory changes may take place where an important functional receptor is lost. 
Compensatory changes may also be affected by the age of the mice used in the study. 
Indeed, Deighan & McGrath (2002) previously demonstrated that expression of hepatic 
apA Rs was affected by age in am-KO mice.
The effect o f age on vasculature
The effect of senescence on vascular stmcture and function is of particular interest as 
advanced age is associated with an increased likelihood of the onset of various 
cardiovascular diseases. Many studies of age-related vascular changes in stmcture and 
function have been perfonned in numerous vessel preparations from several species 
(reviewed by Docherty, 1990; Marin, 1995; and Marin et a l,  1999).
In general ageing is associated with an increased vascular stiffness due to an increase in 
medial thickness (Vinnani et a l, 1991) of the vessel and alterations in functional 
responses, both contractile and relaxant (see review by Docherty et a l, 1990). The 
results however are often variable, as different groups have report different findings. A 
more detailed discussion on the effects of ageing is provided in the Discussion section.
Aim o f study
The aim was to establish if there were any age-related changes in vasoconstrictor and 
vasorelaxant responses both in WT and KO mice. Both WT and am-KO and am-KO 
mice were used in order to establish the differences as a result of receptor apA R  KO 
and ensure that these differences are maintained with age. In order to do this, both 4- 
month-old and 16-month-old mice were studied and cumulative concentration curves to 
PE constructed.
In order to ensure the loss of functional an apA R  did not have an affect on overall 
contractility, the effect of 5-HT and KCl were studied as examples of receptor-mediated 
and depolarising-induced contractions respectively. Furthermore the vasorelaxant 
response to ACh was also assessed.
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Results- Chapter 1
KCl contractile responses
Contractile responses to 125mM KCl were: 4m aiB-WT= 0.63 ± 0.03g {n = 18), 16m 
aiB-WT = 0.79 ± 0.04g {n = 12), 4m am-KO = 0.68 ± 0.06g (n = 13), 16m am-KO = 
0.90 ± 0.06g (n = 7), 4m am-W T were 0.77 ± 0.06g (n = 5), 16m am-W T 0.75 ± 0.04g 
(n = 12), 4m am-KO = 0.66 ± 0,03g {n = 36) and 16m am-KO = 0.67 ± 0.03g (n = 12). 
These results are shown in graphical form in Figure 1-1 and tabulated in Table 1-1.
KCl contractile responses: Effect o f age
The 16m am-WT KCl-indueed response was 25% greater than the 4m am-WT 
responses (p<0.05). Similarly, the 16m am-KO KCl maximum response was 33% 
greater than the 4m am-KO KCl response (p<0.05). However, 4m am-WT mice had a 
similar magnitude of response as the 16m am-WT, and the am-KO was not 
significantly different at 4m or 16m age-points (one-way-ANOVA, Bonferroni post­
test).
KCl contractile responses: Effect o f adrenoceptor-lmockout
The loss of the am-AR (am-KO) had no effect on the 125mM induced contractions at 
the 4m age-point or at the 16m age-point. Likewise the lack of functional am-ARs 
(am-KO) did not affect the response to KCl in 4m mice or in 16m mice. The am-WT 
and am-WT were not significantly different in their contractile responses to KCl at 
either age point. Generally, 125mM ILCl-induced contractile responses were consistent 
and not affected by the loss of a functional apA R or by the mouse strain (one-way- 
ANOVA, Bonferroni post-test).
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Acetylcholine-mediated relaxant responses
The relaxant responses to ACh in the various groups were: 4m am-WT = 51.3 ± 2.6% 
decrease in tone {n = 18), 16m am-WT = 55.2 ± 4.4% {n = 12), 4m am-KO = 61.2 ± 
4.6% {n — 13), 16m am-KO = 37.6 ± 6.1% {n = 7), 4m am-W T = 63.1 ± 6.1% {n = 5), 
16m am-WT = 54.1 ± 2.6% {n = 12), 4m am-KO = 72.6 ± 4.6% {n = 36) and 16m am - 
KO = 57.5 ± 5.4% {n = 12). These results are shown in graphical fomi in Figure 1-2 and 
tabulated in Table 1-2.
Acetylcholine-mediated relaxant responses: Effect o f age
There was no significant difference in ACh-induced relaxations between the 4m am- 
WT and 16m am-WT. The ACh relaxant response responses of 16m am-KO aortae 
were 38% less than 4m am-KO relaxant responses (p<0.01). The 16m am-WT had 
similar responses to their 4m am-WT, whilst the 16m am-KO had a 21% reduced 
relaxant response compared to the 4m am-KO (p<0.05: one-way-ANOVA, Bonferroni 
post-test).
Acetylcholine-mediated relaxant responses: Effect o f adrenoceptor- 
lmockout
The am-WT and am-KO had similar relaxant response at 4m and at 16m. The am-KO 
was not significantly different from its WT counteipart at 4m or at 16m age-points. The 
two WT strains exhibited similar relaxations to ACh at both age points. No significant 
differences in ACh relaxations as a result of age or strain differences were observed 
(one-way-ANOVA, Bonfenoni post-test).
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Adrenergic and serotonergic responses o f  the aig-WT
PE-induced contractile responses of the am-WT had the following maxima: 4m = 0.74 
± 0.05g (n == 18) and 16m = 0.89 ± 0.04g {n = 12). Sensitivity (pECso) was: 4m = 6.33 T 
0.07 and 16m = 6.34 ± 0.08, whilst the Hill slopes were: 4m = 0.60 {95% Confidence 
Interval: 0.49 -0.74) and 16m = 0.54 (0.44-0.63). The Hill slopes did not overlap with 
unity (1.0) at either age-point.
am-WT serotonergic (5-HT) contractile Emax values were: 4m = 1.27 ± 0.15g (n = 15), 
16m = 1.28 ± 0.07g (n = \ 1). The pECso values were: 4m = 6.91 ± 0.04 and 16m = 6.78 
± 0.05 and the Hill slopes were: 4m = 1.12 (0.96-1.28) and 16m = 1.02 (0.87-1.74). The 
Hill slopes overlapped with unity.
The response curves for PE and 5-HT of the am-WT are shown in Figure 1-3 and the 
values shown above are tabulated in Table 1-3.
Adrenergic and serotonergic responses o f the Œjb-KO
am-KO adrenergic contractile responses were: Emax- 4m = 0.97 ± 0.19 (n = 16) and 16m 
= 1.03 ± 0.06 (n = 12); pECso- 4m = 6.73 ± 0.08 and 16m = 6.62 ± 0.09; Hill slopes- 4m 
= 0.61 (0.49-0.72) and 16m = 0.53 (0.38-0.68). The Hill slopes did not overlap with 
unity at either age-point.
am-KO serotonergic contractile responses were: Emax- 4m = 1.36 ± 0.17 (« = 13) and 
16m = 1.35 ± 0.09 (n = 11); pECso- 4m = 7.01 ± 0.12 and 16m = 6.89 ± 0.08; Hill 
slopes- 4m = 1.03 (0.93-1.13) and 16m = 0.98 (0.67-1.28). The Hill slopes overlapped 
with unity.
The response curves for PE and 5-HT of the am-KO are shown in Figure 1-4 and the 
values shown above are tabulated in Table 1-4.
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Adrenergic and serotonergic responses o f  the ajD-WT
aiD-WT adrenergic contractile responses were: Emax- 4m = 0,81 ± 0.08 {n = 5) and 16m 
= 0.66 ± 0.06 {n = 7); pECso- 4m = 6.49 ± 0.07 and 16m = 6.75 ± 0.06; Hill slopes- 4m 
= 0.77 (0.63-0.91) and 16m = 0.98 (0.78-1.18). The Hill slopes did not overlap with 
unity at 4m but overlapped with unity at 16m age-points.
aiD-WT serotonergic contractile responses were: Emax- 4m = 1.27 ±0.13 (n ~ 5) and 
16m = 1.43 ± 0.09 (n = 6); pECso- 4m = 7.08 ± 0.09 and 16m = 7.02 ± 0.06; Hill slopes- 
4m = 1.39 (0.78-2.00) and 16m = 1.20 (1.14-1.26). The Hill slopes for the 4m am-WT 
overlapped with unity although the 16m am-WT which did not overlap with unity.
The response curves for PE and 5-HT of the am-WT are shown in Figure 1-5 and the 
values shown above are tabulated in Table 1-5.
Adrenergic and serotonergic responses o f the ajD-KO
am-KO adrenergic contractile responses were: Emax- 4m = 0.66 ± 0.04 (n = 36) and 
16m = 0.51 ± 0.04 (n = 12); pECso- 4m = 4.97 ± 0.04 and 16m = 5.11 ± 0.07; Hill 
slopes- 4m = 0.81 (0.59-1.04) and 16m = 0.95 (0.69-1.21). The Hill slopes overlapped 
with unity.
am-KO serotonergic contractile responses were: Emax- 4m = 1.15 ± 0.11 (n = 16) and 
16m = 1.24 ± 0.07 (n = 11); pECso- 4m = 7.18 ± 0.06 and 16m = 7.00 ± 0.08; Hill 
slopes- 4m = 1.56 (1.21-1.91) and 16m = 1.70 (1.43-1.97). The Hill slopes overlapped 
with unity.
The response cuiwes for PE and 5-HT of the am-KO are shown in Figure 1-6 and the 
values shown above are tabulated in Table 1-6.
41
Adrenergic and serotonergic responses: Effect o f  Age
No significant change in adrenergic responses between the 4in age point and 16m age 
points within each strain was observed. Similarly, serotonergic responses were not 
significantly different at the two age-points chosen to study (Student’s t-test). The age 
comparisons can be seen in Figures 1-3, 1-4, 1-5 and 1-6 for the am-WT, am-KO, aio- 
WT and am-KO respectively.
Serotonergic responses: Effect o f adrenoceptor-lmockout
The loss of the am-AR did not alter serotonergic responses in the am-KO as am-WT 
and am-KO were comparable in size and sensitivity at both 4m and 16m (one-way- 
ANOVA, Bonferroni post-test). Similarly, serotonergic responses were unaltered by a 
lack of functional am-ARs as the am-KO and its WT counterpart, the am-WT, had 
similar contractile responses at both age points (one-way-ANOVA, Bonferroni post­
test).
The serotonergic responses of the am-WT, am-KO, am-WT and am-KO at the 4m age 
point are shown in Figure 1-7 and the values for Emax, pECso and Hill slopes are 
tabulated in Table 1-7. 5-HT responses of the am-WT, am-KO, am-WT and am-KO at 
the 16m age point are shown in Figure 1-8 and the values for Emax, pECso and Hill 
slopes are tabulated in Table 1-8.
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Adrenergic responses: Effect o f  adrenoceptor-knockout
The 4m am-KO exhibited a 3-fold increase in sensitivity compared to the 4m am-WT 
(p<0.01). However the 16m am-KO was not different from the 16m am-WT. 
Maximum responses were not significantly different in either strain (one-way-ANOVA, 
Bonferroni post-test).
The am-KO was 33-fold less sensitive at 4m (p<0.001) and 44-fold less sensitive at 
16m (p<0.001) to PE compared to the am-WT. Maximum responses of am-KO mice 
were significantly smaller than WT at both 4m (19% less: p<0.05) and 16m (23% less: 
p<0.05: one-way-ANOVA, Bonferroni post-test). The 4m am-WT had hill a Hill slope 
significantly less than unity, whilst the 16m am-WT, 4m am-KO and 16m am-KO all 
had hill slopes that were not different from unity.
The adrenergic responses of the am-WT, am-KO, am-WT and am-KO at the 4m age 
point are shown in Figure 1-9 and the values for Emax pECgo and Flill slope are 
tabulated in Table 1-9. 5-HT responses of the am-WT, am-KO, am-WT and am-KO at 
the 16m age point are shown in Figure 1-10 and the values for Emax, pECso and Hill 
slope are tabulated in Table 1-10.
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Figure 1-1. Maximum responses of 4-month-old & 16-month-old 
aiB-WT, aiB-KO, am-W T & am-KO aortae to a single 125mM 
KCl challenge.
Columns shown are the mean ± S.E.M of the generated responses 
expressed in grams (*p<0.05 against strain matched 4m aortae; 
one-way-ANOVA, Bonferroni post-test).
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Figure 1-2. Relaxant responses to 3pM ACh (PE-induced 
precontraction) of 4-month-old & 16-month-old am-WT, aia-KO, 
am-W T & a  ID-KO aortae.
Columns shown are the mean ± S.E.M and expressed as a 
percentage decrease in tone (*p<0.05 age-matched WT; one-way- 
ANOVA, Bonferroni post-test).
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Figure 1-3. Contractile responses of 4-month-old & 16-month-old 
aiB-WT aortae induced by PE (■; n =18 & # ;  n =12 for 4m and 
16m respectively) & 5-HT (A; n =15 & ▼; n =11 for 4m and 16m 
respectively).
Responses are shown both in giams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M (No statistical difference comparing 4m and 16m age 
points: two-way-ANOVA, Bonfenoni post-test).
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BEmax ( (PE
iram s)
5-HT
4m Œ1B-WT 
16m aiB"WI
0.74 + 0.05, 18 
0.89 ± 0.04, 12
pE
PE
1.27 ± 0.15, 15
1.28 + 0.07, 11
^50 5-HT
4m aiB-WT 
16m aiB-WT
6.33 ± 0.07
6.34 ± 0 .0 8
Hills
PE
6.91 ± 0.04 
6.78 ± 0.05
ilope
5-HT
4m aiB-WT 
16m aiB“WT
0.60 { 0 . 49 - 0 . 74)  
0.54 { 0 . 44 - 0 . 63 )
1.12 {0.96-128)  
1.02 { 0 . 87 - 1. 74)
Table 1-3. PE-induced & 5-HT-induced contractile responses of 4- 
month-old & 16-month-old aiB-WT aoitae.
The maximum responses generated, expressed in grams followed 
by the "n' number (A) and agonist sensitivity, expressed as a pECgo 
value (B) are shown as the mean ± S.E.M. Hill slopes (C) are 
shown as the mean with the 95% confidence intervals shown in 
parenthesis (No statistical difference comparing 4m and 16m age 
points: Student’s t-test).
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Figure 1-4. Contractile responses of 4-month-old & 16-month-old 
aiB”KO aortae induced by PE (■ ; n -16  & # ;  w =12 for 4m and 
16m respectively) & 5-HT (A; n =13 & T; n =11 for 4m and 16m 
respectively).
Responses are shown both in grams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M (No statistical difference comparing 4m and 16m age 
points: two-way-ANOVA, Bonfenoni post-test).
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Emax (C
PE
rams)
5-HT
4m aiB“KO 
16m aiB-KO
B
0.97 ± 0.09, 16 
1.03 ± 0.06, 12
pE
PE
1.36 ± 0.17, 13 
1.35 ± 0.09, 11
^50 5-HT
4m ot'iB”KO 
16m aiB-KO
c
6.73 ± 0.08 
6.62 ± 0.09
Hills
PE
7.01 ± 0.12 
6.89 ±0.08
ilope
5-HT
4m aiB-KO 
16m aiB-KO
0.61 {0.49-0.72) 
0.53 {0.38-0.68)
1.03 {0.93-1.13) 
0.98 {0.67-1.28)
Table 1-4. PE-induced & 5-HT-induced contractile responses of 4- 
month-old & 16-month-old am-KO aortae.
The maximum responses generated, expressed in grams followed 
by the ‘n’ number (A) and agonist sensitivity, expressed as a pECso 
value (B) are shown as the mean ± S.E.M. Hill slopes (C) are 
shown as the mean with the 95% confidence intervals shown in 
parenthesis (No statistical difference comparing 4m and 16m age 
points; Student’s t-test).
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Figure 1-5. Contractile responses of 4-month-old & 16-month-old 
aiD-WT aortae induced by PE (■ ; /î =5 & # ;  « =7 for 4m and 16m 
respectively) & 5-HT (A; n =5 & T; n =6 for 4m and 16m 
respectively).
Responses are shown both in gi'ams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M (No statistical difference comparing 4m and 16m age 
points; two-way-ANOVA, Bonfenoni post-test).
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Mmax (ÇPE
ram s)
5-HT
4m aiD-WT 
16m aiD“WT
B
0.81 ± 0.08, 5 
0.66 ± 0.06, 7
pE
PE
1.27 ±0.13, 5 
1.43 ±0.09, 6
^50 5-HT
4m aiD-WI 
16m aiD-WT
c
6.49 ± 0.07 
6.75 ± 0.06
Hills
PE
7.08 ± 0.09 
7.02 ±0.06
lope
5-HT
4m aiD-WT 
16m aiD-WT
0.77 (0.63-0.91) 
0.98 (0.78-1.18)
1.39 (0.78-2.00) 
1.20 (1.14-1.26)
Table 1-5. PE-induced & 5-HT-induced contractile responses of 4- 
month-old & 16-month-old aïo-W T aortae.
The maximum responses generated, expressed in giams followed 
by the number (A) and agonist sensitivity, expressed as a pECso 
value (B) are shown as the mean i  S.E.M. Hill slopes (C) are 
shown as the mean with the 95% confidence intervals shown in 
parenthesis (No statistical difference comparing 4m and 16m age 
points: Student’s t-test).
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Figure 1-6. Contractile responses of 4-month-old & 16-month-old 
aiD-KO aortae induced by PE (■ ; n =36 & # ;  n =12 for 4m and 
16m respectively) & 5-HT (A; n =16 & T; M =11 for 4m and 16m 
respectively).
Responses are shown both in gi'ams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M (No statistical difference comparing 4m and 16m age 
points: two-way-ANOV A, Bonferroni post-test).
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Emax (C
PE
rams)
5-HT
4m aiD-KO 
16m aiD"KO
B
0.66 ± 0.04, 36 
0.51 ± 0.04, 12
p E
PE
1.15 + 0.11, 16 
1.24 + 0.07, 11
^50 5-HT
4m aiD-KO 
16m aiD-KO
c
4.97 ± 0.04 
5.11 ± 0.07
Hills
PE
7.18 ±0.06 
7.00 ± 0.08
op es
5-HT
4m a-iD"KO 
16m aiD-KO
0.81 (0.59-1.04) 
0.95 (0.69-1.21)
1.56(1.21-1.91) 
1.70 (1.43-1.97)
Table 1-6. PE-induced & 5-HT-induced contractile responses o f 4- 
month-old & 16-montli-old am-KO aortae.
The maximum responses generated, expressed in giams followed 
by the TT number (A) and agonist sensitivity, expressed as a pECgo 
value (B) are shown as the mean ± S.E.M. Hill slopes (C) are 
shown as the mean with the 95% confidence intervals shown in 
parenthesis (No statistical difference comparing 4m and 16m age 
points: Student’s t-test).
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Figure 1-7. 5-HT-induced contractile responses of 4-inonth old 
aiB-WT (■; n = 15), am-KO (□; n = 13), am-W T (♦ ; M = 5) & 
aiD-KO (O; n = \6) aortae.
Responses are shown both in gi'ams (A) and normalised, expressed 
as percentage of maximum response (B ) . Data points are the mean 
± S.E.M (No statistical difference comparing appropriate WT and 
KO: two-way-AND VA, Bonferroni post-test).
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A n Emax ( g r a m s )
a iB - W T 15 1.27 ± 0 .1 5
a iB " K O 13 1.36 ± 0 .1 7
a iD - W T 5 1.27 ± 0.13
otiD “K O 16 1.15 + 0.11
B
p E C s o Hill slope
a i B - W I 6.91 ± 0 .04 1.12 (0.96-1.28)
c tiB "K O 7.01 ± 0.12 1.03 (0.93-1.13)
a i D - W I 7 .08  ± 0.09 1.39 (0.78-2.00)
OG1D-KO 7.18  ± 0 .0 6 1.56 (1.21-1.91)
Table 1-7. 5-HT-induced contractile responses of 4-month-old aiB- 
WT, aiB“KO, aiD-WT & aio-KO aortae.
The ‘/î’ number, maximum responses generated, expressed in 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis (No 
statistical difference comparing 4m and 16m age points: Student’s 
t-test: Student’s t-test).
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Figure 1-8. 5-HT-induced contractile responses of 16-month old 
aiB-WT (■ ; u = 11), am -K O  (□ ; « = 11), am -W T (♦ ;  M = 6) & 
aiD“KO (O; « = 11) aoitae.
Responses are shown both in grams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M (No statistical difference appropriate WT and KO: two- 
way-AND VA, Bonferroni post-test).
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n Emax (grams)
ocib"WT 11 1.28 ±0.07
aiB“KO 11 1.35 ±0.09
aiD"WT 6 1.43 ±0.09
Œ1D-K0 11 1.24 ±0.07
B
pECso Hill slope
aiB-WI 6.78 ± 0.05 1.02 {0.87-1.74)
aiB"KO 6.89 ± 0.08 0.98 {0.67-1.28)
a-jD'WT 7.02 ± 0.06 1.20 {1.14-1.26)
aiD"KO 7.00 ±0.08 1.70 {1.43-1.97)
Table 1-8. 5-HT-induced contractile responses of 16-month-old 
aiB-WT, aiB-KO, am-W T & am-KO aortae.
The number, maximum responses generated, expressed in 
grams (A) and agonist sensitivity, expressed as a pECgo value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis (No 
statistical difference comparing 4m and 16m age points: Student’s 
t-test: Student’s t-test).
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Figure 1-9. PE-induced contractile responses of 4-month old am- 
WT (■; 77 = 18), am-KO (□ ; n = 13), am-W T (♦ ; 77 = 5) & am - 
KO (O ;  n = 36) aortae.
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (*p<0.05, **p<0.01, ***p<0.001 appropriate WT and 
KO: two-way-ANOV A, Bonfenoni post-test).
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n Emax (grams)
aiB-WI 18 0.74 ± 0.05
aiB"KO 16 0.97 ± 0.09
aiD-WI 5 0.81 ± 0.08
aiD"KO 36 0.66 ± 0.04*
B
pECgo Hill slope
aiB-WT 6.33 ±0.07 0.60 {0.49-0.74)
aiB“KO 6.73 ± 0.08** 0.61 {0.49-0.72)
aiD“WT 6.49 ± 0.07 0.77 {0.63-0.91)
aiD"KO 4.97 ± 0.04*** 0.81 {0.59-1.04)
Figure 1-9. PE-induced contractile responses of 4-month-old aiB- 
WT, aiB-KO, am-WT & am-KO aortae.
The ‘n’ number, maximum responses generated, expressed in 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence inteiwals shown in parenthesis 
(*p<0.05, **p<0.01, "^**p<0.001: one-way-ANOV A, Bonferroni 
post-test).
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Figure 1-10. PE-induced contractile responses of 16-month old 
a,B -W T  (■ ; n = 12), am-KO (□ ; n = 12), a m -W T  (♦ ; n = 7) & 
am-KO (O', n = 12) aortae.
Responses are shown both in gi'ams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. ('^p<0.05, **p<0.01, ***p<0.001 comparing appropriate 
WT and KO: two-way-ANOV A, Bonferroni post-test).
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n Emax ( g r a m s )
a iB " W T 12 0.89 ± 0.04
a iB " K O 12 1.03 ± 0.06
a iD - W T 7 0.66 ± 0.06
a iD " K O 12 0.51 ± 0.04*
B
pECso Hill s lo p e
aiB -W T 6.34 ± 0.08 0.54 (0.44-0.63)
a iB “KO 6.62 ± 0.09 0.53 (0.38-0.68)
aiD-W T 6.75 ±0.06 0.98 (0.78-1.18)
am -K O 5.11 ± 0.07*** 0.95 (0.69-1.21)
Table 1-10. PE-induced contractile responses of 16-month-old am- 
WT, am-KO, am-WT & am-KO aortae.
The ‘n’ number, maximum responses generated, expressed in 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence inteiwals shown in parenthesis 
(*p<0.05, '*'**p<0.001: one-way-ANOV A, Bonfenoni post-test).
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Discussion- Chapter 1
Effect o f  genetic background
The use of transgenic mice necessitates the availability of genetic ally-matched controls. 
The effect of genetic background on the cardiovascular system was discussed by 
Schiager (1966), who measured the systolic blood pressure in eight different inbred 
strains of mice. Cavalli et al. (1997) created the am-KO by targeted gene dismption in 
embryonic stem cells from the SV/129 strain of mice. Stem cells were then 
microinjected into C57BL/6J blastocysts which were then transferred to pseudo­
pregnant females. Tanoue et al. (2002) took an almost identical approach in creating the 
am-KO. Thus both KOs had a mixed Sv/129 and C57B1/6J genetic background. The 
WT controls were homozygous littermates that were not carrying the dismpted mutant 
gene.
For this chapter the am-KO was compared with its WT, the am-WT and the am-KO 
was compared with its WT, the am-WT. However the results for both WTs were not 
significantly different at either 4m or at 16m in their contractile KCl, PE and 5-HT 
responses or their ACh relaxant responses. Thus in the remaining chapters, the am-WT 
and am-WT are both used as WT controls but are not distinguished from one another.
Age-related changes in vascular structure
Stmcturally, old age appears to be associated with an increase in vascular stiffness 
(Roach & Burton, 1959) which is more pronounced in large-calibre elastic vessels, such 
as the aorta, than in muscular vessels, such as the brachial artery (Van der Heijden-Spek 
et a l, 2000) . The loss of distensibility of the vasculature can be clinically measured as 
an increase in pulse-wave velocity. In general a thickening of intimal-medial layers with 
increasing age is observed (Virmani et a l, 1991), which significantly contributes to the 
increase in stiffness. However, reductions in vascular compliance may not due to 
structural changes alone.
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Age-related changes in vascular contractile responses
Age-related functional changes of contractile responses vary, dependent on the species 
and the artery studied. Furthermore, various groups studying the same vessel from the 
same species have reported dissimilar findings. For example, the effect of age on 
adrenergic responses in the rat aorta has been shown as a reduction in the potency of 
NE-induced contractility (Tuttle, 1966; Simpkins et a l, 1983). Conversely Hynes & 
Duckies (1987) have reported that there is no age related change in NE potency in the 
rat aorta. ai-adrenoceptor responses in the rabbit aorta have been shown to be 
unaffected by age (Hayashi & Toda, 1978). Furthemiore, 5-HT potency in the rat aorta 
has been reported to decrease (Docherty, 1988; Wanstall & O’Domiell, 1989) or 
increase with age (Emmick & Cohen, 1986). Hence, the effect of ageing on 
vasoconstrictor responses remains unclear in rat aorta but has not been studied in mice.
In the present study the KCl response of the am-WT and am-KO increased 
significantly with age, whereas the am-W T and am-KO did not. This was the first 
indication of a strain-dependent age related change in vascular function but no age- 
related change in the maximal response or potency of PE or 5-HT were observed. 
However, it is important to be aware of the difficulties in inteipreting changes in 
absolute maximal contractile responses.
Structural vascular changes themselves could result in alterations in function, making 
comparisons of maximum responses umeliable. It may be necessary to normalise using 
a stmctural factor such as cross-sectional area, particularly in cases where there is a 
clear alteration in structure. In the present study, no differences in passive lumen 
diameter were obseiwed both when no tension had been applied and when tension 
equivalent to l.Ogratns (9.81mN) had been applied, histead the absolute force generated 
by the vessel has been used as a comparison.
Thus the am-WT and am-KO both had an increased contractile response with age but 
comparison with the other control strain, the am-WT, revealed no significant difference 
at either age point. Such a comparison would have revealed whether the 16m am-WT 
and am-KO KCl response was greater than the am-WT or that the 4m am-WT and
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aiB-KO KCl response was less than the am-WT, so no sound conclusion could be 
made.
Importantly, the PE and 5-HT responses in all strains remained unaltered as a result of 
age, indicating that the receptor mediated contractile mechanism was independent of 
mouse age. Therefore in the mouse aorta, no significant changes with age, on receptor 
mediated contractile mechanisms are observed.
Age-related changes in vascular relaxant responses
The age-related alterations o f relaxant responses have been extensively studied. In most 
studies performed, relaxant responses of conductance vessels appear to decrease with 
age. In particular, reduced relaxation responses mediated by p-AR agonists, such as 
isoprenaline, are well documented and have been shown in the rat aorta by Simpkins et 
a l (1983). Relaxations mediated by P-AR agonists, are primarily the result of receptor 
activation of P-AR on vascular smooth muscle cells (VSMCs) which causes them to 
relax.
The role of the endothelium in ACh-induced relaxations was originally described by 
Furchgott & Zawadzki (1980). It was discovered that the ACh indirectly leads to VSMC 
relaxation by initiating the release of nitric oxide (NO) fi'om endothelial cells into 
surrounding tissue (Palmer et a l, 1987). Endothelial cells are now laiown to release a 
host of other modulating substances which are vasodilators (endothelium-derived 
hyperpolarising factor; EDHF) and vasoconstrictors (endothelin).
ACh responses, in general, are reduced with age which appears to be the result of a 
reduced ability of endothelial cells to release NO (Hongo et a l, 1988) as responses to 
nitrovasodilators are conseiwed (Tominaga et a l, 1994). Some discrepancy does exist in 
these findings as Hynes and Duckies (1987) found that aortic segments from rats 
showed an increased responsiveness to the cholinergic mimetic, methacholine.
The p-ARs response was not investigated as this was beyond the scope of this thesis, hi 
hindsight, studies of the alterations of p-AR activity could have provided useful 
infoimation about age related alterations. The present study does indicate that in control 
aortae (am-WT, am-WT), there were no significant age-related changes whilst the am-
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KO and am-KO both had a significantly reduced ACh relaxant response, the 
significance of which is discussed later. Thus, although this indicated relaxant responses 
of the mouse aorta to ACh were not age-dependent this conclusion cannot be made from 
the present study. A more detailed study would be required, perhaps constructing 
relaxant CCRCs to ACh rather than the single challenge used in the current study. 
However, in the mouse aorta it appears that endothelial cells retain their ability to 
release NO and VSMCs retain their ability to relax to NO.
The age-related reduction of the ACh-induced relaxant response of am-KO and aio-KO 
response initially indicated a clear difference in vasorelaxant responses which were 
dependent on the loss of a functional ai-AR. However, once again analysis with the 
appropriate control strains, the am-WT and am-WT, revealed no significant difference 
at either age point. Therefore, there was no indication of whether the observed changes 
were due to a loss of nonnal relaxant response at 16m in these two KOs or due to an 
greater than normal relaxant response at 4m. Therefore, no further discussion is made 
on this topic.
aj-ARs KOs: Effect on ACh relaxant responses
The relaxant responses to ACh, were not affected by the absence of functional am-ARs 
or the am-ARs. The loss of a vasoconstrictor receptor could upset the line balance of 
tone within the vessel which could be compensated by a reduction in vasodilatator 
release or activity. The am-KO was nonnotensive (Cavalli et a l, 1997) and the am-KO 
mice were moderately hypotensive (Tanoue et a l, 2002), However, the level of 
hypotension may have been less than expected due to a homeostatic reduction in 
vasodilatation. This does not appear to be the case though, as we did not observe a 
significant alteration in the relaxation responses of these vessels. Hence, no effect of a i- 
AR KO on ACh responses was observed.
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ai-ÂRs KOs: Effect on KCl and serotonergic responses
Neither the loss of the am-AR or the ccm-AR in the KO affected the KCl response. 
125mM KCl initiates contraction by causing a depolarisation of all the cells in the 
arterial wall, including endothelial cells that could release NO, but the response is 
contractile since this depolarisation is mainly VSMCs activation. Therefore 125mM 
KCl provides a good indication of overall contractile ability. The loss of am - or am - 
ARs do not affect the overall contractility demonstrating that the contractile 
mechanisms of the VSMCs in the aortae of these KOs are intact and functional.
Serotonergic responses, induced by 5-HT, were also unaltered in the am-KO and am- 
KO aorta. The responses at 4m and 16m were consistent and not different from their 
WT counterparts at both these age points. 5-HT acts mainly tlirough the 5-HT%A 
receptor in the mouse aorta (McKune & Watts, 2001) and has been shown to be a potent 
and efficacious agonist in the mouse thoracic aorta (Russell & Watts, 2000) so can 
provide a useful gauge of receptor-mediated contractility of the mouse aorta.
The 5-HT2A receptor is a membrane bound GPCR coupling to Gq/n second messengers 
and raises IP3 levels and intracellular Ca^^ (Martin, 1998). In this respect the 5-HTzA 
receptor is similar to ai-ARs which are all known to be Gq/n (Byland et al., 1998) 
coupled GPCRs (discussed in the General Introduction). Hence 5-HT2a receptors and 
ai-ARs utilise the initial trigger for their second messenger pathways, but the 
serotonergic response is unaltered in either KO. The contractile mechanism is intact and 
functional and the second messengers that the am- or am-ARs use remain functional so 
the individual KO had not affected the contractile machinery.
ai-ARs KOs: Effect on adrenergic responses
Stassen et al. (1998) compiled a detailed binding study of a ^ -A R  distribution in rats 
and the effect of chemical sympathectomy. They suggested that the a ^ -A R  is the 
‘imiervated’ functional adrenoceptor, likely to be found on arteries with a great degree 
of sympathetic innervation, such as the mesenteric arteries. Accordingly, the other two 
receptors, the am - and am-AR, tend to provide a contractile function in large calibre, 
conductance arteries. The am-AR has been shown to be the major adrenergic
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vasoconstrictor in the rat aorta (Kenny et a l,  1995; Piascik et a l, 1995; Martinez et a l,
1999).
Both NE and PE have shown to be potent agonists in the mouse aorta (Russell & Watts
2000). The major adrenergic vasoconstrictor of the mouse aorta has been characterised 
pharmacologically by Yamamoto et a l (2002) and also by using transgenic mice. 
Pharmacological studies in both the am-AR knockout mouse (Daly et a l, 2002) and 
aiD-AR knockout mouse (am-KO; Tanoue et a l, 2002) have been performed, with all 
groups agreeing that the adrenergic response was predominantly mediated by am-ARs. 
Furthermore, Daly et a l (2002) suggested that the am-AR may play a minor role in 
vasoconstriction.
The loss of functional am-ARs did not significantly alter the response in the aorta 
suggesting there is little or no involvement for am-ARs in contraction of this vessel. 
This was observed at both 4m and 16m age groups and no significant alterations with 
age occurred. Daly et a l (2002) did however suggest that the lack of aie-ARs simplifies 
the pharmacological analysis of the vasculature. In fact, Daly et a l (2002) reported the 
pAz values for prazosin increased from 9.8 in the WT to 10.6 in the am-KO and the pA2 
for BMY 7378 (am-AR selective antagonist) was increased from 8.8 (WT) to 9.3 (am- 
KO).
This obseiwed 6-fold increase and 3-fold increase in sensitivity for prazosin and BMY 
7378 respectively may be due to an increase in the number of am-ARs by a systemic 
compensatory up-regulation of am-ARs as a result of the loss of am-ARs. McBride et 
a l  (2002) reported an uncovered am-AR response in the mouse mesenteric artery of the 
am-KO. The adrenergic contractile response of C  order mesenteric arteries is mainly 
due to aiA-ARs activation (Daly et a l, 2002) but a portion of the adrenergic response 
was found to be 5-MU resistant (aiA-selective antagonist) and BMY 7378 sensitive in 
the am-KO. This BMY 7378 sensitive response was absent in the WT, suggesting that 
there is some compensation by am-ARs in am-KO mice. Even then, there was no 
significant contractile role for am-ARs in the mouse aorta.
The lack of functional am-ARs, however, resulted in an observed 40-fold less sensitive 
PE response in the am-KO (Tanoue et a l, 2002). The present findings were consistent
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with this as we obseiwed 33-fold and 44-fold reductions in potency at 4m and 16m 
respectively (All et a l, 2002). The removal of the major adrenergic subtype involved in 
vasoconstriction in the am-KO, adversely affected the response to PE confirming that 
the adrenergic response is due to am-AR activity. The reduced potency was obseiwed at 
both 4m and 16m age points so no significant alteration due to age or any gi'adual 
upregulation of the remaining ai-A R mediated was obseiwed
Thus we have confmned the am-AR is the major adrenergic vasoconstrictor in the 
mouse aorta. These findings are consistent with the general consensus in the literature. 
We have also shown there is no effect of age on functional responses of aortae fi'om the 
WTs and the KOs. Furthemiore, the loss of either the am-AR or the am-AR has not 
affected the contractile machinery of the VSMCs or their second messenger pathway.
Hill slopes o f agonist activation
Interestingly the slope of the PE responses in the am-WT and am-WT and the am-KO 
were less than unity (1.0). The adrenergic response of the am-KO to PE exhibits a slope 
which overlapped with unity. A shallow Hill slope can be indicative of more than one 
receptor subtype but can also provide some insight into either the intrinsic efficacy of 
the agonist used at the receptor or the kinetics of interaction of the receptor with second 
messengers, discussed by Kenakin (1989) in detail.
We have already discussed that the am-AR is the major adrenergic vasoconstrictor in 
the mouse aorta and the am-AR plays a minor role. The activation of two receptors 
could explain why the Hill slope was shallower than unity in both WTs. However, this 
explanation of multiple receptor activation giving arise to shallow Hill slopes, does not 
explain why the response in the am-KO was still significantly less than unity. The WT 
response is due to the activation am-ARs and am-ARs, and the response in the am-KO 
is only due to am-ARs (Daly et a l, 2002) and no involvement of aiA-ARs in the mouse 
aorta has yet been reported (Chapter 2). Thus, the response in the am-KO is only am - 
AR mediated and should then have had a Hill slope fitting unity, but this was not the 
case but it is possible to explain this.
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The law of mass action describes the relationship between agonist concentration and 
occupancy. The relationship between occupancy and response, though, is dependent on 
the intrinsic efficacy of the agonist used and the kinetics of the receptor in its ability to 
initiate molecular changes, such as a channel opening or in the case of GPCRs, the 
receptor’s ability to interact with a specific G-protein. Generally the occupancy of 
receptors by a full agonist and the response observed is a relationship that fits unity on a 
Hill slope of a log concentration response cuiwe.
Thus the shallow slope of this response is an indication of either the intrinsic efficacy of 
PE at aiD-ARs, or the transducer function of am-ARs i.e. the coupling of am-ARs to 
their second messengers via the Gq/n proteins. However to clear this up it would be 
necessary to plot agonist concentration- occupancy cui*ves and occupancy- response 
cuiwes as well as the standard log-agonist concentration-response curves, but no data on 
the occupancy of the receptor pool of ai-ARs in the mouse aorta was made.
Interestingly, although the am-KO was less sensitive to PE, the Hill slopes were not 
different from unity, suggesting that the remaining ai-AR (the am-AR: see Chapter 2) 
had different kinetics than the am-AR in its relationship of agonist concentration and 
response. Since PE is a non-selective full ai-AR agonist it appears that perhaps the am - 
AR has different kinetics, than the remaining AR(s) in the am-KO, in its coupling to its 
second messenger pathway, via the G q/n protein.
Besides this, the serotonergic response is also due to the 5 -HT2a receptor increasing IP3 , 
PKC and tyiosine kinase activity via Gq/n second messengers. However, the Hill slope 
value for this response was not significantly different from unity in most cases and 
indeed greater than unity in some cases. The serotonergic response seems to be more 
typical of a full agonist in its relationship between agonist concentration, occupancy and 
response.
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Conclusions- Chapter 1
Conclusion
In the present study there was no clear cut general increase or decrease in contractile or 
vasorelaxant responses with age. However, most of the data indicates no change in 
vasoactive responses with age but a more detailed study of the vasoconstrictor and 
vasodilator systems may provide a clearer picture.
The adrenergic, serotonergic and KCl responses of the am-KO were not significantly 
different from the WT, suggesting there is little or no role for the am-AR in contractile 
responses. However, this is complicated by the apparent compensation by am-ARs.
The am-KO mouse exhibited a significantly reduced potency to PE at both 4m and 16m 
age-points. The overall contractility of the am-KO to KCl and 5-HT was conserved 
suggesting the am-KO VSMCs retain their contractile mechanism and the second 
messenger coupling associated with the response. Hence, the reduced adrenergic 
response of the am-KO is due to the loss of the main contractile AR. Therefore, the 
am-AR is the major vasoconstrictor in the mouse aorta.
Thus, the most pertinent question in the case of the am-KO was ‘what is the remaining 
adrenergic response in the am -KO?’ This is discussed in detail in chapter two, where 
various methods were used to establish which AR response remains in the a,D -K O .
70
Chapter 2. Subtyping ai-AR mediated contractile 
responses in mouse aorta.
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Introduction- Chapter 2
The mouse aorta
Increasingly, cardiovascular studies are using murine models, no doubt due to the recent 
advances in molecular biology providing functional knockouts, over-expressed or 
transgenic models of single or multiple genes. However such studies only highlight the 
current lack of background Icnowledge of murine physiology. Recently, Russell and 
Watts (2000) provided a useful reference of the activity of various vasoactive agents in 
the mouse aorta. Observations indicated both NE and PE were potent and efficacious 
agonists.
Adrenoceptors in the mouse aorta
Yamamoto & Koike (2000) pharmacologically sub typed the adrenergic response in the 
mouse aorta using selective ligands. They reported the sensitivity (pA]) of BMY 7378 
(aiD-AR selective antagonist; Saussy et aL, 1994) was approximately 9-fold greater 
than 5-methylurapidil (5-MU: aiA-selective antagonist, Gross et a l, 1988; Schwinn et 
a l, 1995). Thus, they concluded that the aio-AR is the main adrenoceptor involved in 
NE or PE-induced vasoconstriction.
However the difficulty that can arise when using pharmacological approaches alone is 
demonstrated by the numerous studies done in the rat aorta. Using 5-MU and/or BMY 
7378, various authors have come to different conclusions about which of the ai-ARs 
subtypes are involved in vasoconstriction. The majority consensus implicated the am - 
AR (Kenny et a l, 1995; Piascik et a l, 1995; Martinez et al., 1999). However Testa et 
a l (1995) suggested the response was due to aiB-ARs, whilst Aboud et a l  (1993) 
discounted the roles of aiA- and am-ARs but did not go as far as implicating the am- 
AR. Such phaiinacological studies can be complimented by combining them with a 
transgenic approach, perhaps using functional KO models.
The use of transgenic murine models confliined the am-AR is the major vasoconstrictor 
in the mouse aorta. Tanoue et a l (2002) reported that the isolated aoitae from aio-KG 
had significantly reduced responses to NE and PE compared to WT (approximately 50-
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fold and 40-fold less sensitive for NE And PE respectively). Cavalli et al. (1997) 
initially showed a significant reduction in PE-induced contractility in the aiB-KO aortae 
but a detailed pharmacological study by Daly et al. (2002), using aie-KO mice, 
confirmed that the lack of functional ais-ARs did not have an adverse effect on AR- 
mediated contractility, concluding the am-AR is the major vasoconstrictor.
Role o f ajB-ARs in vasoconstriction
However, Yamamoto & Koike (2000), Daly et al. (2002) & Tanoue et al. (2002) did not 
completely rule out the am-AR from having a role in vasoconstriction suggesting it may 
instead have a minor role. In the aio-KO aorta there remained a residual response to PE 
(Chapter 1) that was BMY 7378 resistant (Tanoue et a l, 2002). However, no attempt 
has yet been made to establish which ai-A R subtypes are involved in the adrenergic 
response in am-KO aortae.
Such a study is compelled further by recent findings o f Deighan et a l (In Press), who 
reported an increased involvement of aiA-ARs in the carotid arteries of am-KO mice, 
whereas the aiD-AR is the main adrenergic vasoconstrictor in WT mouse carotid 
arteries. Furthermore, McBride et al (2003) has shown that mesenteric resistance 
arteries from aie-KO mice had an aiD-AR mediated component that was absent in the 
arteries taken from WT mice. Thus, an attempt to determine exactly which of the ai-AR 
subtypes modulate the adrenergic response of aio-KO aortae was made.
aj-AR subtype selective agents
5-MU (aiA-AR selective: Gross et a l,  1988; Schwinn et a l, 1995),
chloroethylclonidine (CEC- aiB-AR selective: Perez et a l, 1994) and BMY 7378 (am - 
AR selective: Saussy et a l, 1994) are currently the most commonly used subtype- 
selective antagonists used for ai-A R studies. 5-MU and BMY 7378 are fairly reliable 
subtype selective competitive antagonists with 50-fold (aiA over a ie  and am ) and 125- 
fold (am  over aiA and am ) selectivity respectively (see Table 2-14 for pKj for these 
antagonists at cloned receptors) and were used in establishing which of the a]-ARs are 
involved in vasoconstriction in the am-KO.
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Alongside this antagonist study a selective agonist was used. A61603 is reported to be 
an aiA-selective agonist. The more potent R-enantiomer has reported 163-fold and 58- 
fold affinity for cloned au-ARs over a^-A R s and aid-ARs respectively (Knepper et a l, 
1995). Therefore, the contractile responses induced by A61603 in WT, am-KO, am - 
KO and aiB-otm-KO were compared. The effect of prazosin on A61603 was also tested 
to ensure responses were ai-A R mediated.
To compliment the phaiinacological approach, the aiB-aio-AR-double-KO was also 
used. The aiB-otio-KO was the result of cross-breeding of homozygous am-KO and 
aiD-KO mice (see Methods section for greater detail).
CEC selectivity and receptor protection
CEC is an irreversible alkylating agent (Leclerc et a l, 1980), therefore, establishing 
pKb or pAa values, normally used for the analysis of the effects of competitive 
antagonists, is problematic. Although initially reported to have selectivity for am-ARs 
(Perez et a l, 1994), recent research has indicated that the selectivity of CEC is less to 
do with subtype selectivity and more to do with receptor availability at the cell 
membrane. Hirasawa et a l,  (1997) reported that CEC is a non-selective AR alkylating 
agent whose apparent selectivity is due to the different cellular distribution of apA R  
subtypes. Thus, a more complex approach in isolating individual subtypes, in particular 
the aiB-AR was required.
A more intricate approach to isolate am-ARs is receptor protection. The aim with such 
a method is to protect specific receptor types using suitable concentrations of subtype- 
selective competitive antagonists (antagonists must be competitive to ensure blockade 
can be reversed by washing away the antagonist). Treatment with an irreversible 
antagonist, such as CEC, should then only affect non-protected receptors. Such a study 
has been nicely demonstrated by Ibarra et a l (2000) who reported that the effect of 
CEC, on NE induced responses in rat aorta, could be protected against, using BMY 
7378, confirming the adrenergic response is am-AR mediated
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Aim o f  study
The aim was to pharmacologically establish which ai-AR subtype is responsible for the 
residual PE-induced response of am-KO mouse aortae. This was done by a combination 
of selective antagonist and agonist studies. To compliment this, functional responses of 
the aiB-otiD-KO aortae were also studied. Finally an attempt was made to isolate the 
aiB-AR-mediated component of the PE response in the WT mouse aorta.
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Results- Chapter 2
Consecutive PE response- curves in the ajo-KO
Emax values for consecutive CCRCs to PE in am-KO aortae were: C  curve = 0.78 ± 
0.14g (n = 6); 2”^  cuiwe = 0.87 ± 0.14g (n = 7). The maxima were not significantly 
different (Student’s t-test).
The pECso values were: cuiwe = 5.17 ± 0.13; 2"  ^ curve = 4.24 ± 0.15. The 2"  ^ curve
showed 9“fold less sensitivity than the control curve (p<0.001: Student’s t-test).
The Hill slopes were: C  curve = 0.93 (0.62-1.23)', time control = 0.57 (0.35-1.04). The 
Hill slopes overlapped with unity.
The PE responses curves are shown in Figure 2-1 and the values shown above are 
tabulated in Table 2-1.
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Effect o f  prazosin in aw-KO PE-induced responses
Emax values for PE responses (first curves) in the presence of InM, lOnM & lOOnM 
prazosin were: control = 0.78 ± 0.14g (n = 6); +lnM  prazosin = 0.53 ± 0.13g (;i = 5); 
+10nM prazosin = 0.58 ± 0.16g (n = 6); +100nM prazosin = 0.77 ± O.lOg (n = 6). No 
significant differences in maximum responses were observed (one-way-ANOVA: 
Student’s t-test).
Sensitivity of the PE responses expressed as pECso values were= 5.17 ± 0.13; +lnM  
prazosin = 4.14 ± 0.29; +10nM prazosin = 3.31 ± 0.29; +100nM prazosin = 3.11 ± 0.13. 
The InM prazosin-treated group was 11-fold less sensitive than the control (p<0.05). 
The lOnM and lOOnM prazosin-treated groups were 72-fold and 115-fold less sensitive 
than control rings, respectively (p<0.001: one-way-ANOVA: Bonferroni post-test).
Hill slopes were: control = 0.93 (0.62-1.23). The Hill slopes for +lnM, +10nM & 
lOOnM prazosin treated groups were not calculated (see Discussion). The control group 
Hill slope overlapped with unity.
A pKe value for prazosin against PE in am-KO aortae was estimated as 9.25 ± 0.26 
(pKs calculated using InM and lOnM prazosin data only: see Diseussion).
The effect of prazosin on the PE response curves in am-KO aortae is shown in Figure 
2-2 and the values shown above are tabulated in Table 2-2.
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Effect o f  5-M U in aio-KO PE-induced responses
Emax values for PE responses (first curves) in the presence of InM, lOnM, lOOnM & 
IpM 5-MU were: control = 0.94 ± 0.09g (n -  10); + I11M 5-MU == 0.90 ± O.lOg (« = 6); 
+10nM 5-MU = 1.03 ± 0.15g (/? = 7); +IOO11M 5-MU = 0.88 ± O.lOg (/? = 11); IpM 5- 
MU == 0.78 ± 0.20g {n = 7). No significant differences in maximum responses were 
obseiwed (one-way-ANOVA: Student’s t-test).
Sensitivity of the PE responses expressed as pECso values were: control = 5.34 ± 0.12; 
+lnM  5-MU = 5.51 ± 0.21; +IO11M 5-MU = 4.77 i  0.10; +100nM 5-MU = 4.48 ± 0.16; 
TlpM  5-MU = 3.81 ± 0.14. The InM 5-MU-treated group was not significantly 
different from the control. The rings treated with lOnM, lOOnM & IpM 5-MU were 4- 
fold (p<0.05), 11-fold (p<0.001) and 50-fold (p<0.001) less sensitive than the control 
PE responses respectively (one-way-ANOVA, Bonferroni post-test).
Hill slopes were: control = 0.73 {0.45-1.03)’, +lnM  5-MU = 0.54 (0.10-0.99)’, +IO11M 5- 
MU = 1.06 (0.80-1.31)’, +IOO11M 5-MU = 0.80 (0.58-1.21)’, + lpM  5-MU = 1.38 (1.03- 
1.74). The Hill slopes overlapped with unity.
A pKb value for 5-MU against PE in am-KO aortae was estimated as 7.65 ± 0,13 (pKb 
calculated using lOnM, lOOnM, IpM 5-MU data only: see Discussion).
The effect of 5-MU on the PE response curves in am-KO aortae is shown in Figure 2-3 
and the values shown above are tabulated in Table 2-3.
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PE~induced responses in WT, ais-cind ajo-KO aortae
The maximum responses to PE in WT, am-KO and am-KO aortae were: 0.74 ± 0.05 (n 
= 18), 0.97 ± 0.09 (n = 16), 0.66 ± 0.04 {n = 36) respectively. The am-KO maximum 
was 34% gi-eater than the WT (p<0.05). The am-KO Emax was 11% less than the WT 
(p<0.05: one-way-ANOVA, Bonferroni post-test).
pECso values of the PE responses: WT = 6.33 ± 0.07; am-KO = 6.73 ± 0.08; am-KO = 
4.97 ± 0.04. The am-KO and am-KO were 3-fold more sensitive (p<0.01) and 23-fold 
less sensitive (p<0.001) than the WT respectively (one-way-ANOVA, Bonferroni post­
test).
Hill slopes were: WT = 0.60 (0.49-0.74); am-KO = 0.61 (0.49-0.72); am-KO 5-MU = 
0.81 (0.59-1.04). The Hill slope for the WT and am-KO aortae did not overlap with 
unity, whilst the Hill slope of the am-KO overlapped with unity.
The PE curves for WT, am-KO and am-KO are shown in Figure 2-4 and the above 
values are tabulated in Table 2-4. The above data is taken from Figure 1-9 and Table 1- 
9 o f Chapter 1.
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A 61603-induced responses in WT, ajB-cind aw-KO aortae
The maximum responses to A61603 were: WT = 0.95 ± 0.08 (n = 6); am-KO = 1.26 ± 
0.07 (n = 8); am-KO = 0.14 ± 0.04 (n = 8). The am-KO maximum was 33% greater 
than the WT (p<0.05), but the am-KO maximum for A61603 was 85% less than the 
WT (p<0.001: one-way-ANOVA, Bonferroni post-test).
pECso values of the PE responses: WT = 6.17 ±0.10; am-KO = 6.79 ± 0.10. It was not 
possible to calculate a pECso value for the am-KO A61603 response. The A61603 
response in the am-KO was 4-fold more sensitive than the WT (p<0.01: one-way- 
ANOVA, BonfeiToni post-test).
Hill slopes were: WT = 0.38 (0.28-0.48); am-KO = 0.41 (0.23-0.61). It was not possible 
to estimate a Hill slope value for the am-KO A61603 response. The Hill slope for the 
WT and am-KO aortae did not overlap with unity.
The A61603 cuiwes for WT, aiB-KO and am-KO are shown in Figure 2-5 and the 
above values are tabulated in Table 2-5.
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Effect o f  prazosin on A 61603-induced contractions ofW T  aortae
The maximum responses to A61603, in the absence and presence of prazosin (first 
curves) and the control PE responses in WT aortae were: A61603 control = 0.95 ± 0.08 
{n — 6); +3nM prazosin = 0.92 ±0.18 (n = 6); ±30nM prazosin = 0.77 ± 0.11 (« = 6); PE 
= 0.74 ± 0.05 (n = 18). There was no significant difference in maxima (one-way- 
ANOVA, Bonferroni post-test).
pECso values of the A61603 and PE responses were: A61603 control = 6.17 ± 0.10; 
±3nM prazosin = 5.94 ± 0.13; ±30nM prazosin = 5.35 ± 0.25; PE = 6.33 ± 0.07. The 
+3nM prazosin-treated group and PE response were similar to the control A61603 
responses. The ±30nM prazosin-treated group had a 7-fold less sensitive response to 
A61603 (p<0.01: one-way-ANOVA, Bonferroni post-test).
Hill slopes were: A61603 curve = 0.38 (0.28-0.48); ±3nM prazosin = 0.35 (0.22-0.49); 
+30nM prazosin = 0.38 (0.29-0.48); PE = 0.60 (0.49-0.74). The Hill slopes for all 
groups did not overlap with unity.
A pKe value for prazosin against A61603 in WT aortae was estimated as 8.45 ± 0.07 
(pKb calculated using 30nM prazosin data only: see Discussion).
The A61603 cuiwe, the effect of prazosin on the A61603 responses and the PE 
responses in WT aortae are shown in Figure 2-6 and the above values are tabulated in 
Table 2-6.
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Effect o f  prazosin on A 61603-induced contractions o f  ajs-KO aortae
The maximum responses to A61603, in the absence and presence of prazosin (first 
cuiwes) and the control PE responses in am-KO aortae were: A61603 control = 1.26 ± 
0.07 (n = 8); +3nM prazosin = 1.13 ± 0.10 {n = 8); +30nM prazosin = 1.13 ± 0.08 (n = 
8); PE = 0.97 ± 0.09 (n ~  16). There was no significant difference in maxima (one-way- 
ANOVA, Bonfen'oni post-test).
pECso values of the A61603 and PE responses were: A61603 control = 6.79 ± 0.10; 
+3nM prazosin = 6.36± 0.21; +30nM prazosin = 5.79 ± 0.09; PE = 6.73 ± 0.08. The 
+3nM prazosin-treated group and PE response were similar to the control A61603 
responses. The +30nM prazosin-treated group was 10-fold less sensitive (p<0.001: one­
way-ANOVA, Bonferroni post-test).
Hill slopes were: A61603 cuiwe = 0.41 (0.23-0.61); +3nM prazosin = 0.40 (0.22-0.59); 
+30nM prazosin = 0.50 (0.29-0.70); PE = 0.61 (0.49-0.72). The Hill slopes for all 
groups did not overlap with unity.
A pKb value for prazosin against A61603 in am-KO aortae was estimated as 8.46 ± 
0.12 (pKb calculated using 30nM prazosin data only: see Discussion).
The A61603 cuiwe, the effect of prazosin on the A61603 responses and the PE 
responses in am-KO aortae are shown in Figure 2-7 and the above values are tabulated 
in Table 2-7.
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Effect o f  prazosin on A 61603-induced contractions o f  ajo-KO aortae
The maximum responses to A61603, in the absence and presence of prazosin (first 
curves) and the control PE responses in am-KO aortae were; A61603 control = 0T4 ± 
0.02 (n = 8); +3nM prazosin = 0.14 ± 0.04 (n = 8); +30iiM prazosin = 0.10 ± 0.03 (n = 
8); PE = 0.66 ± 0.04 (n = 36). The PE response was 371% greater than the A61603 
(p<0.001: one-way-ANOVA, Bonferroni post-test).
It was not possible to estimate pECso values for the A61603 responses. The pECso of the 
PE response was 4.97 ± 0.04.
It was not possible to estimate Hill slope values for the A61603 responses. The Hill 
slope for PE was 0.93 {0.59-1.04). The Hill slope overlapped with unity.
It was not possible to estimate a pKe for prazosin against A61603 in am-KO aortae (see 
Discussion).
The A61603 cuiwe, the effect of prazosin on the A61603 responses and the PE 
responses in am-KO aortae are shown in Figure 2-8 and the above values are tabulated 
in Table 2-8.
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Adrenergic response in the ais-ajo-KO
The maximum PE and A61603 responses in WT and am-aiD-KO were: WT PE = 0.74 
± 0.05 (n = 18); am-am-KO PE = 0.01 ± 0.01 (n = 6); WT A61603 = 0.95 ± 0.08 (n = 
6); aiB-otiD“KO A61603 = 0.04 ± 0.01 (n = 6). The PE and A61603 responses of the 
ocib“OCid-KO aortae were 99% and 96% respectively less than the WT (p<0.001 for both: 
Student’s t-test).
It was not possible to estimate pEC^o values or Hill slopes for PE and A61603-induced 
response in aiB-am-KO aortae.
The comparison of the PE and A61603 responses of the am-aiD-KO with the WT 
responses is shown in Figure 2-9 and relevant values are tabulated in Table 2-9.
Serotonergic response in the ais-ocw-KO
The maxima for the serotonergic responses in WT and am-KO were 1.27 ± 0.14 {n = 
17) and 1.31 ± 0.15 {n = 6) respectively. No significant difference was observed 
(Student’s t-test).
pECso values were: WT = 6.91 ± 0.14; am-otiD-KO = 6.83 ± 0.15. The sensitivity was 
not significantly different (Student’s t-test).
The Hill slopes were: WT =1.17 {0.95-L28); am-cciD-KG = 1.43 {Î.02-1.84). The Hill 
slopes overlapped with unity.
The comparison of the WT and am-cxio-KG serotonergic response is shown in Figure 
2.10 and the above values are tabulated in Table 2.10.
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Effect o f  lO pM CEC and the protective effect o f  lOnM BMY 7378
The Emax values were: control = 0.89 ± 0.08 {n = 23); lOnM BMY 7378 post-removal 
control = 0.83 ± 0.08 (n = 18); +10pM CEC post-removal = 0.07 ± 0.04 {n = 7); +10pM 
CEC, lOnM BMY 7378 protected post-removal = 0.13 ± 0.05 {n = 7). The controls were 
not significantly different. The lOpM CEC-treated group and the lOpM CEC, lOnM 
BMY 7378-treated group were 92% and 85% respectively less than the control 
(p<0.001 for both). The lOpM CEC-treated gioup and the lOpM CEC-treated, lOnM 
BMY 7378 protected gi'oups were not significantly different from one another (one­
way-ANOVA, BonfeiToni post-test).
The pECso values were: control = 6.73 ± 0.07; lOnM BMY 7378 control post-removal =
6.62 ± 0.07. It was not possible to estimate pECso values for the lOpM CEC-treated 
groups. The two controls were not significantly different.
The Hill slopes were: control = 0.84 {0.62-1.07); lOnM BMY 7378 control post­
removal = 0.83 {0.64-1.02). Hill slopes for the lOpM CEC-treated group and the lOpM 
CEC-treated, lOnM BMY 7378 protected gioups were not estimated. The Hill slopes 
overlapped with unity.
The protection study conducted using lOpM CEC and lOiiM BMY 7378 is shown in 
Figure 2-11 and the above values are tabulated in Table 2-11.
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Effect o f  ljuM CEC and the protective effect o f  lOnM BMY 7378
The Emax values were: control = 0.89 ± 0.08 (n = 23); lOiiM BMY 7378 control post­
removal = 0.83 ± 0.08 (n = 18); +lpM  CEC post removal = 0.49 ± 0.07 {n = 18); +lpM  
CEC, lOnM BMY 7378 protected post removal = 0.76 ± 0.10 {n = 11). The controls 
were not significantly different. The IpM CEC-treated group was 45% less sensitive 
than the control (p<0.001). The IpM CEC-treated, lOnM BMY 7378 protected group 
was not significantly different from the control but significantly larger than the IpM 
CEC-treated gioup (p<0.05: one-way-ANOVA, BonfeiToni post-test).
The pECso values were: control = 6.73 ± 0.07; lOnM BMY 7378 control post-removal =
6.62 ± 0.07; +lpM  CEC post-removal = 6.60 ± 0.07; +lpM  CEC, lOnM BMY 7378 
protected post-removal = 6.73 ± 0.09. The pEC^o values of all groups were not 
significantly different (one-way-ANOVA, Bonferroni post-test).
The Hill slopes were: control = 0.84 (0.62-1.07); lOnM BMY 7378 control = 0.83 
(0.64-1.02); +lpM  CEC post-removal = 1.11 (0.87-1.36); + lpM  CEC, lOnM BMY 
7378 protected post-removal = 0.88 (0.64-1.12). The Hill slopes overlapped with unity.
The protection study conducted using IpM CEC and lOnM BMY 7378 is shown in 
Figure 2-12 and the above values are tabulated in Table 2-12.
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Effect o f  1(âM  CEC and the protective effect o f  lOnM 5-M U
The Emax values were: control = 0.89 ± 0.08 (n = 23); lOnM 5-MU control post-removal 
= 1.03 ± 0.10 (/? = 5); + lpM  CEC post-removal = 0.49 ± 0.07 (n = 18); +lpM  CEC, 
lOnM 5-MU protected post-removal = 0.47 ± 0.14 {n = 6). The controls were not 
significantly different. The IpM CEC-treated group and the IpM CEC, lOnM 5-MU - 
protected group were 45% and 47% respectively less than the control (p<0.001 for 
both). The two IpM CEC-treated groups were not significantly different (one-way- 
ANOVA, Bonferroni post-test).
The pECso values were: control = 6.73 ± 0.07; lOnM 5-MU control post-removal = 6.95 
± 0.06; +lpM  CEC = 6.60 ± 0.07; +lpM  CEC post-removal, lOnM 5-MU protected 
post-removal = 6.90 ± 0.06. The pEC^o values of all gioups were not significantly 
different (one-way-ANOVA, Bonferroni post-test).
The Hill slopes were: control = 0.84 {0.62-1.07); lOnM 5-MU control post-removal = 
0.95 {0.52-1.38); TlpM  CEC post-removal = 1.11 (0.87-1.36); + lpM  CEC, lOnM 5- 
MU protected post-removal = 1.84 (1.04-2.62). The Hill slopes overlapped with unity.
The protection study conducted using IpM CEC and lOnM 5-MU is shown in Figure 2- 
13 and the above values are tabulated in Table 2-13.
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Figure 2-1. Comparison of consecutive PE curves constructed in 
aiD-KO mouse aorta (■  curve, /î = 6; □  2nd cui-ve, n = 7).
Responses are shown both in giams (A) and normalised, expressed 
as percentage of the maximum response of the initial curve (B). 
Data points are the mean ± S.E.M. (**p<0.01, ***p<0.001 : two- 
way-ANOVA, BonfeiToni post-test).
n Emax (g ra m s )
1®^  c u rv e 6 0 .78  ± 0.14
2nd  g ^ rv e 7 0.87  ± 0 .14
B
pECso Hill s lo p e
i s t  ( . ^ ^ 0 5.17  + 0 .13 0.93  (0.62-1.23)
2"*^  c u rv e 4 .2 4  ± 0.15*** 0.57 (0.35-1.04)
Table 2-1. Comparison of consecutive PE curves constructed in 
aiD-KO mouse aorta.
The bP number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence inteiwals shown in parenthesis. 
(**^p<0.001: Student’s t-test).
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Figure 2-2. The effect o f InM, lOnM & lOOnM prazosin on PE- 
induced contractile responses (first curves) of aio-KO aortae (■  
control, n = 6; □  InM prazosin, n = 5; A lOnM prazosin, M = 6; V 
lOOnM prazosin n = 6).
Responses are shown both in grams (A) and noiinalised, expressed 
as percentage of the maximum PE wake-up response (B). Data 
points are the mean ± S.E.M. (statistical significance not shown for 
clarity: two-way-ANOVA, Bonferroni post-test).
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n Emax ( g ra m s )
C o n tro l 6 0.78 ± 0 .1 4
+1nM  p r a z o s in 5 0.53 ± 0.13
+ 10nM  p r a z o s in 6 0.58 ± 0.16
+ 100nM  p r a z o s in 6 0.77 ± 0 .1 0
B
pECso Hill s lo p e
C o n tro l 5.17 ± 0 .1 3 0.93 (0.62-1.23)
+1nM  p r a z o s in 4.14 ± 0.29* n.c.
+10nM  p r a z o s in 3.31 ± 0.29*** n.c.
+ 100nM  p r a z o s in 3.11 ±0.13*** n.c.
Table 2-2. The effect of InM, lOnM & lOOnM prazosin on PE- 
induced contractile responses of aio-KO aortae.
The number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis. 
(n.c.: not calculated, *p<0.05, =^**p<0.001: one-way-ANOVA, 
BonfeiToni post-test).
Estimated pKg for prazosin = 9.25 ± 0.26.
(pKe calculated using InM and lOnM prazosin data only: see 
Discussion)
91
B«
I
0  <0
1 I
1.50n
1.25-
1 . 00 -
0.75-
0.50
0.25-
0 . 00-1
2■4 38 7 ■6 5
% 125- £Q.?0>
i
LUCL
0)<0c0CL
1
100 -
75-
50-
25
0
[P E ]  ( lo g  M)
•4 3 26 58 7
[P E ]  ( lo g  M)
Figure 2-3. The effect of InM, lOnM, lOOnM & IjiM 5-MU on 
PE-induced contractile responses (first curves) of aip-KO aortae 
(■  control, « = 10; □  InM 5-MU, n = 6; A  lOnM 5-MU, n = 7; V  
lOOnM 5-MU n = 11; O  IpM 5-MU, n = 7).
Responses are shown both in grams (A) and normalised, expressed 
as percentage of the maximum PE wake-up response (B). Data 
points are the mean ± S.E.M. (statistical sigirificance not shown for 
clarity: two-way-ANOVA, Bonferroni post-test).
92
n Emax ( g ra m s )
C o n tro l 10 0.94 ± 0.09
+1nM  5-MU 6 0.90 ± 0.10
+ 10nM  5-MU 7 1.03 ±0.15
+ 100nM  5-MU 11 0.88 ± 0.10
+1|j M 5-MU 7 0.78 ± 0.20
B
pECso Hill s lo p e
C o n tro l 5.34 ± 0.12 0.73 {0.45-1.03)
+1nM  5-MU 5.51 ± 0.21 0.54 {0.10-0.99)
+10nM  5-MU 4.77 ± 0.10* 1.06 {0.80-1.31)
+ 100nM  5-MU 4.48 ±0.16*** 0.80 {0.58-1.21)
+1pM  5-MU 3.81 ±0.14*** 1.36 {1.03-1.74)
Table 2-3. The effect of InM, lOnM, lOOnM & IfxM 5-MU on PE- 
induced contractile responses of am-KO aortae.
The ‘w’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis. 
(*p<0.05, *'***p<0.001: one-way-ANOVA, Bonferroni post-test).
Estimated pKg for 5-MU = 7.65 ± 0.13.
(pKe calculated using lOnM, lOOnM, IpM 5-MU data only: see 
Discussion)
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Figure 2-4. FE-induced contractile responses of WT (■ ; n = 18), 
aiB-KO (# ; n = 16) & am-KO (♦ ; n = 36) aortae.
Responses are shown both in gi'ams (A) and noiTnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (*p<0.05, **p<0.01, **"^p<0.001: two-way-ANOVA, 
Bonferroni post-test).
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A
n Emax (g ra m s )
W T 18 0.74 ± 0.05
aiB -K O 16 0.97 ± 0.09*
aiD “KO 36 0.66 ± 0.04*
B
pECso Hill s lo p e
W T 6.33 ±0.07 0.60 {0.49-0.74)
aiB"K O 6.73 ± 0.08** 0.61 {0.49-0.72)
ccm"KO 4.97 ± 0.04*** 0.81 {0.59-1.04)
Table 2-4. PE-induced contractile responses of WT, am-KO & 
am-KO aortae.
The ‘w’ number, maximum responses generated, expressed as 
gi'ams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis 
(*p<0.05, *^p<0.01, ***p<0.001: one-way-ANOVA, Bonferroni 
post-test).
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Figure 2-5. A61603-induced contractile responses of WT (□ ; « = 
6), a,B“KO (O; « = 8) & aiD-KO (O; « = 8) aortae.
Responses are shown both in gi*ains (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (statistical significance not shown in B for clarity, 
*p<0.05, *^^p<0.01, **"^p<0.001: two-way-ANOVA, Bonferroni 
post-test).
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n Emax ( g ra m s )
W T 6 0.95 ± 0.08
a iB “KO 8 1.26 ± 0.07*
ocid"KO 8 0.14 ± 0.08***
B
pECso Hill s lo p e
W T 6.17 ± 0.10 0.38 {0.28-0.48)
cciB"KO 6.79 ± 0.10** 0.41 (0.23-0.61)
aiD “KO n.c. n.c.
Table 2-5. A61603-induced contractile responses of WT, aie-KO 
& aiD“KO aortae.
The ‘n’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis (n.c. : 
not calculated, *p<0.05, **p<0.01, *= '^^p<0.001: one-way-
ANOVA, BonfeiToni post-test).
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Figure 2-6. The effect of 3nM & 30iiM prazosin on A61603- 
induced contractile responses of WT aortae (solid lines: ■  control, 
« = 6; □  +3nM prazosin, n = 6 \ 0  +30nM prazosin, % = 6). The PE 
response is also shown for comparison (dashed line: #; « = 18).
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B ) .  Data points are the mean 
± S.E.M. (statistical significance not shown for clarity: two-way- 
ANOVA, BonfeiToni post-test).
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n Emax (g ra m s )
A 6 1 6 0 3 6 0.95 ±0.08
+3nM  p r a z o s in 6 0.92 ± 0.18
+30nM  p r a z o s in 6 0.77 ± 0.11
PE 18 0.74 ± 0.05
B
pECso Hill s lo p e
A 6 1 6 0 3 6.17±0.10 0.38 {0.28-0.48)
+3nM  p r a z o s in 5.94 + 0.13 0.35 {0.22-0.49)
+ 30nM  p r a z o s in 5.35 ± 0.25** 0.38 {0.29-0.48)
P E 6.33 + 0.07 0.60 {0.49-0.74)
Table 2-6. The effect of 3iiM & 30nM prazosin on A61603- 
induced contractile responses of WT aortae. The PE response is 
also shown for comparison.
The ‘w’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis. 
(**p<0.01: one-way-ANOVA, Bonfenoni post-test).
Estimated pKe for prazosin = 8.45 ± 0.07.
(pKe calculated using 30nM prazosin data only: see Discussion)
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Figure 2-7. The effect of 3nM & 30nM prazosin on A61603- 
indiiced contractile responses of aie-KO aortae (solid lines: ■  
control, w = 8; □  +3nM prazosin, M = 8; Q +30nM prazosin, % = 8). 
The PE response is also shown for comparison (dashed line; #;% = 
16).
Responses are shown both in grams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (statistical significance not shown for clarity: two-way- 
ANOVA, Bonferroni post-test).
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A n Emax (g ra m s )
A 6 1 6 0 3 8 1.26 ±0.07
+3nM  p r a z o s in 8 1.13 ± 0.10
+30nIVI p r a z o s in 8 1.13 ± 0.08
P E 16 0.97 ± 0.09
B
pECso Hill s lo p e
A 6 1 6 0 3 6.79 ± 0.10 0.41 {0.23-0.61)
+3nM  p r a z o s in 6.36 ±0.21 0.40 {0.22-0.59)
+ 30nM  p r a z o s in 5.79 ± 0.09*** 0.50 {0.29-0.70)
P E 6.73 ± 0.08 0.61 {0.49-0.72)
Table 2-7. The effect of 3nM & 30nM prazosin on A61603- 
induced contractile responses of aie-KO aortae. The PE response is 
also shown for comparison.
The ‘n’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis. 
(^**p<0.001; one-way-ANOVA, Bonfen'oni post-test).
Estimated pKp for prazosin = 8.46± 0.12.
(pKfi calculated using 30nM prazosin data only: see Discussion)
101
Bu>
Eco
s
0Q.1
1.50-1
1.25-
1.00 -
0.75-
0.50-
0.25-
O.OQJ
4 36 510 9 8 7
*
E
%c0  a1
[ A g o n is t ]  ( lo g  M)
125n
100 -
75-
50-
25-
0
5 •4 36-10 9 8
[ A g o n i s t ]  ( lo g  M)
Figure 2-8, The effect of 3nM & 30nM prazosin on A61603- 
induced contractile responses of aïo-KO aortae (solid lines; ■  
control, ;i = 8; □  +3nM prazosin, « = 8; O +30nM prazosin, n = 8). 
The PE response is also shown for comparison (dashed line: %\n = 
36).
Responses are shown both in grams (A) and noimalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (statistical significance not shown for clarity; two-way- 
ANOVA, Bonferroni post-test).
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n Emax (g ra m s )
A 6 1 6 0 3 8 0.14 ± 0.02
+3nM  p r a z o s in 8 0.14 ± 0 .0 4
+ 30nM  p r a z o s in 8 0.10 ± 0 .0 3
P E 36 0.66 ± 0.04***
B
pECso Hill s lo p e
A 6 1 6 0 3 n.c. n.c.
+3nlVl p r a z o s in n.c. n.c.
+30nM  p r a z o s in n.c. n.c.
P E 4.97 ± 0.04 0.93 (0.59-1.04)
Table 2-8. The effect of 3nM & 30nM prazosin on A61603- 
induced contractile responses of aio-KO aortae. The PE response 
is also shown for comparison.
The ‘rt’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis. 
{n.c.\ not calculated, ***p<0.001: one-way-ANOVA, Bonferroni 
post-test).
No pKp estimated for prazosin: see Discussion.
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Figure 2-9. PE-induced (A) and A61603-induced (B) contractile 
responses of WT and aiB-ctio-KO aortae (■  WT- PE, « = 18; □  
otiB-otiD“KO, M = 6; #  WT-PE, M = 6; O aiB-am-KO- A61603, n = 
6).
Responses are shown in grams. Data points are the mean ± S.E.M. 
(*p<0.05, **p<0.01, "*"**p<G.001: two-way-ANOVA, BonfeiToni 
post-test).
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AB
n Emax ( g ra m s )
P E W T 18 0.74 ± 0.05
ccib“0Cid “K O 6 0.01 ± 0.01***
A 6 1 6 0 3 W TGtlB"(XlD"KO
6
6
pECso
0.95 ± 0.08 
0.04 ± 0.01***
Hill s lo p e
P E W TaiB"0tiD"KO
6.33 ± 0.07  
n.c.
0.60 {0.49-0.74) 
n.c.
A 6 1 6 0 3 W Ta iB “ttiD"KO
6 .1 7 ± 0 .1 0
n.c.
0.38 (0.28-0.48) 
n.c.
Table 2-9. Comparison of consecutive PE curves constmcted in 
aiD-KO mouse aorta.
The number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence inteiwals shown in parenthesis. 
{n.c. \ not calculated, ***p<0.001: Student’s t-test).
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Figure 2-10. 5-HT-induced contractile responses of WT (A; n  ^
17) &  « i B -  a i D - K O  (A; n = 6) aortae.
Responses are shown both in gi'ams (A) and normalised, expressed 
as percentage of maximum response (B), Data points are the mean 
± S.E.M. (no statistical significance: two-way-ANOVA,
BonfeiToni post-test).
106
n Emax (g ra m s )
W T 17 1 .2 7 ±  0 .14
a i B “Cx-iD"KO 6 1.31 ± 0 .15
B
p E C s o Hill s lo p e
W T 6.91 ± 0.14 1.17 {0.95-1.28)
0C lB "0tlD “K O 6 .83  ± 0 .1 5 1.43 {1.02-1.84)
Table 2-10. . 5-HT-induced contractile responses of WT & aiB- 
aiD“KO aortae.
The number, maximum responses generated, expressed as 
gi'ams (A) and agonist sensitivity, expressed as a pEC^o value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intei-vals shown in parenthesis, (no 
statistical significance; one-way-ANOVA, Bonferroni post-test).
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Figure 2-11. Receptor protection study: The effect of lOjiM CEC 
treatment and the protective effect of lOnM BMY 7378 on PE- 
induced responses of WT aortae (■  control, « = 23; A lOnM BMY 
7378 control post-removal, « = 18; O lOpM CEC treated post­
removal, « = 7; O lOpM CEC treated, -flOnM BMY 7378 
protected post-removal, n ^ l ) .
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (statistical significance not shown for clarity: two-way- 
ANOVA, Bonferroni post-test).
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n Emax ( g ra m s )
C o n tro l 23 0.89 ± 0.08
+10nM  BMY c o n tr o l  p.r. 18 0.83 + 0.08
+10piM C E C  p.r. 7 0.07 ± 0.04***
+ 10 |j M C E C , + 10nM  BMY p.r. 7 0.13 ± 0.05***
B
pE C so Hill s lo p e
C o n tro l 6.73 ± 0.07 0.84 {0.62-1.07)
+10nM  BMY c o n tr o l  p.r. 6.62 ± 0.07 0.83 (0.64-1.02)
+10pM  C E C  p.r. n.c. n.c.
+10pM  C E C , +10nM  BMY p.r. n.c. n.c.
Table 2-11. Receptor protection study; The effect of lOpM CEC 
treatment, and the protective effect of lOnM BMY 7378 on PE- 
induced responses of WT aortae.
The number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence inteiwals shown in parenthesis. 
{p.r.: post-removal; n.c.\ not calculated, ***p<0.001: one-way- 
ANOVA, Bonferroni post-test).
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Figure 2-12. Receptor protection study: The effect of IpM CEC 
treatment, and the protective effect of lOnM BMY 7378 on PE- 
induced responses of WT aortae (■  control, n = 23; A  lOnM BMY 
7378 control post-removal, « = 18; □  l|iM  CEC treated post­
removal, n = 18; A IpM CEC treated, +10nM BMY 7378 
protected post-removal, 11).
Responses are shown both in grams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (statistical significance not shown for clarity: two-way- 
ANOVA, BonfeiToni post-test).
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Bn Emax (g ra m s )
C o n tro l 23 0.89 ± 0.08
+10nM  BMY c o n tr o l  p.r. 18 0.83 ± 0.08
+1pM  C E C  p.r. 18 0.49 ± 0.07***
+ 1 mM C E C , + 10nM  BMY p.r. 11 0.76 + 0.10^
pECso Hill s lo p e
C o n tro l 6.73 ± 0.07 0.84 {0.62-1.07)
+10nM  BMY c o n tr o l  p.r. 6.62 ± 0.07 0.83 (0.64-1.02)
+1pM  C E C  p.r. 6.60 ± 0.07 1.11 (0.87-1.36)
+1pM  C E C , +10nM  BMY p.r. 6.73 ± 0.09 0.88 (0.64-1.12)
Table 2-12. Receptor protection study: The effect of IpM CEC 
treatment, and the protective effect of lOnM BMY 7378 on PE- 
induced responses of WT aortae.
The ‘w’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pEC^o value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis. 
(p.r.: post-removal; ***p<0.001 against control; ^p<0.05 against 
IpM CEC treated group: one-way-ANOVA, Bonfenoni post-test).
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Figure 2-13. Receptor protection study; The effect of IpM CEC 
treatment, and the protective effect of lOnM 5-MU on PE-induced 
responses of WT aoidae (■  control, n = 23; A lOnM 5-MU control, 
/Ï = 5; □  IpM CEC treated post-removal, « = 18; V IpM CEC 
treated post-removal, +10nM 5-MU protected post-removal, n = 6).
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (statistical significance not shown for clarity: two-way- 
ANOVA, BonfeiToni post-test).
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A
n Emax (g ra m s )
C o n tro l 23 0.89 ± 0.08
+ 10nM  5-MU c o n tr o l  p.r. 5 1.03 ±0.10
+ 1 |j M C E C  p.r. 18 0.49 ± 0.07***
+1pM  C E C , + 10nM  5-MU p.r. 6 0.47 ± 0.14***
B
pECso Hill s lo p e
C o n tro l 6.73 ± 0.07 0.84 {0.62-1.07)
+10nM  5-MU c o n tr o l  p.r. 6.95 ± 0.06 0.95 {0.52-1.38)
+1gM  C E C  p.r. 6.60 ± 0.07 1.11 {0.87-1.36}
+ 1 |j M C E C , + 10nM  5-MU p.r. 6.90 ± 0.06 1.84 (1.04-2.62)
Table 2-13. Receptor protection study: The effect of IpM CEC 
treatment, and the protective effect of lOnM 5-MU on PE-induced 
responses of WT aortae.
The ‘n’ number, maximum responses generated, expressed as 
gi'ams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intei*vals shown in parenthesis. 
(p.r.\ post-removal; n.c.\ not calculated, ***p<0.001: one-way- 
ANOVA, Bonferroni post-test).
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Discussion- Chapter 2
Œj-AR in mouse aorta
The tti-AR mediated response in the mouse aorta has previously been subtyped 
pharmacologically by Yamamoto & Koike (2001). The rank order of potency of 5-MU 
is aia > aib = aid (see following Table 2-14). Conversely the rank order of potency of 
BMY 7378 is aid > a ^  = aib- Yamamoto & Koike (2001) reported an order of 
antagonist potency of BMY > 5-MU in mouse aorta with respective pA% values of 8.4 
and 7.5, implicating the aio-ARs as the major adrenergic vasoconstrictor. Daly et al. 
(2002) and Tanoue et al. (2002) also subtyped the response using functional KO 
models. Their studies confirmed that the aio-AR is the major adrenergic vasoconstrictor 
in the mouse aorta, and our data in the previous chapter supports this.
However, all these authors suggested that the aie-AR has a minor vasoconstrictor 
component in the mouse aorta. Cavalli et al. (1997) had initially shown that PE was 
significantly less sensitive in am-KO aortae. Later, Daly et al. (2002) reported that the 
aiB-KO was not significantly different from the WT in contractile responses to ai-AR 
agonists. Although the aie-AR has been implicated as having a minor role in 
vasoconstriction in mouse aorta by these authors, it had not yet been directly shown.
In contrast, Daly et al. (2002) reported a relatively high potency for 5-MU, an aiA-AR 
subtype selective antagonist (Gross et a l,  1988; Schwimi et a l ,  1995). 5-MU has an 
approximately 50-fold selectivity for cloned aia-ARs (pKj = 8.8, see following Table 2- 
14) over cloned aib-ARs and aid-ARs (pKj = 7.1 for both). Daly et al. (2002) reported 
5-MU pAz values o f 8.3 and 8.1 for WT and aiB-KO aortae respectively. These values 
suggested a possible role for aiA-ARs in function, yet Daly et al. (2000) concluded that 
there was no aiA-AR mediated response.
Furthermore, recently, Deighan et a l  (hi Press) reported an aiA-AR mediated response 
in aiD-KO mouse carotid arteries, whilst the adrenergic response in WT mouse carotid 
arteries is primarily due to aio-AR activation. Thus, the suggestion that the aiA-AR 
may be involved in the ai-A R mediated response in mouse aortae is further
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strengthened. Therefore, it was essential that the role of aiA- and am-ARs in mouse 
aorta be investigated. As such, the aio-KO mouse provided an excellent starting point.
Time Control
Before any detailed pharmacological analysis of the adrenergic PE-induced response of 
the aiD-KO could be made, it was necessary to establish if the PE responses within a 
single aortic ring were repeatable. Thus, in order to make a fair comparison, the second 
cuiwe was expressed as the percentage of the maximum of the first cuiwe. Figure 2-1 
shows that the second PE curve was significantly less sensitive.
The aim was to establish the receptor(s) involved in the residual adrenergic response in 
aiD-KO aortae, not the residual response after desensitisation in aio-KO aortae. 
Although the desensitisation of the response was intriguing and merited further 
investigation, it was not followed up as it was out with the aims for this chapter. 
However, it was now clear that the PE-induced response in aio-KO aorta was prone to 
desensitisation.
Therefore, due to this desensitisation, the construction of consecutive PE cuiwes in the 
aortic rings from am-KO mice was something to be avoided. As a result, the antagonist 
studies done in the am-KO were done by testing the effect of the antagonists on the first 
curve. The curves were nonnalised using the response of the single dose of PE during 
the wake-up as the maximal response. The sensitivity shifts of the antagonists could 
then be calculated, allowing the determination of the pKe values.
Effect o f prazosin
It was essential to establish whether PE-induced responses in aiD-KO aorta were ai-AR 
mediated or not before doing any detailed antagonist studies, therefore, the effect of 
prazosin was tested. The pKs estimate for prazosin was 9.25. This value was calculated 
using the InM and lOnM data only. Although lOOnM prazosin caused a shift, it had not 
significantly shifted the PE curve further than the shift produced by lOnM prazosin 
(Figure 2-2). Including this data would have artificially lowered the pKo value 
calculated for prazosin.
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The responses in the presence of lOnM and lOOnM prazosin are at concentrations of PE 
at and above lOOpM, bringing into question the selectivity of PE at aj-ARs at these 
concentration. Laher et a l  (1986) reported that at very high concentrations of AR 
agonists (lOOpM and higher), the responses are non-selective and do not appear to be 
susceptible to blockade by classical ai-A R antagonists.
Laher et a l  (1986) suggested that at high concentrations of aj-AR agonists the response 
was due to the presence of ‘extrareceptors’. This explains why lOOnM prazosin did not 
have a significantly greater effect than lOnM prazosin as the PE may have lost 
selectivity for ai-ARs.
Furthennore, the PE cuiwes in the aio-KO particularly in the presence of prazosin did 
not achieve a true maximum. The presence of extrareceptors (Laher et a l ,  1986) again 
explains this as at such high concentration of PE selectivity had been lost. This also 
further reinforces the rationale behind normalising the curves using the PE response 
during the wake-up as the maximmu response, as this would clearly identify a shift in 
agonist sensitivity independent of cuiwe maximum.
The control PE response in aio-KO was already significantly less sensitive than WT 
aortae and was approaching such concentrations where PE response may be due to 
activation of non-ai-ARs. lOnM prazosin pushed the cuiwe further to the right, to the 
point that lOOnM prazosin could not block the response any further. Therefore the 
1 OOnM data was not included when estimating a pKg for prazosin.
However, Table 2-14 shows a comparison of the affinities of various agonists and 
antagonists in aortic rings h'oin WT, ais-KO, am-KO and aiB-otio-KO mice. The pA] 
value for prazosin in WT and aiB-KO mice is 9.7 and 10.6 respectively (Daly et a l,  
2002). The pK,- value for prazosin at cloned at cloned aia, aib and aid receptors is 9.0 
(Mackenzie et a l,  2001).
Thus, although the pKb for prazosin (9.25) in the am-KO is about 3-fold and 30-fold 
less than in the WT and aiB-KO respectively (Daly et a l ,  2002), the pKs value is still 
consistent with the action of prazosin at ai-ARs. As there were no functional am-ARs 
in the am-KO, that prazosin could block, the adrenergic response must have been due
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to either a i a- or aie-ARs activation. The next step was an attempt to subtype the ai-AR 
mediated response of the aio-KO.
Strain PE A-61603 praz.* 5-MU
BMY
7378
CEC
sensitive Concl,
albino ddY^ 6.7^ ND^ 9 .7 \nE) 7 .5 \nE) q a \ ne) yes^ OtjD, a,o
WT 6.3 6.2 9.8= 8.3= 8.8= yes= OtiD, «ID
cC]b“K O 6.7 6.8 10.6= 8.1 = 9.2= yes= UiD
ctjo-KO 5.0 nr 9.3 (p W 7 .7 {pKb) < 7 .0 \nE) yes^ OCiB
0^1B"CtlD"KO nr nr nd nd nd nd N o U pAR s
B
BMY
ai-subtvne snecies praz* 5-MU 7378 Reference
Human 9.0 9.2 7.1 MacKenzie e( al. (2001)
Bovine 8.6 6.1 Saussy el al. (1994)
^ l a Bovine 8.5 Goetz el al. (1993)
Bovine 6.1 Goetz et al. (1995)
MEAN 9.0 8 .8 6.4
Human 9.0 7.2 6.8 MacKenzie et al. (2001)
Hamster 7.0 6.2 Saussy et al. (1994)aib Hamster 7.0 Goetz et al. (1993)
Hamster 6.2 Goetz et al. (1995)
MEAN 9.0 7.1 6.4
Human 9.0 7.9 9.3 MacKenzie e( al. (2001)
Rat 7.3 8.1 Saussy et al. (1994)
(%ld Rat 6.1 Goetz el al. (1993)
Rat 8.2 Goetz et al. (1995)
MEAN 9.0 7.1 8.5
Table 2-14. The affinities of several ai-selective agents in transgenic mice (A) and 
their appropriate affinities in cloned receptors (B). The conclusions are shown in the 
right-hand column of (A).
A. For PE and A61603, the pEC o^ values are shown. For the antagonists the pAg value 
is shown unless otherwise indicated (agonist used was PE, unless otherwise stated). 
Greyed out boxes indicate values taken from reference sources (’Yamamoto & 
Koike, 2001; ^Daly et al ,  2002; ^Tanoue et al ,  2002 demonstrated no shift at 
lOOnM BMY 7378; ^observed in initial experiments- not shown).
B . pKj values from several authors are shown. The mean pKj values for the antagonists 
at each cloned receptor have been calculated. These values are used for discussion.
(Abbreviations: prazosin*; NE -  agonist used was norepineplrrine; nr- no response; nd- not 
determined)
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Effect o f  5-M U
The estimated pKe for 5-MU was 7.65. Previously Daly et ah (2002) reported pAi 
values of 8.3 and 8.1 in WT and am-KO aortae. They concluded that the mouse aorta 
adrenergic response is aio-AR. mediated as BMY 7378 (aio-selective antagonist; 
Saussy et a l, 1994) was 3-fold and 13-fold more sensitive than 5-MU in WT and aiB- 
KO aortae respectively.
In their study of the am-KO, Tanoue et a l  (2002) reported that in aio-KO aortae, BMY 
7378 demonstrated no significant antagonism even when used at 1 OOnM, suggesting the 
PKb be gieater than 7.0 and at most, equal to 7.0. Therefore the antagonist potency in 
the aiD-KO was 5-MU > BMY 7378, indicating that aiA-ARs may be involved.
Yet, even with a pAi value o f 8.3 for 5-MU in WT mice, Daly et a l  (2002) discounted 
the role of aiA-ARs in vasoconstriction in mouse aorta, instead suggesting the response 
was mainly due to am -AR activation with a minor role for aie-ARs. Therefore the 
response subtyped in the present study is likely to be aig-AR mediated.
This hypothesis is further strengthened by the affinity for 5-MU at cloned receptors. 5- 
MU has pKi values of 8.8 and 7.1 at cloned bovine au-ARs and cloned hamster aib- 
ARs respectively (see Table 2-14). Thus the pKe estimate of 7.65 in aio-KO aortae is 
more consistent with the binding of 5-MU at aib-ARs, further reinforcing the presented 
hypothesis that the aie-AR is the adrenergic vasoconstrictor in aio-KO aortae.
It must be noted that the pKs for 5-MU was calculated with the lOnM, lOOnM and IpM  
5-MU data. No significant effect of InM 5-MU was obseiwed therefore the data was not 
included as it was not always possible to calculate a pKe.
However, the estimation of a pKe for an antagonist is dependent on competitive 
antagonism which assumes a Schild slope of unity (Arunlakshana & Schild, 1959). This 
describes a direct relationship between antagonist concentration and the blockade 
produced, i.e. a tenfold increase in antagonist concentration should result in a tenfold 
increase in blockade, which would be visualised by a tenfold shift of the log-drug 
concentration-response cui*ve.
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The 5-MU data does not fit this model though. At lOnM BMY 7378 a 4-fold decrease in 
PE sensitivity was observed, whilst a 7-fold decrease at lOOnM 5-MU and a 34-fold 
decrease in PE sensitivity at IpM  5-MU were observed. From the estimated pKg of 
7.65, the shifts should have been the following: lOnM 5-MU = no shift, lOOnM 5-MU = 
9-fold decreased PE sensitivity and IpM 5-MU = 90-fold decreased sensitivity. These 
estimations are based on the assumptions that the calculated pKe was accurate, and 
assuming the Schild slope for 5-MU fits unity and therefore the pKe = pA2, which 
results in a two-fold shift of the PE response.
Therefore, a shadow is cast over the confidence that can be placed in the pKg for 5-MU 
in aiD-KO aortae. As such, another approach taken was the use of the aiA-AR selective 
agonist, A61603 in an effort to confinn the hypothesis that the response in aiD“KO 
aortae was aie-AR mediated.
PE &A61603 responses in WT, aiB~KO and ajo-KO
A61603 is reported to be an Œia-AR agonist. Knepper et a l (1995) reported that the 
A61603 has a chiral carbon, and as such, has two enantiomers. The R-enantiomer was 
found to be the most active with an affinity of 163-fold and 58-fold selectivity for 
cloned aia-ARs over aib- and a^-A R s respectively (the discussion about A61603 
following in this section is about the R-enantiomer unless othei^wise stated). Thus, the 
affinity for A61603 for cloned receptors is a%a> aid ^  aib.
On the other hand, PE was reported to have an affinity for aid-ARs, over aib- and aia- 
ARs (6-fold and 8-fold respectively: Knepper et a l, 1995) but this selectivity is not as 
profound as the selectivity of A61603 and, therefore, is less useful for analysis.
As was discussed in the previous chapter, am-KO aortae were more sensitive to PE than 
WT aortae whilst, am-KO aortae were less sensitive (shown in Figure 2-4). This trend 
is continued with A61603, where the aig-KO was more sensitive than the WT. 
However, the aio-KG did not exhibit a notable contractile response to A61603. This 
result confirmed that there was no significant aiA-AR mediated component in the aio- 
KO, but the relatively high sensitivity of A61603 in WT and am-KO aortae was 
somewhat suiprising.
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PE and A61603 exhibited similar sensitivity in WT and aiB-KO aortae. In contrast, 
using the racemate mix of A61603 and comparing it to PE in rat aorta (vasoconstriction 
due to aiD-ARs), Knepper et a l (1995) reported the EC50 for PE was 33-fold less than 
A61603 (i.e. PE was significantly more sensitive). Therefore it was deemed necessary 
to establish if A61603 was acting only at ai-ARs.
The effect o f  prazosin on A61603 responses
A61603 is an imidazoline derivative. Classically, imidazoline derivatives have been 
associated with az-AR activation or blockade, but recent research findings indicate that 
imidazolines can elicit responses independent of a-ARs, but thiough a new category of 
receptors, imidazoline or I receptors (Reviewed by Molderings & Gother, 1999). 
Furthennore, Minyan et a l (2000) recently reported that contractile responses to 
oxymetazoline in porcine rectal arteries, were I3 receptor mediated, and not az-AR 
mediated as initially hypothesised, whilst Willems et a l (2001) reported A61603 could 
elicit vasoconstriction in porcine carotid arteries through a non-ai-AR mechanism. 
Therefore, it was essential to verify that the A61603-induced contractile responses were 
ai-A R mediated, which was done by testing the effect of prazosin.
The pKb estimates for prazosin in WT and aiB-KO aortae were 8.45 and 8.46 
respectively. Therefore the A61603 response was oci-AR mediated, but no attempt to 
phamiacologically subtype this response was made. However, the indications are that 
the A61603 response was due to ai-AR activation.
A61603 and PE had similar pECso values in WT aortae, where the response is believed 
to be aiD-AR mediated, with a minor role for aiB-ARs in vasoconstriction. In aie-KO 
aortae A61603 and PE also had similar sensitivity and efficacy. Daly et a l (2002) 
reported that the response in ocm-KO aortae is only am-AR mediated, therefore A61603 
must be activating am-ARs as no role for œia-ARs has been reported. Furthennore, 
A61603 did not elicit a significant response in am-KO aortae, confirming that the 
contractile response is aio-AR mediated, and that there were no functional a  1 a-A R s.
Knepper et a l (1995) reported that there was no detectable increase in IP3 levels when 
cells transfected with cloned aib-ARswere stimulated with the racemate mix of A61603,
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whereas the EC50 for A61603 (racemate mix) for a^-A Rs was 14.5iiM. Therefore, 
although A61603 had affinity for aib-ARs it did not have efficacy. In the present study, 
no activity of A61603 was observed in the aio-KO. Had there been functional aia-ARs 
in aiD-KO aortae A61603 should have had functional response but it did not. Therefore, 
the lack of reactivity of aio-KO aortae to A61603, indicates no role for a  1 A-ARs, 
leaving only the am-AR subtype.
Response o f the ajB-ccm-KO
The serotonergic responses in the double-KO, the aiB-ctio-AR KO, were not 
significantly different from WT serotonergic responses, confimiing the contractile 
machinery was intact and functional. However, there was a distinct lack of ai-AR 
mediated responses. Neither PE nor A61603 was able to elicit a significant response 
that could be phannacologically studied.
This evidence further supports the present hypothesis, that the adrenergic response in 
mouse aorta is am-AR mediated, with a minor role for aiB-ARs, as the lack of 
functional am-ARs does not have a significantly adverse effect. In the absence of 
functional aio-ARs the response is am-AR mediated. The lack of both am - and am - 
ARs results in a complete loss of adrenergic response.
However a few uni'esolved issues remained. The relatively high estimated pAz values 
for 5-MU in WT aortae reported by Daly et a l (2002), merited further investigation, 
whilst an attempt to evaluate the minor role of am-ARs in WT aortae was also made.
Receptor protection
No suitable am-AR antagonist is available cuiTently, so a more intricate approach was 
taken. Chloroethylclonidine (CEC) was initially reported to be an ajB-AR selective 
alkylating agent (Perez et a l, 1987). A more recent report by Hirasawa et a l (1997) 
argued that ai-ARs present on the cell membrane are preferentially alkylated, 
irrespective of ai-A R subtype. They suggested the apparent selectivity is due to the 
heterogeneous distribution of apA R s subtypes at the cellular level.
1 2 1
However, the irreversible nature of CEC was useful in the receptor protection protocol 
used. By pre-incubating the tissue with a subtype-selective surmountable antagonist, 
before CEC treatment and then removing CEC and then the competitive antagonist, the 
assumption is that the only response remaining was subtype protected by the 
competitive antagonist used. Such a receptor protection teclmique has successfully been 
used previously by IbaiTa et a l (2000) to demonstrate that am-ARs are the major 
adrenergic vasoconstrictors in mouse aorta.
In the present study, it was necessary to ensure that the competitive antagonists used 
could be washed away without adverse effects on contractility. Figures 2-11 and 2-12 
show that lOnM BMY 7378 could be successfully washed away, so that the response 
was not significantly affected. Similarly, when lOnM 5-MU was used it could also be 
washed away (Figure 2-13). Thus, the antagonism of these two ligands is reversible by 
removal of the antagonist from the baths.
The next aim was to establish a suitable concentration of CEC required for the study. 
1 OpM CEC almost completely ablated the PE response. However, 1 pM CEC treatment 
halved the maximal PE response. CEC treatment was able to decrease the efficacy of PE 
in mouse aorta in a concentration-dependent mamier.
Normalising the responses revealed there was no significant difference in sensitivity 
when treated with CEC, consistent with the effects of a classical insurmountable 
antagonist. CEC alkylation decreased the total number of receptors available without 
affecting the affinity of PE. The pECso is a measure of the affinity of the agonist, not of 
the efficacy, and was unchanged.
lOnM BMY 7378 was unable to protect any of the response, when the tissue was treated 
with lOpM CEC indicating the concentration of CEC was too high. This result also 
further highlighted the non-selective nature of CEC. In contrast, IpM CEC reduced the 
response by about 50%. Pre-incubation with lOnM BMY 7378 was able to protect the 
response, such that the entire response was maintained, and no effect of CEC treatment 
was observed. Therefore the effect of CEC observed at both IpM and lOpM was due to 
aiD-AR alkylation. The concentration of BMY 7378 was selectively chosen so as not to 
have an effect at either aiA- or aiB-ARs. Since lOnM BMY 7378 was able to protect the 
entire response from IpM CEC treatment, no significant role for aie-ARs was detected.
1 2 2
lOnM 5-MU was unable to protect any of the response from IpM CEC treatment, 
confirming the original hypothesis that there were no aiA-ARs in the mouse aorta. 
However, this result still does not explain the relatively high affinity of 5-MU in WT 
mouse aorta reported by Daly et a l (2002).
This new evidence, from the receptor protection study, compels a revision of the 
previous hypothesis that am-ARs have a minor role in vasoconstriction. The indications 
are that neither the aiA- nor aiB-ARs are involved in contraction of WT mouse aorta. 
Thus the ajo-AR is the sole adrenergic vasoconstrictor in WT mouse aorta. However, in 
the absence of am-ARs, the am-AR is the adrenergic vasoconstrictor.
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Conclusion- Chapter 2
Conclusion
A61603 is a potent and efficacious agonist at am-ARs, bringing into question its 
usefulness as an aiA-AR selective agonist. It has no significant am-AR activity.
No aiA-AR mediated contractile response has been detected in any of the studies 
perfonned.
From this data presented in this study, it is clear that there is no significant role for aiA- 
or am-ARs in WT mouse aorta. A lack of functional am-ARs did not affect the 
response. A lack o f am-ARs in am-KO aortae, uncovered an am-AR mediated 
response which has not been detected in the WT.
The lack o f both am- and am-ARs in the am-otm-KO resulted in no functional 
adrenergic responses, whilst the serotonergic responses remained unaltered confinning 
that the contractile machinery was functional.
Thus, the adrenergic response in WT mouse aorta is only am-AR mediated, with no 
significant contractile role for am - or am-ARs.
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Chapter 3. Adrenergic and serotonergic synergy 
in the mouse aorta.
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Introduction- Chapter 3
Serotonergic and adrenergic synergism
The vasoactive nature of serotonin and its synergistic interactions have been studied 
extensively (reviewed by Yildiz et a l, 1998). The effect of co-activation of the 
serotonergic and adrenergic vasoconstrictor systems was originally discussed by de la 
Lande et a l (1966) who demonstrated a functional interaction between 5- 
hydroxytryptamine (5-HT) and norepineplnine (NE). In particular, oc]-adrenergic and 
serotonergic contractile synergy has been described in several vascular preparations, 
such as the rabbit aorta (Stupecky et a l, 1986), rabbit femoral artery, (Chen et a l, 
2000), rat aorta (Clirist and Jean-Jacques, 1990) and the rat caudal artery (Van Nueten et 
a l, 1981).
5-HT and aradrenoceptors
It has previously been reported by Purdy et a l (1987) that 5-HT-induced responses in 
the rabbit aorta are due to the partial involvement of ai-adrenoceptors (ai-ARs). 
Recently, Shaw et a l (2000) established concentration-dependent prazosin blockade of 
5-HT responses in rat pulmonary arteries, estimating a pKs of 10.2, consistent with the 
sensitivity of prazosin at ai-ARs.
However, such studies, perhaps due to a lack of suitably selective ligands, have not 
ascertained which of the ai-A R subtypes are involved in the adrenoceptor mediated 
response of 5-HT. Commonly used ai-A R ligands such as the am-AR antagonist, 5- 
methylurapidil (5-MU: Gross et a l, 1988, Schwinn et a l, 1995) and the am-AR 
antagonist, BMY 7378 (Saussy et at., 1994) are known to be 5-HTm partial agonists 
(Gross et a l, 1987 and Yocca et a l, 1987 for 5-MU and BMY 7378 respectively). 
Therefore results obtained using these ligands could be ambiguous. On a similar note, 
kitanserin, a widely used 5-HT% receptor antagonist has been shown to have a high 
affinity for ai-ARs (Van Neuten et a l, 1981).
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The mouse aorta
Murine models are increasingly being used in cardiovascular studies, primarily due to 
the numerous functional knockouts, overexpressing and transgenic mice that are now 
available. Recently, Russell & Watts (2000) demonstrated an extensive agonist profile 
of the “Vascular reactivity of the isolated thoracic aorta of the C57/BL/6J mouse.” It 
was observed that the aorta exhibited both a high degree of sensitivity and a substantial 
contractile response to 5-HT. McKune & Watts (2001) subtyped this response, 
concluding the serotonergic response of the mouse aorta was primarily the result of 5- 
HT2A receptor activation.
In addition, both NE and phenylephiine (PE) were shown to be potent agonists, 
indicating that the mouse aorta had a significant ai-A R mediated contractile response. 
The major adrenergic vasoconstrictor of the mouse aorta has been characterised 
phamiacologically by Yamamoto et a l (2002) and also by using transgenic mice. 
Pharmacological studies in both the am-AR knockout mouse (Daly et a l, 2002) and 
aiD-AR knockout mouse (am-KO; Tanoue et a l,  2002) have been perfonned, with all 
groups agreeing that the adrenergic response was predominantly mediated by am-ARs.
Hence, studying synergy and the AR-mediated response of 5-HT in the mouse aorta 
using both traditional phamracological teclmiques and transgenic mice may provide 
useful insights into the roles and interactions of the serotonergic and ai-adrenergic 
vasoconstrictor systems.
Aim o f study
Initially, an attempt was made to uncover any functional interactions between the 
serotonergic and adrenergic vasoconstrictors in the mouse aorta. The activation of ARs 
by 5-HT in the mouse aorta was then studied in detail by sub typing the ai-AR 
component of the 5-HT-mediated response, employing a combination of selective 
pharmacological agents and transgenic am-KO mice. Finally, the 5-HT receptor 
subtypes involved in the 5-HT responses of both the WT and am-KO mice were 
established.
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Results- Chapter 3
Effect o f  5-HT on PE-induced contractions o f  WT aortae
lOnM 5-HT caused a response of 0.04 ± 0.03g {n = 6) whilst 30nM 5-HT resulted in a 
response of 0.14 ± 0.02g (n = 7).
Emax values for PE-induced contractile responses in the presence and absence of 5-HT 
were: cui"ve = 0.85 ± 0.04g (n = 13); time control = 0.97 ± 0.06g {n = 12); +10nM 5-
HT = 1.01 ± 0.12g (n = 6); +30nM 5-HT = 1.01 ± 0.07g {n = 7). None of the groups 
were significantly different fi'om the time control in maximum responses (one-way- 
ANOVA, Bonferroni post-test).
The sensitivities of the PE responses were:
pEC25 values- cuiwe = 6.98 ± 0.06; time control = 7.18 ± 0.12; +10nM 5-HT = 7.07 ± 
0.13; +30nM 5-HT = 7.98 ± 0.14.
pECjo values- E^  cuiwe = 6.26 ± 0.06; time control = 6.47 ± 0.09; +10nM 5-HT = 6.44 ± 
0.15; +30nM 5-HT = 7.29 i  0.14.
The E  ^curve, and +10nM 5-HT treated groups were not significantly different from the 
time control in sensitivity. The +30nM 5-HT treated group was 6-fold (p<0.001) and 7- 
fold (p<0 .001) more sensitive than the time control at the EC25 and EC50 respectively 
(one-way-ANOVA, Bonferroni post-test).
The Hill slopes were: E ‘ cuiwe = 0.56 (0.39-0.73)’, time control = 0.56 (0.43-0.70)', 
+10nM 5-HT = 0.58 (0.41-0.75)’, +30nM 5-HT = 0.57 (0.49-0.66). The Hill slopes did 
not overlap with unity.
The PE responses cui*ves are shown in Figure 3-1 and the values shown above are 
tabulated in Table 3-1.
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Effect o f  PE on 5-HT-induced contractions o f WT aortae
lOnM PE caused a response of 0.05 ± 0.03g (n = 6) whilst 30nM PE resulted in a 
response of 0.19 ± 0.05g {n = 7).
Emax values for 5-HT-induced contractile responses in the presence and absence of PE 
were: W  curve = 1.41 ± 0.07g (n = 13); time control = 1.33 ± O.lOg (n = 12); +10nM PE 
= 1.53 ± 0.18g (n = 6); +30iiM PE = 1.12 ± 0.09g {n = 7). None of the groups were 
significantly different from the time control in maximum responses (one-way-ANOVA, 
Bonferroni post-test).
The sensitivities of the 5-HT responses were:
pEC25 values- W  cuiwe = 7.26 ± 0.05; time control = 7.20 ± 0.12; +10nM PE -  7.23 ± 
0.09; +30nM PE = 7.87 ± 0.21.
pECso values- cui-ve = 6.91 ± 0.05; time control = 6.84 ± 0.02; +10nM PE = 6.86 ± 
0.06; +30nM PE -  7.34 ± 0.20.
The W  cuiwe, and +10nM PE treated gioups were not significantly different from the 
time control in sensitivity. The +30nM PE treated group was 5-fold (p<0.01) and 3-fold 
(p<0.05) more sensitive than the time control at the EC25 and EC50 respectively (one­
way-ANOVA, BonfeiToni post-test).
The Hill slopes were: E ‘ curve = 1.22 (1.05-0.38); time control = 1.23 (1.00-1.45); 
+10nM PE = 1.19 (1.07-1.32); +30nM PE = 0.68 (0.38-0.99). The Hill slopes 
overlapped with unity but the Hill slope of the +30nM PE treated group was shallower 
than the other gi'oups (not statistically tested).
The 5-HT responses curves are shown in Figure 3-2 and the values shown above are 
tabulated in Table 3-2.
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Effect o f  prazosin on 5-HT-induced contractions o f  WT aortae
Emax values for 5-HT responses in the absence and presence of various concentrations of 
prazosin in WT aortae were: control = 1.27 ± 0.13g (n = 5); +lnM  prazosin = 1.00 ± 
0.30g (n = 3); +10nM prazosin ^  1.07 ± 0.17g (n = 5); +100nM prazosin = 0.91 ± 0.14g 
(72 = 5). None of the groups were significantly different from the control in maximum 
responses (one-way-ANOVA, Bonferroni post-test).
The sensitivities were:
pECis values- control = 7.53 ± 0.13; +lnM  prazosin = 7.03 ± 0.18; +IO11M prazosin = 
6.95 ± 0.08; +100nM prazosin = 6.89 ± 0.02.
pECso values- control = 7.08 ± 0.09; +lnM  prazosin = 6.76 ± 0.15; +IO11M prazosin = 
6.70 ± 0.07; +IO11M prazosin = 6.69 ± 0.02.
The InM prazosin treated gi'oup was 3-fold less sensitive (p<0.05) than the control at 
the EC25 but not significantly different at EC50. Both the lOnM prazosin and lOOnM 
prazosin treated groups were 4-fold (p<0.01) and 2-fold (p<0.05) less sensitive than the 
WT at the EC25 and EC50 respectively (one-way-ANOVA, Bonferroni post-test).
The Hill slopes were: control = 1.39 (0.78-2.00); +lnM  prazosin = 1.78 (1.23-2.32); 
+IO11M prazosin = 2.25 (1.78-2.72); -HlOOnM prazosin = 3.00 (1.03-4.97). The control 
curve overlapped unity. The InM, lOnM and lOOnM prazosin treated groups did not 
overlap with unity.
The effects of prazosin on the 5-HT response curve in WT aortae are shown in Figure 3- 
3 and the values shown above are tabulated in Table 3-3.
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Effect o f  BMY 7378 on 5-HT-induced contractions ofW T  aortae
Emax values for 5-HT responses in the absence and presence of various concentrations of 
BMY 7378 in WT aortae were: control = 1.45 ± 0.19g {n = 6); +lnM  BMY 7378 = 1.35 
± 0.14g {n = 5); +IO11M BMY 7378 = 1.19 ± 0.12g (n -  6); +IOO11M BMY 7378 -  1.15 
± 0.13g {n = 6). None of the groups were significantly different from the control in 
maximum responses (one-way-ANOVA, Bonferroni post-test).
The sensitivities were:
PEC25 values- control = 7.73 ± 0.11; + I11M BMY 7378 = 7.44 ± 0.05; +10nM BMY 
7378 -  7.21 ± 0.11; +100nM BMY 7378 = 7.05 ±0.11.
pECso values- control = 7.34 ± 0.11; +lnM  BMY 7378 = 7.02 ± 0.04; +IO11M BMY 
7378 = 6,90 ± 0.09; +100nM BMY 7378 = 6.77 ± 0.08.
The InM BMY 7378 treated group was 2-fold less sensitive (p<0.05) at the EC25 but 
not significantly different at the ECso.The lOnM BMY 7378 treated group was 3-fbld 
less sensitive at both the EC25 (p<0.01) and EC50 (p<0.05). The lOOiiM BMY 7378 
treated group was 5-fold (p<0.001) and 4-fold (p<0.01) less sensitive at the EC25 and 
EC50 respectively (one-way-ANOVA, Bonferroni post-test).
The Hill slopes were: control = 1.03 (0.66-1.38); + I11M BMY 7378 = 1.40 (1.12-1.67); 
+10nM BMY 7378 = 1.59 (1.35-1.84); + BMY 7378 prazosin = 1.80 (1.57-2.03). The 
control cui've overlapped unity. The InM, lOnM and lOOnM BMY 7378 treated groups 
did not overlap with unity.
The effects of prazosin on the BMY 7378 response curve in WT aortae are shown in 
Figure 3-4 and the values shown above are tabulated in Table 3-4.
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Effect o f  prazosin on 5-HT-induced contractions o f  ajo-KO aortae
Emax values for 5-HT responses in the absence and presence of various concentrations of 
prazosin in WT aortae were; control = 0.99 ± 0.14g (/? = 7); +lnM  prazosin = 0.90 ± 
0.13g {n = 6); +10nM prazosin = 1.21 ± 0.1 Og (« = 7); +100nM prazosin = 1.10 ± 0.1 Og 
(n = 7). None of the gi'oups were significantly different from the control in maximum 
responses (one-way-ANOVA, Bonferroni post-test).
The sensitivities were:
pEC25 values- control = 7.33 ± 0.08; +lnM  prazosin = 7.17 ± 0.07; +10nM prazosin ^  
7.38 ± 0.09; +100nM prazosin = 7.28 ± 0.04.
pECso values- control = 7.05 ± 0.07; +lnM  prazosin = 6.91 ± 0.06; +IO11M prazosin = 
7.08 ± 0.07; +100nM prazosin = 7.00 ± 0.05.
No significant difference in sensitivity between the control and the prazosin treated 
gi'oups was observed (one-way-ANOVA, Bonferroni post-test).
The Hill slopes were: control = 1.56 {1.18-1.95), +lnM  prazosin = 1.91 (1.46-2.35), 
+IO11M prazosin = 1.53 (1.33-1.73), +100nM prazosin = 1.80 (1.15-2.45). The Hill 
slopes did not overlap with unity.
The effects o f prazosin on the 5-HT response curve in am-KO aortae are shown in 
Figure 3-5 and the values shown above are tabulated in Table 3-5.
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Comparing the effects o f  prazosin & BMY 7378 in WT & aw-KO aortae
Figure 3-6 and Table 3-6 compares the effects of lOnM prazosin and lOnM BMY 7378 
in the WT with the effect of lOnM and lOOnM prazosin in the am-KO. In the W1 
lOiiM prazosin resulted in a serotonergic response which was 4-fold (p<0.01) and 2-fold 
(p<0.05) less sensitive than the control at the EC25 and EC50 respectively. Furthermore, 
lOnM BMY 7378 in the WT resulted in a 5-HT response which was 3-fold less 
sensitive at both the EC25 (p<0.01) and EC50 (p<0.05), but lOnM and lOOnM prazosin 
had no effect on the serotonergic response of am-KO aortae (one-way-ANOVA, 
Bonferroni post-test).
The effect o f aio-AR activation on 5-HT contractile responses
Figure 3-7 and Table 3-7 shows a comparison between the effects of 30nM PE and 
lOnM prazosin on the serotonergic response of the WT. The presence of 30nM PE 
caused the 5-HT response to be 5-fold (p<0.01) and 3-fold (p<0.05) more sensitive than 
the control at both the PEC25 and pECso values respectively and the Hill slope was 
shallower. lOnM prazosin resulted in the serotonergic response to be 4-fold (p<0.01) 
and 2-fold (p<0.05) less sensitive than the WT at the EC25 and EC50 respectively (one- 
way-ANOVA, Bonfemoni post-test). Furthermore, in the presence of prazosin, the Hill 
slope steepened.
Serotonergic and adrenergic responses o fW T and ajo-KO aortae
No significant difference between the control 5-HT responses of the WT and am-KO 
were obseiwed (one-way-ANOVA, BonfeiToni post-test). The comparison is shown in 
Figure 3-8 and values are tabulated in Table 3-8.
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Effect o f  ritanserin on 5-HT & BRL 54443-induced contractions o f  WT
aortae
The Emax values for 5-HT or BRL 54443 responses in the absence and presence of 
lOnM ritanserin in WT aortae were: 5-HT, control ^  1.49 ± 0.13 (n = 7); 5-HT +10nM 
ritanserin = 0.43 ± 0.11 (n = 6); BRL 54443, control -  1.04 ± 0.24 {n -  7); BRL 54443 
+10nM ritanserin = 0.01 ± 0.01 (n = 7). The presence of lOnM ritanserin significantly 
reduced the maximal responses for 5-HT (p<0.001) and BRL 54443 (p<0.001). 5-HT 
and BRL 54443 maxima were not significantly different from one another (one-way- 
ANOVA, BonfeiToni post-test).
The sensitivities (pECso values) of the responses were: 5-HT control = 7.23 ± 0.13; 
BRL 54443 control = 6.47 ±0.16. It was not possible to estimate the EC50 values for the 
responses in the presence of lOnM ritanserin. BRL 54443 responses were 6-fold less 
sensitive than 5-HT responses (p<0.05: one-way-ANOVA, Bonferroni post-test).
The Hill slopes were: 5-HT control = 1.37 (1.00-1.74); BRL 54443 control = 1.03 {0.71- 
1.35). It was not possible to estimate the Hill slopes for the responses in the presence of 
lOnM ritanserin. The Hill slopes overlapped unity.
The effects of lOnM ritanserin on serotonergic responses of the WT are shown in Figure 
3-9 and the above values are tabulated in Table 3-9.
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Effect o f  ritanserin on 5-HT & BRL 54443-induced contractions o f  aw-KO
aortae
The Emax values for 5-HT or BRL 54443 responses in the absence and presence of 
lOnM ritanserin in am-KO aortae were: 5-HT, control = 1.67 ± 0.23 {n = 7); 5-HT 
+10nM ritanserin — 0.16 ± 0.09 {n = 6); BRL 54443, control = 1.18 ± 0.24 {n = 7); BRL 
54443 +10nM ritanserin = 0.02 ± 0.01 {n = 7). The presence of lOnM ritanserin 
significantly reduced the maximal responses for 5-HT (p<0.001) and BRL 54443 
(p<0.001). 5-HT and BRL 54443 maxima were not significantly different fi'om one 
another (one-way-ANOVA, Bonferroni post-test).
The sensitivities (pECso values) of the responses were: 5-HT control = 7.48 ± 0.23; 
BRL 54443 control = 6.49 ± 0.13. It was not possible to estimate the EC50 values for the 
responses in the presence of lOnM ritanserin. BRL 54443 responses were 10-fold less 
sensitive than 5-HT responses (p<0.05: one-way-ANOVA, Bonferroni post-test).
The Hill slopes were: 5-HT control = 0.96 {0.47-1.10); BRL 54443 control = 1.02 {0.59- 
1.45). It was not possible to estimate the Hill slopes for the responses in the presence of 
lOnM ritanserin. The Hill slopes overlapped unity.
The effects of lOnM ritanserin on serotonergic responses of the am-KO are shown in 
Figure 3-10 and the above values are tabulated in Table 3-10.
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Comparison o f the effects o f ritanserin on 5-HT-induced contractions o f  
WT& aiD-KO
The control 5-HT responses of WT and am-KO aortae were not significantly different 
in maxima or sensitivity (one-way-ANOVA, Bonferroni post-test). In the presence of 
ritanserin, the WT (0.43 ± O.llg) had a significantly gi'eater (p<0.05) maximal response 
than the am-KO (0.16 ± 0.09). The comparison of 5-HT responses in WT and am-KO 
aortae is shown in Figure 3-11 and Table 3-11.
Comparison o f the effects o f ritanserin on BRL 54443-induced contractions
Comparison of the control BRL 54443-induced contractile responses in WT and am - 
KO revealed no significant difference. The effect of ritanserin was almost identical in 
both strains (one-way-ANOVA, Bonferroni post-test). The comparison of BRL 54443 
responses in WT and am-KO aortae is shown in Figure 3-12 and Table 3-12.
136
Effect o f  ritanserin on PE-induced and U46619-induced contractile
responses o f  WT
Responses to a single challenge of lOpM PE in WT aortae in the absence and presence 
of lOnM ritanserin were: control == 0.85 ± 0.07g {n = 6), +lGnM ritanserin = 0.69 ± 
0.09g {n ^  6). Responses induced by a single U46619 (lOOnM) challenge were: control 
= 1.74 ± O.lOg {ji = 5), +10nM ritanserin = 1.81 ± O.lOg {n = 5). Responses of WT 
aortae to single challenges of PE and U46619 aortae were not affected by the presence 
of lOnM ritanserin (one-way-ANOVA, Bonferroni post-test). The effect of lOnM 
ritanserin on PE and U46619 responses in WT aortae are shown in Figure 3-13 and 
Table 3-13.
Effect o f  ritanserin on PE-induced and U46619-induced contractile 
responses o f am-KO aortae
Responses to a single challenge of lOpM PE in am-KO aortae in the absence and 
presence of lOnM ritanserin were: control = 0.57 ± 0.08g {n = 7), +10nM ritanserin = 
0.40 ± 0.07g {n = 7). Responses induced by a single U46619 (lOOnM) challenge were: 
control = 1.73 ± 0.07g {n = 7), +IO11M ritanserin = 1.60 ± 0.06g {n = 7). Responses of 
am-KO aortae to single challenges of PE and U46619 aortae were not affected by the 
presence of lOnM ritanserin (one-way-ANOVA, BonfeiToni post-test). The effect of 
lOnM ritanserin on PE and U46619 responses in am-KO aortae are shown in Figure 3- 
14 and Table 3-14.
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Figure 3-1. The effect of lOnM and 30nM 5-HT on PE-induced
contractile responses of WT aortae ( I  
control, n = 12; Y  lOnM 5-HT, n = 6;
E cui've, M -  13; I 
30nM 5-HT, n = 7).
time
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (*p<0.05, '"*p<0.01, ***p<0.001 against time control; 
two-way-ANOV A, BonfeiToni post-test).
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n Emax (g ra m s )
1®* C u rv e 13 0.85 ±0.04
T im e  c o n tr o l 12 0.97 ±0.06
10 ®M 5-H T 6 1.01 ±0.12
3x1 O^M 5-HT 7 1.01 ±0,07
B
pEC zs pECso
1®^  C u rv e 6.98 ±0.06 6.26 ± 0.06
T im e  c o n tr o l 7.18± 0.12 6.47 ± 0.09
10'®M 5-H T 7.07 ± 0.13 6.44 ±0.15
3x1 5-H T 7.98 ± 0.14*** 7.29 ± 0.14***
Hill s lo p e
1®^  C u rv e 0.56 (0.39-0.73)
T im e  c o n tr o l 0.56 (0.43-0.70)
lO'^M 5-HT 0.58 (0.41-0.75)
3 x 1 0  5-H T 0.57 (0.49-0.66)
Table 3-1. The effect of lOnM and 30nM 5-HT on PE-induced 
contractile responses of WT aortae.
The "n' number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as both pECis and 
pECgo values (B) are shown as the mean ± S.E.M. Hill slopes (C) 
are shown as the mean with the 95% confidence intervals shown in 
parenthesis (***p<0.001 against time control: one-way-ANOVA, 
Bonferroni post-test)
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Figure 3-2. The effect of lOiiM and 30nM PE on 5-HT-induced 
contractile responses of WT aortae (■  curve, n = 13; #  time 
control, n = 12; T  lOnM PE, n = 6; A  30nM PE, n = 7).
Responses are shown both in giams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (*p<0.05, ***p<0.001 against time control: two-way- 
ANOVA, BonfeiToni post-test).
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n Emax (g ra m s )
1®* C u rv e 13 1.41 ± 0.07
T im e  c o n tr o l 12 1.33 ±0.10
10 ®IVI P E 6 1.53 ± 0.18
3x1 P E 7 1.12 ± 0.09
B
pE C as pECgo
C u rv e 7.26 ± 0.05 6.91 ± 0.05
T im e  c o n tr o l 7.20 + 0.12 6.84 ± 0.02
10 ®M P E 7.23 ± 0.09 6.86 ±0.06
3 x 1 0  P E 7.87 ±0.21** 7.34 ± 0.20*
Hill s lo p e
is t  C u rv e 22 (1.05-1.38)
T im e  c o n tr o l 23 (1.00-1.45)
10 ®M P E 1.19 (1.07-1.32)
3x10'®M P E 0.68 (0.38-0.99)
Table 3-2. The effect of lOnM and 30nM PE on 5-HT-indnced 
contractile responses of WT aortae.
The 'n ’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as both pECis and 
pECso values (B) are shown as the mean ± S.E.M. Hill slopes (C) 
are shown as the mean with the 95% confidence intervals shown in 
parenthesis (*p<0.05, **p<0.01 against time control: one-way- 
ANOVA, Bonferroni post-test).
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Figure 3-3. The effect of InM, lOnM and lOOnM prazosin on 5- 
HT-induced contractile responses of WT aortae (■  control, « = 5; 
A InM prazosin, « = 3; T lOnM prazosin, « = 5; ♦  lOOnM 
prazosin, n = 5),
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (Statistical significance not shown for clarity: two-way- 
ANOVA, BonfeiToni post-test).
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Bn Emax (g ra m s )
C o n t r o l 5 1.27 ± 0.13
10'®M p r a z o s in 3 1.00 ± 0.30
10 ®M p r a z o s in 5 1.07 + 0.17
10"^M p r a z o s in 5 0.91 ±0.14
PEC25 pECso
C o n t r o l 7.53 + 0.13 7.08 + 0.09
10 ®M p r a z o s in 7.03 + 0.18* 6.76 + 0.15
10 ®M p r a z o s in 6.95 ± 0.08** 6.70 ± 0.07*
10'^M p r a z o s in 6.89 ± 0.02** 6.69 ± 0.02*
Hill s lo p e
C o n t r o l 1.39 (0.78-2.00)
10'®M p r a z o s in 1.78(123-2.32)
10 ®M p r a z o s in 2.25 (178-2.72)
1 0 ’^ M p r a z o s in 3.00 (1.03-4.97)
Table 3-3. The effect of InM, lOnM & lOOnM prazosin on 5-HT- 
induced contractile responses of WT aortae.
The number, maximum responses generated, expressed as 
gi’ams (A) and agonist sensitivity, expressed as both pECis and 
pECio values (B) are shown as the mean ± S.E.M. Hill slopes (C) 
are shown as the mean with the 95% confidence intervals shown in 
parenthesis (*p<0.05, *=^p<0.01: one-way-ANOVA, Bonferroni 
post-test).
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Figure 3-4. The effect of liiM, lOnM and lOOnM BMY 7378 on 5- 
HT-induced contractile responses of WT aoitae (■  control, n = 6; 
A InM BMY 7378, n = 5; T  lOnM BMY 7378, M -  6; A lOOiiM 
BMY 7378, tî = 6).
Responses are shown both in grams (A) and noiinalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (Statistical significance not shown for clarity: two-way- 
ANOVA, BonfeiToni post-test).
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'n ’ Emax ( g ra m s )
C o n t r o l 6 1.45 ±0.19
10'®M BMY 7 3 7 8 5 1.35 ± 0.14
10 ®M BMY 7 3 7 8 6 1.19 ± 0.12
1 0 ‘^ M BMY 7 3 7 8 6 1.15 + 0.13
B
pECzs pECso
C o n t r o l 7.73 ± 0.11 7.34 ± 0.11
10 ®M BMY 7 3 7 8 7.44 ± 0.05* 7.02 ± 0.04
10 ®M BMY 7 3 7 8 7.21 ±0.11** 6.90 ± 0.09*
10'^M BMY 7 3 7 8 7.05 ± 0.11*** 6.77 ± 0.08**
Hill s lo p e
C o n t r o l  
10 ®M BMY 7 3 7 8  
10'®M BMY 7 3 7 8  
10'^M BMY 7 3 7 8
1.03 (0.66-138) 
1.40 {1.12-1.67) 
1.59 {1.35-1.84) 
1.80 {1.57-2.03)
Table 3-4. The effect of liiM, lOnM & lOOnM BMY 7378 on 5- 
HT-induced contractile responses of WT aortae.
The number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as both pECzs and 
pECso values (B) are shown as the mean ± S.E.M. Hill slopes (C) 
are shown as the mean with the 95% confidence intervals shown in 
parenthesis (*p<0.05, **p<0.01, ***p<0.001: one-way-ANOV A, 
Bonferroni post-test).
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Figure 3-5. The effect of liiM, lOiiM and lOOnM prazosin on 5- 
HT-induced contractile responses in aïo-KO aortae (□  control, n == 
5; A  InM prazosin, « = 3; V  lOnM prazosin, h = 5; O  lOOiiM 
prazosin, n = 5).
Responses are shown both in grams (A) and noimalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (No statistical significance: two-way-ANOV A,
Bonferroni post-test).
146
AB
n Ema> (g ra m s )
C o n tro l 7 0.99 ± 0.14
10'®M p r a z o s in 6 0.90 ± 0.13
10'®M p r a z o s in 7 1.21 ± 0.10
10"^M p r a z o s in 7 1.10 ± 0.10
pEC zs pECso
C o n tro l 7.33 ± 0.08 7.05 ± 0.07
10 ®M p r a z o s in 7.17 + 0.07 6.91 ± 0.06
1 0 ’^ M p r a z o s in 7.38 ± 0.09 7.08 ± 0.07
10"^M p r a z o s in 7.28 ± 0.04 7.00 ± 0.05
Hill s lo p e
C o n tro l 1.56 {1.18-1.95)
10'®M p r a z o s in 1.91 {1.46-2.35)
10'®IVI p r a z o s in 1.53 {1.33-1.73)
10'^IVI p r a z o s in 1.80 {1.15-2.45)
Table 3-5. The effect o f InM, lOnM & lOOnM prazosin on 5-HT- 
induced contractile responses of aio-KO aortae.
The number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as both pECzs and 
pECso values (B) are shown as the mean ± S.E.M. Hill slopes (C) 
are shown as the mean with the 95% confidence intervals shown in 
parenthesis (No statistical significance: one-way-ANOVA,
Bonferroni post-test).
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Figure 3-6. Comparison o f  the effects o f  lOnM prazosin (A: ■  control; ▼ lOnM prazosin) & 
lOnM BMY 7378 (B: ■  control; T lOnM BMY 7378) in WT aortae and lOnM & lOOnM 
prazosin in a^o-KO aortae (C: □  control; V  lOnM prazosin; O  lOOnM prazosin) on 5-HT- 
induced contractile responses.
Responses are shown normalised, expressed as percentage o f maximum. Data points are the 
mean ± S.E.M. (**p<0.01, ***p<0.001: two-way-ANOVA, Bonferroni post-test).
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BW T pEC25 pECso Hill s lo p e
C o n t r o l  
10'®M p r a z o s in
7.53 ±0.13 
6.95 ± 0.08**
7.08 ± 0.09 
6.70 ± 0.07*
1.39 (0.78-2.00) 
2.25(1.78-2.72)
W T pEC25 pECso Hill s lo p e
C o n t r o l  
1 0 ‘®M BMY 
7 3 7 8
7.73 ± 0.11 
7.21 ± 0.11**
7.34 ± 0.11 
6.90 ± 0.09*
1.03 (0.66-1.38) 
1.59 (1.35-1.84)
cx-id “K O PEC25 pECso Hill s lo p e
C o n t r o l 7.33 ± 0.08 7.05 ± 0.07 1.56 (1.18-1.95)
10"®M p r a z o s in 7.38 ±0.09 7.08 ± 0.07 1.53 (1.33-1.73)
10"^M p r a z o s in 7.28 ± 0.04 7.00 ± 0.05 1.80 (1.15-2.45)
Table 3-6. Comparison of the effects of lOnM prazosin (A) & 
lOnM BMY 7378 (B) in WT aortae and lOnM & lOOnM prazosin 
in aiD-KO aortae (C) on 5-HT-induced contractile responses.
The pECis & pECso values are shown as the mean ± S.E.M., whilst 
the Hill slopes are shown as the mean with the 95% confidence 
inteiwals shown in parenthesis. ('^'p<0.05, "^*p<0.01: one-way- 
ANOVA, BonfeiToni post-test).
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Figure 3-7. Comparison of the effect of ocm-AR activation with 
30nM PE (A: ♦  control; ▲ 30nM PE treated) and aio-AR 
blockade with lOnM prazosin (B: ■  control; ▼ lOnM prazosin 
treated) on the 5-HT-induced contractile responses o f WT aortae.
Responses are shown noiinalised, expressed as percentage of 
maximum response. Data points are the mean ± S.E.M. (*p<0.05, 
**p<0.01, "^**p<0.001: two-way-ANO VA, BonfeiToni post-test).
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Bn Emax ( g ra m s )
C o n tro l  1 12 1.33 ±0.10
+ 3 x 1 0 '“M P E 7 1.12 ±0.09
C o n tro l  2 5 1.27 ± 0.13
+ 10"®M p rz 5 1.07 ± 0.17
pEC zs pECso
C o n tro l  1 7.20 ±0.12 6.84 ± 0.02
+ 3 x 1 0 %  P E 7.87 ± 0.21** 7.34 ± 0.20*
C o n tro l  2 7.53 ±0.13 7.08 ± 0.09
+ 1 0 ’^ M p rz 6.95 ± 0.08** 6.70 ±0.07*
Hill s lo p e
C o n tro l  1 1.23 {1.00-1.45)
+ 3 x 1 0 %  P E 0.68 (0.38-0.99)
C o n tro l  2 1.78 (1.23-2.32)
+ 1 0 ‘^M p rz 2.25 (1.78-2.72)
Table 3-7. Comparison of the effect of aio-AR activation with 
30nM PE and aio-AR blockade with lOnM prazosin on the 5-HT- 
induced contractile response of WT aortae.
The 7T number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as both pECzs and 
pECso values ( B )  are shown as the mean ± S.E.M. Hill slopes (C) 
are shown as the mean with the 95% confidence intervals shown in 
parenthesis (*p<0.05, **p<0.01: one-way-ANOVA, Bonferroni 
post-test).
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Figure 3-8. 5-HT-induced contractile responses of WT (♦ ; n - 5 )  8c 
aiD-KO (O; « = 16) aortae.
Responses are shown in both gi’ams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (No statistical significance: two-way-ANO VA,
Bonferroni post-test).
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n Emax ( g r a m s )
W T 5 1.27 + 0.13
(Xid "KO 16 1.15 ± 0.11
B
p E C so H ill s l o p e
W T 7.08 ± 0.09 1.39 {0.78-2.00)
otiD"KO 7.18 ± 0 .0 6 1.56 (7.21-7.97)
Table 3-8. 5-HT-induced contractile responses of WT & aïo-KO 
aortae.
The ‘n ’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as both PEC25 and 
pECso values (B) are shown as the mean ± S.E.M. Hill slopes (B) 
are shown as the mean with the 95% confidence intervals shown in 
parenthesis (No statistical significance: one-way-ANOVA,
Bonferroni post-test).
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Figure 3-9. The effect of lOuM ritanserin on 5-HT-induced (■  
control, w = 7; □  lOnM ritanserin treated, n = 6) 8c BRL 54443- 
induced contractile responses (#  control, n ~ l \ 0  lOiiM ritanserin 
treated, n = l )  of WT aortae.
Responses are shown both in grams (A) and normalised as a 
percentage of the maximum response of the single IpM 5-HT 
challenge (B). Data points are the mean ± S.E.M. (Statistical 
significance not shown for clarity: two-way-ANOVA, Bonferroni 
post-test).
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Bn Emax (g ra m s )
5-H T 7 1.49 ±0.13
5-H T + 10 R tn 6 0.43 ±0.11***
B R L  5 4 4 4 3 7 1.04 ± 0.24
B R L  + 10 R tn 7 0.01 ± 0.01"'
pECso Hill s lo p e
5-H T 7.23 ±0.13 37 {1.00-1.74)
5-HT + 10 ®M R tn n.c. n.c.
BR L 5 4 4 4 3 6.47 ±0.16* 1.03 (0.71-1.35)
B R L + 10 %  R tn n.c. n.c.
Table 3-9. The effect of lOnM ritanserin on 5-HT-induced & BRL 
54443-induced contractile responses of WT aortae.
The ‘/ï’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis; u.c.: 
not calculable (*p<0.05, ***p<0.001 against 5-HT control; 
“^p<0.05 against BRL 54443 control: one-way-ANOVA, 
Bonferroni post-test).
155
BU)
E
2D)
2.00
1.75-
1.50-
1.25-
1 .0 0 -
0.75-
0) 
go  a  (0© 0.504 
0.25- 
0 .00 -
*
HX
lÔ
5?
Sic0Q.
1
150n
125-
1 0 0 -
75-
50-
25
0
-10 -8 -7 -6 -5
[A g o n is t ]  ( lo g  M)
-4 -3
•10 -9 -8 -7 -6 -5
[ A g o n i s t ]  ( lo g  M)
-4 -3
Figure 3-10. The effect of lOiiM ritanserin on 5-HT-induced (■  
control, « = 7; □  lOnM ritanserin treated, « = 6) & BRL 54443- 
induced contractile responses ( #  control, tï = 7; O lOnM ritanserin 
treated, n ~ l )  oî  a iD - K O  aortae.
Responses are shown both in grams (A) and nonnalised as a 
percentage of the maximum response of the single IpM  5-HT 
challenge (B). Data points are the mean ± S.E.M. (Statistical 
significance not shown for clarity: two-way-ANO VA, Bonferroni 
post-test).
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n Emax (g ra m s )
5-HT 7 1.67 ±0.23
5-H T + 10 ®M R tn 6 0.16 ±0.09***
B R L  5 4 4 4 3 7 1.18 ±0.24
B R L + 10-°M R tn 7 0.02 ± 0.01’"
B
pECso Hill s lo p e
5-H T 7.48 ± 0.23 0.96 {0.47-1.10)
5-HT + 10'®M R tn n.c. n.c.
BR L 5 4 4 4 3 6.49 ±0.13* 1.02 {0.59-1.45)
B R L + 1 0 ‘^ M R tn n.c. n.c.
Table 3-10. The effect of lOnM ritanserin on 5-HT-induced & BRL 
54443-induced contractile responses of aio-KO aortae.
The ‘n’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis; n.c.: 
not calculable (*p<0.05, ***p<0.001 against 5-HT control; 
i'ip<0.05 against BRL 54443 control: one-way-ANOVA,
BonfeiToni post-test).
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Figure 3-11. Comparison of the effect of lOnM ritanserin on 5-HT- 
induced contractile responses of WT (■  control, « = 7; □  lOnM 
ritanserin treated, n = 6) and am-KO ( #  control, r? = 6; O lOnM 
ritanserin treated, n ~ l )  aortae.
Responses are shown in grams. Data points are the mean ± S.E.M. 
(*p<0.05 WT vs. aiD-KO: two-way-ANO VA, Bonferroni post­
test).
Emax
( g ra m s ) pECso Hill s l o p e
5-H T 1.49 ± 0.13 7.23 ±0.13 '\.37 {1.00-1.74)
W T 5-H T + 1 0 “®1V1 R tn 0.43 ± 0.11 n.c. n.c.
a m - 5-H T 1.67 ±0.23 7.48 ± 0.23 0.96 (0.47-1.10)
KO 5-H T + 10'®M R tn 0.16 ± 0.09* n.c. n.c.
Table. 3-11 Comparison of the effect of lOnM ritanserin on 5-HT- 
induced contractile responses in WT and am-KO aortae.
The, maximum response generated, expressed as grams and agonist 
sensitivity, expressed as a pECgo value are shown as the mean ± 
S.E.M whilst the Hill slopes are shown as the mean with the 95% 
confidence intervals shown in parenthesis; n.c.; not calculable 
(*p<0.05, WT vs. am-KO one-way-ANOVA, Bonferroni post­
test).
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Figure 3-12. Comparison of the effect of lOnM ritanserin on BRL 
54443-induced contractile responses of WT (■  control, « = 7; □  
lOnM ritanserin treated, n ~ 6) and aio-KO ( #  control, n = 6; O  
lOnM ritanserin treated, n = 7) aortae.
Responses are shown in grains. Data points are the mean ± S.E.M. 
(no significant difference, WT vs. aio-KO: two-way-ANO VA, 
Bonferroni post-test).
Emax
( g ra m s ) pECso Hill s lo p e
B R L  5 4 4 4 3 1.04 ± 0.24 7.23 ±0.13 1.03 {0.71-1.35)
W T BR L + 1 0 “®IVI R tn 0.01 ± 0.01 n.c. n.c.
OtlD" BR L 5 4 4 4 3 1.18 ± 0.24 7.48 ± 0.23 1.02 (0.59-1.45)
KO B R L  + 10 %  R tn 0.02 ±0.01 n.c. n.c.
Table. 3-12 Comparison of the effect of lOnM ritanserin on BRL 
54443-induced contractile responses in WT and am-KO aortae.
The, maximum response generated, expressed as grams and agonist 
sensitivity, expressed as a pECgo value are shown as the mean ± 
S.E.M whilst the Hill slopes are shown as the mean with the 95% 
confidence intervals shown in parenthesis; n.c.: not calculable (no 
significant difference, WT vs. am-KO one-way-ANO V A, 
Bonferroni post-test).
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Figure 3-13. The effect of lOnM ritanserin on PE-induced (lOpM) 
& U46619-induced (lOOnM) contractile responses of WT aortae.
Columns shown the mean ± S.E.M of the generated responses 
expressed in grams. No statistical significance: one-way-ANOVA, 
Bonferroni post-test.
n Emax (g ra m s )
P E 6 0.85 ± 0.07
P E  + 10 %  R tn 6 0.69 ± 0.09
U 4 6119 5 1.74 ± 0.10
U 4 6 6 1 9  + 10 %  R tn 5 1.81 ± 0.10
Table 3-13. The effect of lOnM ritanserin on PE-induced (lOpM) 
& U46619-induced (lOOnM) contractile responses of WT aortae.
The n number and the maximum response generated expressed in 
grams are shown. Values are the mean ± S.E.M.
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Figure 3-14. The effect of lOnM ritanserin on PE-induced (lOpM) 
& U46619-induced (lOOnM) contractile responses of am-KO 
aortae.
Columns shown the mean ± S.E.M of the generated responses 
expressed in grams. No statistical significance: one-way-ANOVA, 
Bonferroni post-test.
n Emax (g ra m s )
P E 7 0.57 ± 0.08
P E  + 10 %  R tn 7 0.40 ± 0.07
U 46619 7 1.73 ± 0 .0 7
U 4 6119  + 10 %  R tn 7 1.60 ± 0.06
Table 3-14. The effect of lOnM ritanserin on PE-induced (lOpM) 
& U46619-induced (lOOnM) contractile responses of a  n r  KO 
aortae.
The n number and the maximum response generated expressed in 
grams are shown. Values are the mean ± S.E.M.
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Discussion- Chapter 3
Synergy in the mouse aorta
Synergy can be defined as the application of two or more agonist concentrations (or 
doses) in combination resulting in a response which is much larger than the sum of the 
responses of the individual agonists alone. Synergy between the adrenergic and 
serotonergic vasoconstrictor systems in the mouse aorta has now been demonstrated. 
The responses to PE and 5-HT were significantly more sensitive in the presence of 
30nM 5-HT and PE respectively.
Types o f synergy studies
Synergy can be studied by either combining single doses or concentrations of agonists 
or by constructing agonist concentration-response cuiwes. Stupecky et al. (1986) 
performed both types of study in the rabbit aorta. They used single equi-effective 
concentrations of agonists that resulted in a response of 0.1 grams and combined these 
individual doses and demonstrated synergism, since the resulting responses varied from 
0.5g to 2,7g.
They also constructed CCRCs in the presence and absence of synergists. The synergist 
displaced the concentration-response cuiwe of the agonist to the left indicating an 
increased sensitivity. Therefore, concentration response curves to PE and 5-HT in the 
mouse aorta were constructed in order to observe synergy. Crucially, the amplification 
of the response was only observed when the synergist concentration used was able to 
cause a contraction.
Threshold stimulus
Ariens et al. (1960) perfonned an early study of synergy and discussed a hidden 
precontraction, suggesting the contractile elements had to reach a particular contractile 
“inertia” before a measurable contraction occurred. Stupecky et al. (1986) associated 
this inertia with a biochemical event, arguing an agonist has to elevate second 
messengers to reach tlrreshold concentrations for contraction. They termed this 
“thieshold stimulus”.
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The synergist concentrations used in Stupecky’s study were all supratlneshold, as they 
raised tone within the vessel, hi the mouse aorta, lOnM concentrations of PE or 5-HT 
resulted in a contractile response on occasion but generally they did not, hence, no 
synergy was observed. 30nM PE or 5-HT was able to cause a contraction, i.e. the tissue 
passed the tliieshold stimulus required for contraction. Thus in the mouse aorta synergy 
is only obseiwed when the synergist concentrations used caused a contractile response 
but this does not always need to be the case. However addition of an agonist on top of 
this tone the synergist had produced resulted in an amplification of the contractile 
response of that agonist. The dose response curves were measured using the elevated 
tone as the baseline and a larger response was observed, i.e. for any given concentration 
of agonist, the response was significantly greater than normal.
Curve shape in relation to synergy
The effect a synergist has on the shape of the concentration-response curve of an agonist 
can provide a useful insight into the synergist-agonist interaction. Drasckozy & 
Trendelenburg (1968) studied synergy by comparing agonist curves in the presence and 
absence of a synergist and described two types of synergy. Stupecky et al. (1986) also 
discussed the resulting changes in the agonist curves. A parallel shift of the curve to the 
left was considered to be “potentiation”, which is likely to be found where the two 
agonists used initiate their responses by acting tlrrough separate receptors.
The type of synergy where a synergist caused the curve to shift to the left at tlireshold 
but converged at higher agonist concentrations was thought to be the result of an 
additive effect (Drasckozy & Trendelenburg, 1968). Stupecky et a l  (1986) termed this 
“tlneshold synergism” and suggested that this type of synergy is likely to occur when 
the two agonists used act tlrrough the same receptor system, essentially a two-agonist- 
one-receptor model. The example the authors used was the effect of methoxamine on 
the concentration-curve curve to NE.
By applying these terms to the shape changes in the CCRCs of PE and 5-HT in the 
mouse aorta, it is apparent that the effect of 30nM 5-HT on the PE response was 
potentiation and the effect of 30nM PE on the 5-HT response was tlireshold synergy. 
The significance of these differing conclusions is discussed later, but first a possible 
explanation of the synergistic interaction is discussed.
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Mutual effect amplification
Leff (1987) mathematically modelled synergy, using a system where the two agonists 
effect a response by coupling tlrrough the same second-messenger pathway and 
discussed the resulting “mutual effect amplification”. Leff demonstrated this 
experimentally using 5-HT and histamine in the rabbit aorta. A 2-fold increase in 
sensitivity was observed when 0.3pM 5-HT and IpM histamine were used as synergist 
concentrations for histamine and 5-HT responses respectively.
Chi'ist et a l  (1990) evaluated L eff s model with relation to adrenergic and serotonergic 
interaction in the rabbit aorta. Using a ‘Fixed Molar Equivalent Ratio (FMR)’ protocol, 
where PE was substituted for the molar equivalent of 5-HT in various ratios, Clnist et 
al  (1990) showed that adrenergic and serotonergic co-activation resulted in a 2 to 3-fold 
increase in PE sensitivity.
Later, Clnist & Jean-Jacques (1991) demonstrated the Leff model accurately predicted 
the synergy between ai-A R and 5-HT receptor co-activation in the rat aorta. The rat 
aorta was 10-fold more sensitive for PE than 5-HT, so 5-HT was partially substituted 
with PE using the novel FMR protocol developed by Clnist et a l  (1990). A 2-3 fold 
increase in 5-HT sensitivity was observed.
The aiD-AR and the 5-HT%A receptors in the mouse aorta both couple tlnough the Gq/n 
protein in order to elevate [Ca^ '*’]i by increasing PI hydrolysis and IP3 turnover (Byland 
et al ,  1988 & Martin, 1998 for am-ARs and 5-HTzA receptors respectively), so they fit 
L eff 8 two-receptor-one-transducer model. The sensitivity increases were of a 
magnitude to be expected by mutual effect amplification, ranging from 3-fold to 7-fold. 
However, no attempt was made to establish the mathematical fit of L eff s model of 
mutual effect amplification. But the synergy we obseiwed is most likely due to mutual 
effect amplification.
The mathematical model of Leff (1987) lies somewhere between the two types of 
synergy discussed by Stupecky et a l  (1986) i.e. potentiation and threshold synergy. 
L eff s two-receptor-one-transducer model is most closely related to tlneshold synergy, 
which describes a two-agonist-one-receptor system. However, the Leff model is limited 
by the assumption that the two receptors couple only to a single transducer. In the
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mouse aorta, McKune & Watts (2001) showed that L-type Ca channels and tyi'osine 
kinases are also involved in the response mediated by 5-HT2A receptors as well as Gq/n 
protein activation to elevate [Ca^ "^ ]i by increasing PI hydrolysis and IP3 turnover. Hence, 
the vasoconstrictor system in the mouse aorta did not completely fulfil the criteria of 
L eff s model. Therefore, although the synergy is due to mutual effect amplification, the 
difference in the shape changes of the PE and 5-HT cuiwes suggest there is a 
fundamental difference in the interaction at the receptor level, and Stupecky’s models of 
potentiation and thieshold synergy may explain this and is discussed later.
Synergy and the involvement o f ‘silent receptors '
In contrast to the Leff model where small (less than 10-fold) increases in sensitivity are 
obsei-ved, occasionally large 100-fold or 1000-fold, sensitivity increases in the agonist 
cuiwe are apparent when a synergist is added, hr such cases the synergy is believed to be 
the result of the activation of “silent receptors”. This is a very powerful type of 
amplification resulting in 100-fold plus increases in sensitivity to an agonist. Generally 
this type of augmentation of the response is seen when the two agonists couple tln ough 
receptors that preferentially couple with different G-proteins i.e. Gq/n with Gi/o (Selbie & 
Hill, 1998).
Movahedi et a l  (1995), Chen et al  (2000) and Yildiz & Tuncer (1995) studied the 
serotonergic responses of the rabbit ear artery, femoral artery and iliac artery 
respectively, and uncovered “silent” 5-HTi_iike receptor responses to 5-HT which were 
only umnasked when a contractile tlireshold concentration of PE or NE was applied to 
the tissue. Such interactions have been associated with the pathophysiology of 
conditions such as pulmonary hypertension (Maclean & Morecroft, 2001). However, 
little evidence for synergists uncovering “silent” ai-ARs or 5-HT2A receptors exists, and 
no such large shifts were obseiwed.
Heterodimérisation o f GPCRs
Although the synergy obseiwed was probably due to mutual effect amplification via the 
activation of a mutual second messenger system, current cellular studies are revealing 
the heterodimerisation properties of G-protein-coupled-receptors (GPCRs; reviewed by 
Rios et a l ,  2001). Recently, research has found that all thi'ee ai-A R subtypes have the
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ability for direct receptor-receptor interactions. The aie-AR can fonn both homodimers 
and heterodimers with both the aiA-AR and the am-AR, but no aiA/otio-AR 
heterodimers have been obseiwed (Stanasila et al ,  2003; Uberti et al ,  2003; Hague et 
al,  2004). Thus the aio-AR has the ability to interact with other GPCRs.
Some of the family of 5-HT receptors have also been shown to form heterodimers. Xie 
et al  (1999) found that 5-HTm and 5-HTid receptors fonn homodimers when expressed 
on their own, in cultured cell lines, but when co-expressed, they can fonn heterodimers. 
No evidence of 5-HT2a receptors having the ability to fomi heterodimers is cunently 
available but such an interaction cannot be mled out. It is known that 5-HT2a receptors 
have the ability to cross-talk with 5-HTia receptors although this is attributed to post­
receptor events (Zhang et al ,  2004).
Thus, although there is no evidence yet available of whether there is direct interaction 
between a , o-ARs and 5-HT2a receptors, it may be possible that these two receptors can 
heterodimerise. Such a study was beyond the scope of this thesis but it is not possible to 
completely rule out this type of direct receptor-receptor interaction, although the 
synergy we observed is most likely due to the downstream amplification of the 
response.
Potentiation
Thus, by applying the terms used by Stupecky et al  (1986) to our data, the effect of 
30nM 5-HT on the PE curve is ‘potentiation’ as the PE curve shifted to the left in a 
parallel fashion. This is consistent with the effect of NE and 5-HT in combination in the 
rabbit aorta (Stupecky et al ,  1986). In the mouse aorta, PE induces its response tlrrough 
aiD-ARs but when 5-HT is used as a synergist, a new receptor is introduced into the 
response, namely the 5-HT2a receptor, so we see potentiation. As previously discussed, 
it is likely that the potentiation obseiwed is due to “mutual effect amplification”.
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Threshold synergy
On the other hand, incubation with 30nM PE before constructing a CCRC to 5-HT does 
not result in a parallel shift but a curve that is enlianced at lower agonist concentrations 
resulting in tlneshold synergism. This curve shifts to the left at tlneshold concentrations 
and converges with the control curve at higher 5-HT concentrations, effectively making 
the slope of the cuiwe shallower (Fig 3-2).
This is contrary to the findings of Stupecky et al. (1986) in the rabbit aorta. They 
demonstrated that the 5-HT curve was shifted in a parallel fashion when the tissue had 
NE or methoxamine as a synergist present. But threshold synergy is observed where the 
two synergists used are either full or partial agonists of the same receptor, for example 
methoxamine and NE acting at ai-ARs. There have been many reports of 5-HT having 
activity at a,-ARs. 5-HT acting at aio-ARs would help explain the tlneshold synergy 
obseiwed when PE is used as a synergist with 5-HT.
5-HT and aj-ARs
It has previously been demonstrated that 5-HT responses can be mediated via ai-ARs. 
The 5-HT response of the rabbit ear artery is believed to be due to the significant 
involvement of ai-ARs (Purdy et a l ,  1981). Furthermore, the 5-HT response in the 
rabbit aorta is partly mediated by ai-ARs (Purdy et al ,  1987). Recently Shaw et al  
(2000) demonstrated concentration-dependent prazosin blockade of 5-HT responses in 
rat pulmonary arteries and concluded that 5-HT is acting tlrrough a,-ARs. However, 
they were unable to elaborate specifically which ai-AR subtypes are involved.
The complexity of sub typing an ai-A R mediated response to 5-HT is due to the nature 
of the selective ligands available. BMY 7378 is the most commonly used aio-AR 
selective antagonist (Saussy et al ,  1994) but is also Icnown to be a 5-HTia partial 
agonist (Yocca et al., 1987). Similarly the aiA-selective antagonist 5-Methylurapidil, 
(Gross et al ,  1988; Schwimi et al ,  1995), was originally reported to be a partial 5- 
HTiA-receptor agonist (Gross et a l ,  1987), thus making the detailed study of 
adrenoceptor mediated 5-HT responses problematic. Furthermore the adrenergic
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response may be masked by responses driven by 5-HT2a receptor activation, making it 
difficult to uncover the adrenergic component of the 5-HT response.
However, the serotonergic response of the WT mouse aorta was antagonised by 
prazosin. The effect of BMY 7378 on the 5-HT response was very similar to the effect 
of prazosin. The blockade of am-ARs using both antagonists resulted in a rightward 
shift at tlneshold, which converged with the control cui*ve. Attempts to establish pA2 
values for prazosin and BMY 7378 against 5-HT were unsuccessful as shallow Schild 
slopes were observed (not shown). This is most likely due to the majority of the 
response being 5-HT2a receptor-mediated, making it difficult to accurately isolate the 
smaller ai-AR component.
Although these observations confirm an ai-A R mediated serotonergic response, they 
are inconclusive as to which subtype is involved. As well as being a commonly used 
aiD“Selective antagonist BMY 7378 is known to be a partial agonist of the 5-HTia- 
Although no evidence for the role of 5-HTiA-receptors is yet available the use of BMY 
is overshadowed by its activity at other receptors than the aiD-AR, but the use of the 
aiD“KO helped resolve this issue. Circumstantially though, BMY 7378 had a similar 
effect as prazosin, indicating that am-ARs have a role in the serotonergic response in 
the mouse aorta.
The use of the am-KO mouse confirmed this conclusion as the serotonergic response of 
the am-KO mouse aorta was not antagonised by prazosin, verifying the am-AR is 
involved in the serotonergic response. The adrenergic response am-KO mouse aorta is 
aiB-AR mediated. The lack of blockade of the serotonergic response by prazosin in the 
am-KO excludes the am-AR from the serotonergic response.
Role o f constitutivefy active aio-ARs in the 5-HT response
The effect of prazosin or BMY 7378 in the WT appears to be most apparent in the 
30nM to lOOnM region of the 5-HT curve, suggesting 5-HT has a high degiee of 
sensitivity for ai-AR. Recently Gisbert et al. (2000) discussed the evidence for a 
constitutively active population of am-ARs in rat aorta. In their study, the am -AR’s 
were activated using NE in Ca^'^-free PSS and the NE was then washed out using Ca^^-
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free PSS. On exposure to an increase in tone was observed suggesting a
constitutively active population of receptors. A population of constitutively active am - 
ARs in the mouse aorta, may be why the ai-AR activity of 5-HT was so sensitive, as 
only a small amount of agonist was required to ‘switch on’ the am-ARs. The 
constitutive activity of am-AR along with the synergistic interaction with 5-HT2A 
receptors, may explain why the response at am-ARs is apparently at such low 
concentrations of 5-HT.
The concept of constitutively active am-ARs provides another possible explanation to 
the sensitivity of 5-HT responses to prazosin or BMY 7378. It is possible that the 5-HT 
has no effect at am-ARs but that the sensitivity is simply due to the inverse agonist 
effect of prazosin or BMY 7378 at am-ARs. Thus, in the WT the less sensitive 5-HT 
curve in the presence of prazosin or BMY 7378, may have been due to the ‘switching 
o ff  of constitutively active am-ARs which were synergistically amplifying the 5-HT2a 
receptor response. The absence of such a shift in am-KO aortae would also be 
consistent with this hypothesis as well as the presented hypothesis o f the activity of 5- 
HT at am-ARs.
However, the 5-HT ciii've was constructed after a 40-minute incubation with antagonist, 
once the original baseline had been re-established. Thus, the time difference between 
the initial PE challenge and the constmction of the 5-HT cuiwe was approximately 2 
hours, allowing time for the constitutively active population of receptors to become 
“silent”. Additionally, the baseline was established in normal Ca^ "*" PSS so any 
significant activity of am-ARs would show up as a contraction. It is possible that there 
may have been a residual sub-tlneshold activity of am-ARs, but this activity of am - 
ARs should not have a synergistic interaction with the 5-HT2a receptors. As previously 
discussed, a supra-threshold concentration of synergist, and hence, an elevation in tone 
is required in order to amplify the agonist response.
Therefore, 5-HT has activity at a,-ARs and the serotonergic response in the WT mouse 
aorta is partly mediated by the am-AR.
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Synergy o f  5-HT responses
Hence, the tlireshold synergy observed when PE is used as a synergist for 5-HT can 
now be explained due to the activation of the am-AR, a receptor involved in both 
responses. Stupecky et al., (1986) suggested that two agonists of the same receptor 
would result in tlireshold synergy consistent with the findings in the mouse aorta as a 
common receptor is involved in both responses, the am-AR. Figure 3-7 compares the 
effect of am-AR activation on the serotonergic response, showing the effect of an 
increased level of activation with 30nM PE present and the effect of a decreased level of 
activation with lOnM prazosin.
The application of PE primarily involves the activation of am-ARs, a receptor shown to 
be involved in the response to 5-HT. 5-HT primarily acts tlnough 5-FIT2A receptors but 
the presence of PE affected the cuiwe by increasing the level of activation of a receptor, 
the am-AR, which was already involved in the 5-HT response. The resulting curve was 
leftward shifted at tlneshold, converged at 300nM 5-HT and the slope was shallower.
In contrast, the blockade of am-ARs results in a rightward shift of the curve, 
converging with the control curve at 300nM 5-HT and a steeper slope. Hence the 
synergistic effect of PE on the 5-HT response is similar to the synergistic effect of using 
another agonist of the same receptor (Stupecky et al ,  1986). A diagrammatic 
representation of the interaction is provided in Figure 3-15.
Thus, the relatively sensitive nature of the mouse aorta to 5-HT can be explained due its 
effects at both 5-HT2a receptors and am-ARs. The normal 5-HT response is itself 
synergistically amplified at tlmeshold as am-ARs are co-activated along with 5-HT2a 
receptors for the 5-HT-induced response. Since both receptors are coupled tlnough the 
same second messenger pathway they are likely to be interacting in a synergistic fashion 
due to “mutual effect amplification” as described by Leff (1987) and Christ & Jean- 
Jacques (1991).
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Figure 3-15. A diagrammatic representation o f  the activity o f  PE, 5-HT, 
prazosin, BM Y 7378, and ritanserin on the activity o f  the a ,o -A R  and the 
5-HT2A receptor. Both the am -A R  and 5-HT2a receptor preferentially 
couple to the Gq/,, protein and is shown.
Serotonergic responses o f  the ajp-HO
Interestingly the overall serotonergic response of the am-KO was not significantly 
different from the WT although the adrenergic (PE) response of the am-KO mouse was 
significantly less sensitive than the WT, as previously shown by Tanoue et al. (2002). 
The serotonergic responses in the am-KO should have been analogous to the 
serotonergic response of WT aortae in the presence of prazosin or BMY 7378. But the 
am-KO appears to have ‘reset’ its serotonergic response back to the WT serotonergic 
response.
There may have been some compensatory mechanism in the a,D-KO to adjust for the 
loss of the am-AR mediated vasoconstrictor response. The lack of one vasoconstrictor 
may have been offset by the alteration in function of another vasoconstrictor. 5-HT is 
very potent in the mouse aorta (Russell & Watts, 2000) and the serotonergic response in 
the mouse aorta is mainly 5-HT:A receptor-mediated (McKune & Watts, 2001) so it is 
possible that the 5-HT2A receptor is involved in the compensatory mechanism.
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The commonly used 5-HTzA receptor antagonist, ketanserin, has been shown to have an 
affinity for ai-ARs (Cohen et al ,  1988), thus was unsuitable. The activity of 5-HT at 
both 5-HT2A receptors and am-AR would have been blocked by ketanserin making it 
incompatible with the aim of isolating the contribution of the 5-HT2a receptors to the 5- 
HT induced response. Cohen et al  (1988) provided a pKe value for ketanserin (7.9) at 
ai-ARs. They also demonstrated that an insurmountable 5-HT2 receptor antagonist, 
ritanserin had a pKe value of 6.0 at ai-ARs. Therefore ritanserin was chosen as the 
selective antagonist for isolating the 5-HT response.
Ritanserin completely ablated the 5-HT response of the aio-KO. Ritanserin did not 
affect the adrenergic responses of PE or the responses of the tlnomboxane mimetic, 
U46619 confirming its selectivity in blocking only the 5-HT2A-mediated response. A 
residual serotonergic response remained in the WT and is likely to be the adrenergic 
aiD-AR-mediated response of 5-HT. Thus, the serotonergic response of the am-KO was 
ritanserin-sensitive and prazosin-resistant, suggesting the 5-HT2a receptor compensates 
for the missing am-AR in the aiD-KO,
BRL 54443-induced contractions
Ritanserin completely ablated the 5-HT-induced response in both WT and am-KO 
aortae. Therefore, it was necessary to use another ligand to study the function of the 5- 
HT2A receptor. BRL 54443 is a full agonist at the 5-HTie and 5-HTip receptors (Brown 
et a l ,  1998) but McKune and Watts (2001) demonstrated that BRL 54443 also has 
affinity for 5-HT2A receptors, acting as a partial agonist in the mouse aorta.
BRL 54443 was used in an attempt to establish and quantify any differences in the 5- 
HT2A mediated serotonergic responses o f the WT and aio-KO aortae. However, BRL 
54443 was equipotent in both the WT and the aio-KO and the responses were 
completely abolished by ritanserin in both strains. This confiimed that BRL 54443 has 
affinity for 5-HT2A receptors but suggested that there was no significant difference in 
the 5-HT2A-niediated response between WT and aio-KO aortae.
Although the maximum responses to BRL 54443 were not significantly different from 
5-HT, there was a tendency for the maximum responses induced by BRL 54443 to be
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smaller than the maximum 5-HT responses in both WT and aio-KO (consistent with 
McKune and Watts, 2001). The lack of significant difference is probably due to the 
large variability observed in these experiments. The inability of BRL 54443 to highlight 
differences in the 5-HT2a receptor mediated contractions between WT and aio-KO was 
probably due to the fact that BRL 54443 is a partial agonist.
A characteristic of a partial agonist is that even with receptor occupancy of 1.0 or 100%, 
the partial agonist may still not be able to induce a maximal response (Rang et al ,  
1999). Since we observed only a minor role for the aio-AR in the serotonergic response 
in WT mouse aorta, there may have been compensatory alterations 5-HT2A receptor 
population in aiD-KO aortae that weretoo subtle to distinguish using BRL 54443 as an 
agonist.
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Conclusions- Chapter 3
Conclusion
A synergistic interaction between adrenergic and serotonergic vasoconstrictor systems 
has now been demonstrated in the mouse aorta. The am-ARs and the 5-HT2A receptors 
both couple tlmough the same G-protein, in order to initiate a response, thus the synergy 
is due to mutual effect amplification. However, it is not possible to completely rule out 
a direct receptor-receptor interaction.
The sensitivity of the PE response was increased 6- to 7-fold in the presence of 30nM 5- 
HT. The PE curve was shifted to the left in a parallel fashion exhibiting ‘potentiation’. 
The introduction of 5-HT synergist concentrations involves the recruitment of 5-HT2A 
receptors, which are ‘new’ receptors in the PE response.
Conversely the sensitivity of the 5-HT response was increased 3- to 5-fold when a 
synergist concentration of 30nM PE was applied. However, the curve was shifted to the 
left primarily at tlireshold, converging at higher concentrations, demonstrating 
‘threshold synergy’. The threshold synergism of the 5-HT response was due to the 
increased involvement o f aio-ARs.
The 5-HT response in the WT mouse aorta is partly mediated by aio-ARs. The 
relatively sensitive nature of the 5-HT response in the mouse aorta was, therefore, the 
result o f the co-activation of both 5-HT2a receptors and aio-ARs, which synergistically 
interact to amplify the functional response of 5-HT. Thus the tlueshold synergy 
obseiwed was due to increased participation of aio-ARs, which are already involved in 
the 5-HT-induced response.
The serotonergic response of the aio-KO was not significantly different fi.*om the WT 
serotonergic response. However, the 5-HT response of the WT was sensitive to both 5- 
HT and prazosin, whilst the aio-KO response was prazosin-resistant and ritanserin- 
sensitive suggesting that in the am-KO mouse aorta 5-HT2A receptors compensate for 
the lack of functional aio-ARs.
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Chapter 4. The effect of L-NAME on contractile 
responses in the mouse aorta
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Introduction- Chapter 4
Role o f endothelium in the vasculature
Historically, the endothelium had been primarily considered to be a physical barrier 
controlling the movement of cells, proteins and molecules between blood fluid and 
interstitial fluid within and beyond the vascular wall. Research over the last 25 years has 
now indicated the functional importance of the endothelium in modulating vascular 
tone. Endothelial cells (ECs) can release a myriad of modulators, both contractile, such 
as endothelin and some prostaglandins, and relaxatory, such as nitric oxide (NO), 
prostacyclin (PGI2) and endothelium derived hyperpolarising factor (EDHF). 
Furthermore the endothelium is an important site for the enzymatic conversion of 
angiotensin I to angiotensin II as well as affecting the activity of other vasoactive 
peptides. The endothelium has also been linked to the pathology of such conditions as 
hypertension (reviewed by Marin, 1995).
Nitric oxide
One of the most profound discoveries was that endothelial cells have the ability to 
release the simple molecule nitric oxide (NO) which acts as a dilator of vascular smooth 
muscle cells. Originally, NO was tenned endothelium-derived relaxing factor (EDRF) 
by Furchgott & Zawadski (1980) who reported that the functional responses of ACh in 
the rabbit aorta were either contractile or relaxatory dependent on endothelial 
preservation during dissection and setup.
Initially EDRF was suspected to be a peptide, but was later identified as NO (Palmer et 
a l, 1987). Palmer et al. (1988) then discovered the metabolic pathway for NO 
synthesis. NO is synthesised by an enzyme-controlled five-electron oxidation of the 
terminal guanidino nitrogen atom of L-arginine. The recognition of NO as EDRF lead to 
an explosion in the study of NO, and its associated metabolic pathways and actions, as 
potential therapeutic targets. As such, blockers of the class of nitric oxide synthase 
(NOS) enzymes such as Nm-nitro-L-arginine methyl ester (L-NAME: Rees et a l, 1990) 
are now available for phannacological and physiological studies.
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Endothelial a-adrenoceptors
Vascular ai-adrenoceptors (ARs) are generally considered to be vasoconstrictor 
receptors, being primarily distributed amongst the medial layer of blood vessels. 
Conversely, in large conductance arteries such as the aorta, az-ARs have been 
associated with endothelium-dependent vasodilatation (Cocks & Angus, 1983). 
Vanlioutte & Miller (1989) then related a 2-AR activation with the release of nitric oxide 
from ECs.
However, authors are beginning to report the distribution of ai-ARs amongst the 
adventitial layer (Faber et a l, 2001) and in endothelial cells (Filippi et a l,  2001). 
Indeed, Filippi et a l (2001) demonstrated, in perfused rat mesenteric vascular bed, that 
the activation of aio-ARs on ECs results in NO release, and hence, vasodilatation. 
Therefore, the ai-AR-mediated contractile responses to agonists such as PE were 
somewhat attenuated by the simultaneous activation of aio-ARs on ECs which released 
NO. Similarly Zschauer et a l (1997) showed NE-induced vasoconstriction in rabbit 
bronchial artery was modulated by NO release from ECs which were stimulated by a i- 
and a 2-AR activation.
The mouse aorta
As yet, no studies on the effect of NO release on contractility in the mouse aorta have 
been perfoiined. The mouse aorta has a significant ai-adrenoceptor mediated contractile 
response (Russell & Watts, 2000) which is primarily am-AR mediated (Yamamoto & 
Koike, 2001). The role of the individual ai-AR subtypes has been studied using 
transgenic mice (Daly et a l, 2002; Tanoue et a l,  2002). 5-HT also exhibits a high 
degree o f sensitivity and efficacy in the mouse aorta (Russell & Watts, 2000), thus 
providing a useful gauge of contractile responses.
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Aim o f  Study
The aims were to determine the effects of NO release on PE, 5-HT and KCl-induced 
responses in the mouse aorta by blocking NO production using L-NAME. The 
involvement of a is- and am-ARs in NO release was investigated using WT, am-KO 
and aiD“KO aortae. The PE-mediated involvement of ag-ARs in contraction or 
relaxation was tested in both control and L-NAME treated aortic rings.
178
Results- Chapter 4
Effect ofL-NAME on ACh-induced relaxations
The ACh-indiiced relaxations in the absence and presence of lOOpM L-NAME were: 
WT control = 52.8 ± 2.6% decrease in tone {n = 25); WT 4- L-NAME = 14.5 ± 3.1% {n 
= 21); am-KO control = 61.7 ± 3.8% {n -  10); am-KO + L-NAME = 1.4 ± 3.9% {n = 
9); aiD“KO control = 70.3 ± 7.6% {n = 5); am-KO + L-NAME = 10.3 ± 14.1% (n = 7),
The ACh-induced relaxations were signiEcantly reduced by L-NAME in WT (p<0.001), 
am-KO (p<0.001) and am-KO aortae (p<0.01). These results are shown in graphical 
form in Figure 4-1.
The ACh response of WT and am-KO were not significantly different, whilst the am- 
KO ACh response was significantly less sensitive than WT (p<0.01: one-way-ANOVA, 
Bonfen'oni post-test).
Effect o f L-NAME on KCl-induced contractile responses
The KCl-induced contractile responses in the absence and presence of lOOpM L-NAME 
were: WT control = 0.72 ± 0.02 {n = 25); WT + L-NAME = 0.95 ± 0.04 {n = 21); am- 
KO control = 0.69 ± 0.04 {n = 16); am-KO + L-NAME = 1.25 ± 0.08 {n = 9); am-KO 
control = 0.74 ± 0.05 {n = 8); am-KO 4- L-NAME = 0.95 ± 0.05 {n — 6). The KCl- 
induced contractile responses were significantly greater in the L-NAME treated groups 
than in the controls (WT- p<0.001; am-KO- p<0.001; am-KO- p<0.01: Student’s t- 
test). These results are shown in giaphical form in Figure 4-2.
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Effect o f  L-NAME on 5-HT-induced contractions o f  WT aortae
Emax values for 5-HT-induced contractile responses of WT aortae in the absence and 
presence of lOOpM L-NAME were: control = 1.62 ± 0.09 (n = 11); + L-NAME = 1.66 ± 
0.09 (n = 7). The maximum responses were not significantly different (Student’s t-test).
pECso values were: control = 7.00 ± 0.07; + L-NAME = 7.58 ± 0.21. The L-NAME 
treated group was 4-fold more sensitive (p<0.01: Student’s t-test) than the control 
group.
Hill slopes were: control = 1.15 (0.96-1.34); + L-NAME = 0.82 (0.69-0.95). The Hill 
slopes overlapped with unity.
The effect of L-NAME on the 5-HT cuiwe in the WT aorta is shown in Figure 4-3 and 
the values shown are tabulated in Table 4-3.
Effect o f L-NAME on 5-HT-induced contractions o f  Œ/b-KO aortae
Emax values for 5-HT-induced contractile responses of am-KO aortae in the absence and 
presence of lOOpM L-NAME were: control = 1.51 ± 0.13 (n = 12); -L L-NAME = 1.80 ± 
0.17 (n = 9). The maximum response to 5-HT in the am-KO were not significantly 
altered by L-NAME (Student’s t-test).
pECso values were: control = 7.04 ± 0.10; + L-NAME = 7.48 ± 0.13. L-NAME 
treatment resulted in a 3-fold more sensitive response (p<0.05: Student’s t-test).
Hill slopes were: control = 0.98 (0.79-1.16); + L-NAME = 0.80 (0.65-1.04). The Hill 
slopes overlapped with unity.
The 5-HT curves of the am-KO aorta and the effect of L-NAME are shown in Figure 4- 
4 and the values shown are tabulated in Table 4-4
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Effect o f  L-NAME on 5-HT-induced contractions o f  ajo-KO aortae
Emax values for 5-HT-induced contractile responses of am-KO aortae in the absence and 
presence of lOOpM L-NAME were; control = 1.35 ± 0.09 (n = 6); + L-NAME = 1.40 ± 
0.08 (n = 7). There was no significant difference in the maximal 5-HT-induced response 
of am-KO aortae as a result of L-NAME treatment (Student’s t-test).
pECso values were: control = 7.39 ± 0.07; + L-NAME = 7.62 ± 0.05. The serotonergic 
response of the L-NAME treated group was 2-fold more sensitive than the control 
(p<0.05: Student’s t-test).
Hill slopes were: control = 1.04 (0.35-1.73); + L-NAME = 1.02 (0.60-1.44). The Hill 
slopes overlapped with unity.
The serotonergic responses in the absence and presence of L-NAME in the a i d-K O  are 
shown in Figure 4-5 and the values shown are tabulated in Table 4-5.
Comparison o f 5-HT-induced contractions ofWT, ajs-KO &aiD~KO aortae
The comparison of the serotonergic responses of the WT, am-KO & am-KO aortae are 
shown in Figure 4-6 and the respective values are tabulated in Table 4-6. The Emax and 
pECso values of the 5-HT-induced responses of the am-KO and am-KO were not 
significantly different from the WT (one-way-ANOVA).
Comparison o f 5-HT-induced contractions ofWT, ajB~KO &aw~KO aortae 
in the presence o f L-NAME
The comparison of the serotonergic responses in the presence of L-NAME in WT, am- 
KO & am-KO aortae are shown in Figure 4-7 and the respective values are tabulated in 
Table 4-7. L-NAME treated WT, am-KO & am-KO aortae exhibited similar maxima 
and sensitivity (pEC^o) (one-way-ANOVA).
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Effect o f  L-NAME on PE-induced contractions o f  WT aortae
Emax values for PE-induced contractile responses of WT aortae in the absence and 
presence of lOOpM L-NAME were: control = 1.01 ± 0,05 (n = 26); + L-NAME = 1.37 ± 
0.07 (n = 21). The maximum PE response was 36% significantly greater in the L- 
NAME treated gi'oup compared to the control gioup (p<0.001: Student’s t-test).
pECgo values were: control = 6.66 ± 0.07; + L-NAME = 7.11 ± 0.11. The PE response 
was 4-fold sensitive in the presence of L-NAME (p<0.001: Student’s t-test).
Hill slopes were: control = 0.59 (0.44-0.74); + L-NAME = 0.55 (0.42-0.67). The Hill 
slopes did not overlap with unity.
The effect of L-NAME on the PE curve in the WT aorta is shown in Figure 4-8 and the 
values shown are tabulated in Table 4-8.
Effect o f  L-NAME on PE-induced contractions o f ajs-KO aortae
Emax values for PE-induced contractile responses of am-KO aortae in the absence and 
presence of lOOpM L-NAME were: control = 0.97 ± 0.09 (n = 16); + L-NAME = 1.73 ± 
0.11 (n = 9). L-NAME treatment resulted in a 78% increase in sensitivity of the PE 
response of the am-KO (p<0.001: Student’s t-test).
pECso values were: control = 6.73 ± 0.08; + L-NAME = 7.21 ± 0.11. A 3-fold increase 
in sensitivity was observed in the presence of L-NAME (p<0.01 : Student’s t-test).
Hill slopes were: control = 0.55 (0.45-0.66); + L-NAME = 0.67 (0.51-1.82). The Hill 
slopes did not overlap with unity.
The effect of L-NAME on the PE curve in the am-KO aorta is shown in Figure 4-9 and 
the values shown are tabulated in Table 4-9.
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Effect o f  L-NAME on PE-induced contractions o f  aw-KO aortae
Emax values for PE-induced contractile responses of am-KO aortae in the absence and 
presence of lOOpM L-NAME were: control = 0.64 ± 0.12 (n = 6); + L-NAME = 0.98 ± 
0.09 (n = 7). L-NAME treatment resulted in a 53% increase in the maximum PE- 
induced contractile responses of the ajo-KO aortae (p<0.05: Student’s t-test)
pECso values were: control = 5.52 ± 0.13; 4- L-NAME = 5.29 ± 0.13. There was no 
significant alteration in sensitivity as a result o f L-NAME treatment (Student’s t-test)
Hill slopes were: control = 0.85 {0.57-1.13y, 4- L-NAME = 0.86 {0.57-1.17). The Hill 
slopes overlapped with unity.
The effect of L-NAME on the PE curve in the am-KO aorta is shown in Figure 4-10 
and the values shown are tabulated in Table 4-10,
Comparison o f the PE-induced contractions o f WT, ajB~KO &aiD-KO 
aortae
A comparison of the PE-induced responses of the WT, am-KO & am-KO aortae are 
shown in Figure 4-11 and the respective values are tabulated in Table 4-11. The WT and 
am-KO exhibited similar maxima and sensitivity (pEC^o) (one-way-ANOVA, 
Bonferroni post-test). The maximum of the am-KO PE response was decreased 37% 
(p<0.05: one-way-ANOVA, Bonferroni post-test) and the pECso was 14-fold less 
sensitive than the WT (p<0.001).
Comparison o f the PE-induced contractions o f WT, ajB-KO &ajo-KO 
aortae in the presence o f L-NAME
A comparison of the WT, am-KO and am-KO PE-induced responses in the presence of 
L-NAME is shown in Figure 4-12 and the relevant values are tabulated in Table 4-12. In 
the presence of L-NAME, am-KO aortae exhibited a significantly larger (26%, p<0.05. 
one-way-ANOVA, BonfeiToni post-test) but no significant alteration in sensitivity 
(pECso). The am-KO aorta maxima to PE was decreased 28% and the sensitivity was 
66-fold less sensitive than the PE responses of the WT.
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Effect o f rauwolscine in the absence and presence o f L-NAME on 
adrenergic responses o f WT aortae
Emax values for PE-induced contractile responses of am-KO aortae in the absence and 
presence of 30nM rauwolscine and/or were lOOpM L-NAME: nonnal control = 1.01 ± 
0.05 (n = 26); normal + rauwol. = 1.06 ± 0.09 (n = 8); + L-NAME control = 1.37 ± 0.07 
(n = 21); + L-NAME 4- rauwol. = 1.45 ± 0.09 (n = 7). The rauwolscine treated gi'oups 
did not exhibit significantly different maxima from their appropriate control (Student’s 
t-test).
pECso values were: normal control = 6.67 ± 0.07; 4- rauwol. = 6.71 ± 0.08; 4- L-NAME = 
7.11 ± 0.11; 4- L-NAME & rauwol. = 6.98 ± 0.19. Rauwolscine treatment did not affect 
the sensitivity of the non-L-NAME treated and L-NAME treated groups (Student’s t- 
test).
Hill slopes were: nonnal control = 0.59 {0.44-0.74)', 4- rauwol. == 0.60 (0.43-0.77)', 4- l -  
NAME = 0.54 (0.41-0.67)', 4- L-NAME & rauwol. = 0.58 (0.47-0.69). The Hill slopes 
did not overlap with unity.
The above data is shown in graphical fonn in Figure 4-13 and the relevant values are 
tabulated in Table 4-13.
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100-1
Figure 4-1. The effect of lOOpM L-NAME on 30pM ACh-induced 
relaxant responses of WT, am-KO and am-KO aortae.
Columns shown are the mean ± S.E.M of the generated responses 
expressed in grams force (**p<0.01, ***p<0.001, against strain- 
matched control; °°p<0.01 against WT control: one-way-A VO VA, 
Bonferroni post-test).
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Figure 4-2. The effect of lOOpM L-NAME on 125mM KCl- 
induced contractile responses of WT, am -K O  and a i  d-K O  aortae.
Columns shown are the mean ± S.E.M of the generated responses 
expressed in grams force. (**p<0.01, ***p<0.001 against strain- 
matched control: one-way-AVOVA, Bonferroni post-test)
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Figure 4-3. The effect of lOOjiM L-NAME on 5-HT-induced 
contractile responses of WT aortae (■  control, « = 11; □  lOOpM 
L-NAME, n = 7).
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (*p<0.05, **p<0.01, ***p<0.001: two-way-ANOVA, 
Bonferroni post-test).
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n Emax ( g r a m s )
C o n t r o l 11 1.62 ±0.09
+ l -NAME 7 1.66 ± 0.09
B
pECso Hill s l o p e
C o n t r o l 7.00 ± 0.07 1.15(0.96-134)
+ l -NAME 7.58 + 0.21** 0.82 (0.69-0.95)
Table 4-3. The effect of lOOpM L-NAME on 5-HT-induced 
contractile responses of WT aortae.
The ‘w’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECjo value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in pai'enthesis 
(**p<0.01: Student’s t-test).
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Figure 4-4. The effect of lOOjiM L-NAME on 5-HT-induced 
contractile responses of ais-KO aortae ( #  control, /?. = 12; O 
lOO i^M L-NAME, n = 9).
Responses are shown both in grams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. ('‘'*p<0.01, ***p<0.001: two-way-ANOV A, Bonferroni 
post-test).
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n Emax ( g r a m s )
C o n t r o l 12 1.51 ±0.13
+ l -NAME 9 1.80 + 0.17
B
pECgo Hill s l o p e
C o n t r o l 7.04 ± 0.10 0.98 (0.79-1.16)
+ l -NAME 7.48 + 0.13* 0.80 (0.65-1.04)
Table 4-4. The effect of lOOpM L-NAME on 5-HT-induced 
contractile responses of am-KO aortae.
The number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis 
(*p<0.05: Student’s t-test).
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Figure 4-5. The effect of 100}.iM L-NAME on 5-HT-induced 
contractile responses of a m -K O  aortae ( ♦  control, n = 12; O  
lOOpM L-NAME, n = 6).
Responses are shown both in gi'ams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (*p<0.05, **p<0.01: two-way-ANOVA, Bonferroni post­
test).
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n Emax ( g r a m s )
C o n t ro l 6 1.35 ± 0.09
+ l -NAME 7 1.40 ± 0.08
B
pECso Hill s l o p e
C o n t ro l 7.39 ± 0.07 1.04 (0.35-1.73)
+ l -NAME 7.62 ± 0.05* 1.02 (0.60-1.44)
Table 4-5. The effect of lOOpM L-NAME on 5-HT-induced 
contractile responses of ajo-KO aortae.
The ‘n’ number, maximum responses generated, expressed as 
gi'ams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis 
(*p<0.05: Student’s t-test).
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Figure 4-6. Comparison of the 5-HT-induced contractile responses 
of WT, aiB-KO & aiD-KO aortae (■  WT, n = 12; #  aie-KO, n = 
6; ♦  a i  d-K O , n =  6).
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (No statistical significance against WT: two-way- 
ANOVA, Bonferroni).
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n Emax ( g r a m s )
W T 11 1.62 ± 0 .0 8
oiib"KO 12 1.51 ± 0 .1 3
(%1D-K0 6 1.36 ± 0.09
B
pECso Hill s l o p e
W T 7.00  ± 0.07 1 .1 5 (0 .9 6 -7 .3 4 )
aiB"KO 7.04  ± 0 .10 0.97  (0.79-1.16)
(X1D-KO 7.39  ± 0 .07 1.04 (0.35-1.72)
Table 4-6. Comparison of the 5-HT-induced contractile responses 
of WT, aiB-KO & a  1 D-KO aortae.
The ‘77’ number, maximum responses generated, expressed as 
gi'ams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis (No 
statistical significance against WT: one-way-ANOVA, Bonfenoni 
post-test).
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Figure 4-7. Comparison of the 5-HT-induced contractile responses 
of WT, aiB-KO & am-KO aortae in the presence of lOOpM L- 
NAME (□  WT, n = 12; O am-KO, n = 6; O am-KO, n = 6).
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (No statistical significance against WT: two-way- 
ANOVA, Bonferroni).
195
A n Emax ( g r a m s )
W T 7 1.66 + 0 .09
9 1.80 ± 0 .17
0-1D "KO 7 1.40 ± 0 .08
B
pECso Hill s l o p e
W T 7 .58  + 0.21 0.82 (0.69-0.95)
a iB " K O 7.48  ± 0 .1 3 0 .80  (0.65-1.04)
(xid"KO 7 .62  + 0 .05 1.02 (0.60-1.44)
Table 4-7. Comparison of the 5-HT-induced contractile responses 
of WT, a iB “K O  & aiD -K O  aortae in the presence of lOOpM L- 
NAME.
The 'n' number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are sho'wn as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis (No 
statistical significance against WT: one-way-ANOVA, Bonferroni 
post-test).
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Figure 4-8. The effect of lOOpiM L-NAME on PE-induced 
contractile responses of WT aortae (■  control, n = 12; □  lOOpM 
L-NAME, n = 6).
Responses are shown both in gi'ams (A) and nonnalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. ( **p<0.01, ^^**p<0.001: two-way-ANOVA, Bonferroni 
post-test).
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n Emax ( g r a m s )
C o n t r o l 26 1.01 ±0.05
+ L-NAME 21 1.37 ±0.07***
B
pECso Hill s l o p e
C o n t r o l 6.66 ± 0.07 0.59 (0.44-0.74)
+ L-NAME 7.11 ± 0.11*** 0.55 {0.42-0.67)
Table 4-8. The effect of lOOpM L-NAME on PE-induced 
contractile responses of WT aortae.
The ‘n’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis 
(***p<0,001: Student’s t-test).
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Figure 4-9. The effect of lOOjiM L-NAME on PE-induced 
contractile responses of aiB-KO aortae (#  control, n = 12; O 
lOO^M L-NAME, n = 6).
Responses are shown both in gi*ains (A) and normalised, expressed 
as percentage of maximum response (B), Data points are the mean 
± S.E.M. (*p<0.05, *»p<0.01, ***p<0.001: two-way-ANOV A, 
Bonferroni post-test).
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n Emax ( g r a m s )
C o n t r o l 16 0.97 ± 0.09
+ L-NAME 9 1.73 ± 0.11***
B
pECso Hill s l o p e
C o n t r o l 6.73 ± 0.08 0.55 (0.45-0.66)
+ L-NAME 7.21 ± 0.11** 0.67 (0.51-1.82)
Table 4-9. The effect of lOOjiM L-NAME on PE-induced 
contractile responses of aiB-KO aortae.
The number, maximum responses generated, expressed as 
gi'ams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence inteiwals shown in parenthesis 
(**p<0.01, •^'’'*p<0.001: Student’s t-test).
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Figure 4-10. The effect of lOOpiM L-NAME on PE-induced 
contractile responses of aïo-KO aortae ( ♦  control, n ^  12; O  
lOOpM L-NAME, n = 6).
Responses are shown both in gi'ams (A) and normalised, expressed 
as percentage of maximum response (B), Data points are the mean 
± S.E.M. (*p<0.05: two-way-ANOVA, BonfeiToni post-test).
201
A
n Emax ( g r a m s )
C o n t r o l 6 0.64 ± 0.12
+ L-NAME 7 0.98 ± 0.09*
B
pECso Hill s l o p e
C o n t r o l 5.52 ± 0.13 0.85 {0.57-1.13)
+ L-NAME 5.29 ± 0.13 0.86 {0.57-1.17)
Table 4-10. The effect of lOOpM L-NAME on PE-induced 
contractile responses of aio-KO aortae.
The ‘n’ number, maximum responses generated, expressed as 
gi'ams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis 
(*p<0.05; Student’s t-test).
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Figure 4-11. Comparison of the PE-induced contractile responses 
of WT, aiB-KO & aiD-KO aortae (■  WT, n ~  12\ % aie-KO, n = 
6; ♦  aiD-KO, n = 6).
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (**p<0.01, *’^ *p<0.001 against WT; two-way-ANOV A, 
BonfeiToni).
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A
n Emax (grams)
WT 26 1.01 ±0.05
aiB"KO 16 0.97 + 0.09
aiD“KO 6 0.64 ±0.12*
B
pECso Hill slope
WT 6.66 ± 0.07 0.59 {0.44-0.74)
aiB“KO 6.73 ± 0.08 0.55 {0.45-0.66)
aiD"KO 5.52 ± 0.13*** 0.85 {0.57-1.13)
Table 4-11. Comparison o f the PE-induced contractile responses of 
WT, aiB-KO & aiD-KO aortae.
The TP number, maximum responses generated, expressed as 
gi’ams force (A) and agonist sensitivity, expressed as a pECso value 
(B) are shown as the mean ± S.E.M. Hill slopes (B) are shown as 
the mean with the 95% confidence intei*vals shown in parenthesis 
C^p<0.05, ***p<0.001: one-way-ANOV A, Bonferroni post-test).
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Figure 4-12. Comparison of the PE-induced contractile responses 
of WT, a iB -K O  & a ,D -K O  aortae in the presenee of lOOpM L- 
NAME (□  WT, u = 12; O a ,B -K O , «. = 6; O  a ,D -K O , n = 6).
Responses are shown both in giams (A) and normalised, expressed 
as percentage of maximum response (B). Data points are the mean 
± S.E.M. (*p<0.05, **p<0.01, ***p<0.001 against WT: two-way- 
ANOVA, Bonferroni).
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n Emax (grams)
WT 21 1.37 ±0.07
9 1.73 + 0.11*
dm-KO 7 0.98 ± 0.09*
B
pECso Hill slope
WT 7.11 ± 0.11 0.55 (0.42-0.67)
diB"KO 7.21 ± 0.11 0.67 (0.51-1.82)
diD"KO 5.29 ± 0.13*** 0.86 (0.57-1.17)
Table 4-12. Comparison of the PE-induced contractile responses of 
WT, aiB-KO & aiD-KO aortae in the presence of lOOpM L- 
NAME.
The number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pECso value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis 
(*p<0.05, p<0.001; one-way-ANOV A, Bonferroni post-test).
206
AB
2 .00-1 
»  1 7 5 -  
i  1 50 
3  1.254
(D« 1.004 
Q. 0.754 
I  0.50- 
0.25 
0 .00^
-10
0)E
23ïc0
1
-9 ■8 -7 -6
[PE] (log M)
-5 -4
125n
100 -
75-
50-
25-
0
■5 47 6-10 9 8
[PE] (log M)
Figure 4-13. The effect of 30nM rauwolscine on the PE-induced 
contractile responses of WT both in the control and lOOpM L- 
NAME treated rings (■  control, = 12; □  -f rauwolscine, n = 12; 
#  L-NAME control, ?/ -  6; O  L-NAME + rauwolscine, n -  6).
Responses are shown both in grams (A) and normalised, expressed 
as percentage of maximum response (B ) . Data points are the mean 
± S.E.M. (No No statistical significance against controls: two-way- 
ANOVA, BonfeiToni).
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Bn Emax (grams)
Normal Control + rauwol.
26
8
1.01 ±0.05 
1.06 + 0.09
+ L-NAME Control + rauwol.
21
7
pEC50
1.37 ± 0.07 
1.45 ± 0.09
Hill slop e
Normal Control + rauwol.
6.67 ± 0.07 
6.71 ± 0.08
0.59 {0.44-0.74) 
0.60 {0.43-0.77}
+ L-NAME Control + rauwol.
7.11 ± 0.11 
6.98 ± 0.19
0.54 {0.41-0.67) 
0.58 {0.47-0.69)
Table 4-13. The effect of 30nM rauwolscine on the PE-induced 
contractile responses of WT both In the control and lOOpM L- 
NAME treated rings.
The h?’ number, maximum responses generated, expressed as 
grams (A) and agonist sensitivity, expressed as a pEC^o value (B) 
are shown as the mean ± S.E.M. Hill slopes (B) are shown as the 
mean with the 95% confidence intervals shown in parenthesis (No 
statistical significance against either normal control or L-NAME 
treated control: Student’s t-test).
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Discussion- Chapter 4
NO production and l-NAME
Palmer et al. (1988) discovered that NO is liberated during the catalytic conversion of 
L-arginine into L-citrulline by the nitrogen oxide synthase (NOS) family of enzymes. 
Three subsets of NOS have been described (reviewed by Ricciardolo et ah, 2004): 
endothelial NOS (eNOS or NOS III), inducible NOS (iNOS or NOS II), and neuronal 
NOS (nNOS or NOS I).
iNOS is generally involved in inflammatory responses and is produced de novo as a 
result of pre-transcriptional regulation. nNOS and eNOS are constitutive forms of NOS 
(cNOS) who are dependent on the level of intracellular calcium ([Ca^^],). Thus, eNOS 
activity is controlled by Ca^ "^  /calmodulin (Busse & Mulch, 1990) and as a result, 
elevation in [C a2+ ]i leads to an increased eNOS activity and NO liberation.
As such, pharmacological agents to block NO production are commercially available. L- 
NAME is such an agent. It is a competitive eNOS blocker (Rees et a l, 1990) whose 
effects can be overcome by increasing L-arginine availability, but can be used in 
vascular preparations to inliibit NO production.
ACh-induced relaxations
The discovery of the role of endothelium-derived relaxing factor (EDRF) was originally 
due to apparent inconsistencies of the vascular effects of ACh in rabbit aorta (Furchgott 
& Zawadzki, 1980). They explained these inconsistencies by reporting the vasorelaxant 
properties of ACh were dependent on the presence of an intact endothelium. Palmer et 
at. (1987) identified EDRF as the simple molecule nitric oxide (NO).
Thus, it has become the noun in vascular preparations to test for endothelial function by 
testing for ACh-induced vasodilatation. The results show ACh relaxatory responses 
were significantly smaller in those vascular rings that had been treated with L-NAME. 
Thus, l-NAME has inliibited the production and therefore the effects of NO in the 
mouse aorta.
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However L-NAME only inliibits NO production. Endothelial cells (ECs) are able to 
release a host of other vasoactive agents such as the relaxants, prostaglandin and EDHF 
(endothelium-derived hyperpolarising factor), or vasoconstrictors, such as endothelin 
(Rang et a l 1999). The effect of these agents has not been taken into account as this 
was out-with the scope of the thesis.
To compliment the use o f L-NAME, attempts were made to denude the mouse aorta 
rings of their endothelium, hiitial attempts were often unsuccessful, resulting in variable 
responses. When the endothelium was successfully removed, no ACh-induced 
relaxation was obseiwed but the maximum contractile responses to KCl, PE and 5-HT 
were significantly reduced (data not shown), suggesting that, as well as endothelial 
removal, damage to the vascular smooth muscle (medial) layer was being done. No 
further attempts to denude the endothelium were made.
An interesting note was that although the aie-KO and WT aortae were not significantly 
different the aio-KO had a significantly larger relaxation. However this difference 
could be attributed to experimental design. The relaxatory response to 3pM ACh was 
tested on tone raised by addition of lOgM PE in all strains. Since the am-RO was 
significantly less sensitive than the WT to PE the tone was significantly less, and the 
effect of 3]liM ACh was notably gieater.
K C l responses
In the mouse aorta, KCl responses were significantly increased in the presence of L- 
NAME, confirming that in control vessels, KCl exposure was either resulting in NO 
liberation or there was constitutive release of NO. Either way, the observed contractile 
response of the control rings was the summation of simultaneous contractile and 
relaxatory responses. The contractile response was due to VSMC depolarisation and the 
relaxant response due to NO liberation.
The effect of L-NAME on the KCl responses was probably due to KCl activity at ECs. 
125mM KCl PSS is a depolarising solution, hence, when used in a vessel with intact 
endothelium, ECs are depolarised along with VSMCs. The depolarisation of ECs results 
in an increased [Ca^’^ Ji and henee, an increase in the production and release of NO.
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Therefore, the KCl response of control vessels was not a true representation of the 
maximal contractile response of the vessel as the response was blunted by NO. Instead, 
the KCl-induced contraction in the presence of L-NAME is more representative of the 
absolute maximum contractile response of the mouse aorta, although the release of other 
substance from ECs has not been taken into account.
Furthermore, the use of KCl results in the depolarisation of cells within the adventitia, 
which is now becoming increasingly implicated in vaseular function (reviewed by Faber 
et a l, 2001) and has not been considered.
In general, KCl contractile responses were significantly increased by l-NAME due to 
the loss of NO liberation from ECs.
Serotonergic responses and l-NAME
5-HT is a potent vasoconstrictor in the mouse thoracic aorta (Russell & Watts, 2000) 
mediating its contractile response through 5-HTiA receptors (McKune & Watts, 2001). 
l-NAME treatment in the mouse aorta did not affect the maximum responses to 5-HT 
but resulted in an increased sensitivity in WT, aie-KG and aio-KG aortae.
Cocks & Angus (1983) demonstrated, in dog coronary arteries, that both NE and 5-HT 
were more potent and efficacious vasoconstrictors in the absence of endothelium. 
Maclean et a l (1994) reported that 5-HT responses of bovine pulmonary arteries were 
enhanced by endothelium removal and by L-NAME treatment confirming 5-HT also has 
NG-mediated endothelium-dependent vasorelaxant properties. Generally, the 
vasorelaxant response of 5-HT are associated with the activation of 5-HTi-Hke receptor 
subtypes (reviewed by Saxena & Villalon, 1991).
In the mouse aorta no evidence is yet available of the involvement of 5-HTi_ijke 
receptors in vasoconstriction or dilation. However, the data indicates that there is NG- 
dependent attenuation of the serotonergic response. However, this cannot confidently be 
attributed to the activation of 5-HT receptor on the endothelium.
The presence and role of myoendothelial gap junetions is a novel and growing area of 
study (reviewed by Dhein, 2004a; Dhein & Jongsma, 2004; Griffith et a l, 2004; 
Griffith, 2004). Gap junctions allow the transmission of both chemical and electrical
211
signais between cells. Thus, alterations in the membrane potential or [Ca^’^ Ji of VSMCs 
can affect ECs and vice versa. As a result, the effect of 5-HT on VSMCs may have been 
transmitted tlu'ough these gap junctions on VSMCs.
Furtheimore, eNOS is a constitutive enzyme that is [Ca^^jj-dependent, therefore, there 
may have been constitutive basal release of NO, which would attenuate the 5-HT 
response. If NO was constitutively released, the attenuation would have been constant 
i.e. concentration independent. Careful analysis of the curve expressing the 5-HT 
responses in grams (Figures 4-3[A], 4-4[A] and 4-5[A] for WT, aiB-KO and aio-KO 
respectively), reveals that the effect of L-NAME seems to have been constant over the 
entire curve except towards the maximum. At this point the cuiwes tended to converge 
and this may have been because the maximal 5-FIT response is the tissue maximal 
response and L-NAME treatment could not increase it further. Therefore it appears there 
may have been constitutive basal release of NO, attenuating the control 5-HT responses.
However, the sensitivity increase of the serotonergic response was present in all tliree 
strains of mice studied (WT, aiB-KO and am-KO). Thus, the effect of L-NAME, on the 
serotonergic response was ai-AR subtype independent. Furtheimore the comparison of 
WT, aiB-KO and ajo-KO 5-HT responses both in the absence (Figure 4.6; Table 4.6) 
and the presence (Figure 4.7; Table 4.7) of L-NAME shows that the serotonergic 
responses are not significantly different between mouse strains.
In the previous chapter (Chapter 3) the involvement of aio-ARs in the 5-HT-induced 
response was discussed. The effect of 5-HT at aio-ARs was amplified by a synergistic 
interaction with 5-HT2a receptors on VSMCs. Further on in this discussion, the 
involvement of aio-ARs in vasorelaxant responses is examined. However, the effect of 
5-HT at aiD-ARs resulting in vasodilatation can by discounted as no evidence for 5- 
HT2a receptors causing vasodilatation is available and, thus, it is unlikely there was a 
synergistic interaction (discussed in Chapter 3) causing NO dependent vasodilatation.
ai-ARs and l-NAME
l-NAME treatment resulted in an increased maximal response for PE induced 
contractions in all tluee strains studied. However, it resulted in increased PE sensitivity 
in only WT and aiB-KO aortae. In am-KO aortae, the response in the presence of L-
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NAME was not significantly altered. The difference is therefore due to the lack of 
functional aio-ARs in the aio-KO aorta.
In all strains, the effect of L-NAME on the response appeared to be PE-concentration 
dependent (Figures 4-8[A], 4-9[A] & 4-10[A] for WT, am-KO and aio-KO 
respectively), i.e. the higher the PE concentration, the greater the increase in response in 
the presence of L-NAME, indicating a vasorelaxant response of PE may be involved. 
This evidence combined with the lack of sensitivity increase in the aio-KO appeared to 
point to a role for aio-ARs in vasodilatation.
aiD-ARs and the endothelium
The role of ai-ARs in endothelium-dependent relaxant responses has been shown in 
rabbit bronchial arteries (Zschauer et a l, 1997) and rat muscular arterioles (Tuttle & 
Falcone, 2001). Recently, Fillipi et a l (2001) demonstrated that the aio-ARs are 
involved in endothelium-dependent vasodilatation in the rat mesenterie vascular bed. 
They also demonstrated aio-ARs, on bovine coronary venular postcapillary endothelial 
cells, could raise fPi levels (an IP3 metabolite) and, hence, NOS activity.
Thus, the presence of aio-ARs on the endothelium in the mouse aorta could explain 
why the aio-KO did not exhibit an increased sensitivity to PE in the presence of L- 
NAME. The findings in the mouse aorta, demonstrate that there is a fundamental 
difference in the effect of L-NAME in aio-KO mice compared with WT (and aie-KG), 
and this was due to the lack of functional aio-AR with the ability to cause NO- 
dependent vasodilatation as well as vasoconstriction.
PE responses ofWT, ais-KO and aw-KO compared: The effect o f  l-NAME
Comparison of the PE responses of aie-KG and aio-KG aortae with the WT aortae 
(Figure 4.11; Table 4.11) reveals that the aio-KG and WT were not significantly 
different, but PE was less sensitive and had a lower maximum response in the a^-K G .
However, in the presence of L-NAME (Figure 4.12; Table 4.12) the differences between 
the strains appear to be accentuated. The aie-KG has a significantly larger maximum 
response although no significant difference in sensitivity. The aio-KG has a
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significantly lower maximum response similar to the difference in WT and aio-KO in 
the absence of L-NAME. However, the sensitivity was 66-fold less sensitive in the 
presence of L-NAME compared with only 14-fold less sensitive in the absence of L- 
NAME.
The difference between WT and aiB-KO responses uncovered by L-NAME could be 
due to compensatory mechanisms. McBride et al. (2003) reported a BMY 7378- 
sensitive (aiD-AR selective antagonist: Sauusy et a l, 1994), 5-MU-resistant (aiA-AR 
selective antagonist: Gross et a l, 1988; Schwinn et a l, 1995) contractile component in 
aiB-KO mesenteric arteries, that was not observed in the WT. The authors concluded 
that there was an apparent up-regulation of am-ARs as a result of the loss of aiB-ARs. 
FurtheiTnore, in some vessels from the aiB-KO, the response to PE was significantly 
larger than the WT (Daly et a l, 2002).
Thus, a systemic up-regulation of aio-ARs not only in VSMCs but also in ECs could 
explain the uncovered difference by L-NAME. It may be that in the aie-KO, the 
contraction to PE is actually larger than in the WT but this contraction is attenuated by a 
greater degree, due to an increased role for aio-AR mediated NO release from 
endothelial cells.
Furtheimore, the difference between WT and am-KO is enlianced in the presence of L- 
NAME, not due to an alteration of the PE response in aio-KG, but due to the increased 
sensitivity of WT aortae to PE. Thus the am-KG is involved with NG-dependent 
vasodilatation in the mouse aorta. This is consistent with the findings reported by Fillipi 
et a l (2001), but further studies involving removal of the endothelium of the mouse 
aorta are required to confirm that the aio-AR relaxant effect is endothelium-dependent.
Involvement o f  Œ2-ARs in the PE response
Notably, in the am-KG, L-NAME treatment, although not affecting sensitivity, resulted 
in an increased maximum response to PE. az-ARs involvement with relaxatory response 
was originally described by Cocks & Aigus (1983) in porcine and dog coronary 
arteries. Vanlioutte & Miller (1989) performed a study in selected arteries from dog rat 
and pig and associated endothelium dependent relaxations with NG release. Thus, the
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increased maxima of PE responses in aio-KO aorta as a result o f L-NAME treatment 
may have been due to the involvement of endothelial az-ARs. Therefore, the sensitivity 
o f the PE responses to rauwolscine (az-antagonist: Perry & U ’Prichard, 1981) was 
tested in the WT to determine the involvement of az-ARs in the PE response.
No significant effect of rauwolscine in the mouse aortae was observed either in the 
absence or presence of L-NAME. The experiments were performed in both the presence 
and absence of L-NAME in order to determine the involvement of az-ARs at both 
endothelial sites and VSMCs. It was hypothesised that az-ARs may be involved in both 
vasoconstriction and vasodilatation, thus if  no effect of rauwolscine was observed in 
control tissue, the effect of rauwolscine in L-NAME treated tissues would be to decrease 
sensitivity or efficacy of PE.
We did not obseiwe any effect of rauwolscine, therefore there was no role for az-ARs in 
mediating the PE response. However, these experiments were carried out in the WT 
thus the involvement o f am-ARs made the analysis more difficult as am-AR-mediated 
NO-dependent vasodilatation had to be taken into account.
Furthermore, the CCRC to PE in the WT was terminated at 30pM, whereas, in the am - 
KO the effect of L-NAME was only observed at PE concentrations of 30pM, lOOpM 
and 300pM. Therefore the effect of L-NAME observed in the am-KO may have been 
due to az-AR activation but been missed in the study conducted in the WT, by 
prematurely ending the construction of the PE CCRC.
Thus the involvement of az-AR activation resulting in NO release camrot be eompletely 
ruled out in the am-KO. Aiother explanation may be the constitutive release of NO 
from the endothelial cells since eNOS is a constitutive enzyme. Furthermore, bearing in 
mind, eNOS is Ca^’^ -dependent for its activity, the role of ionic movement or electronic 
transmission via myo endothelial gap junctions cannot be mled out.
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Conclusions- Chapter 4
Conclusions
L-NAME treatment revealed that KCl, 5-HT and PE responses in the mouse aorta are 
attenuated by NO release. 5-HT and PE responses were significantly more sensitive in 
the presence of L-NAME with the exception of the PE response of am-KO aortae which 
was not significantly more sensitive.
Thus the am-AR is involved in both vasoconstriction and NO-dependent vasodilatation 
in the WT mouse aorta.
However, in am-KO there remained an NO-dependent attenuation of the PE response 
that may have been one of the other ai-ARs, az-ARs, basal NO release, or the result of 
ionic or electrical movement via gap junctions.
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General Conclusions
Conclusions
The evidence presented within this thesis has demonstrated the application of a 
pharmacological approach aided with the use of functional KOs of specific receptors.
In Chapter 1 the results showed that no significant age-related alterations in vasoactive 
responses occurred in the mouse aorta. It has also now been shown that the ai-AR 
knockout mice used in the study maintained their contractile mechanisms, the 
phenotypic differences were receptor specific and maintained with age.
Furthermore the results demonstrated that the lack of functional am-ARs in the mouse 
aorta, did not adversely affect adrenergic responses. Contrastingly, the m-KO had 
significantly reduced sensitivity to PE, at both age points studied confiiming the am - 
AR is the major adrenergic vasoconstrictor in the mouse aorta.
Chapter two provided further evidence confirming the am-AR is the major adrenergie 
vasoconstrictor in WT aortae. In fact, am-AR appears to be the sole ai-AR involved in 
functional contractile responses, hr the absence of am-ARs the response was due to 
am-ARs and in the absence of both am  and am-ARs no adrenergic response was 
observed, suggesting the am-AR has a minor vasoconstrictor role. However in the WT 
no functional contractile role for am-AR could be obseiwed thus the am-AR is the sole 
contractile AR in the mouse aorta although it appears the am-AR is held in reserve.
The involvement of the am-AR in synergy with the serotonergic response of the mouse 
aorta was then reported in Chapter 3. The co-activation of the am-AR along with the 
serotonergic vasoconstrictor, the 5-HTza receptor resulted in a potentiated response 
which was due to mutual effect amplification.
A minor role for am-ARs in the serotonergic response was also reported in Chapter 3. 
The activity of 5 -HT at both 5-HTza and am-ARs, two receptors which potentiate one 
another’s responses, somewhat explained the relatively high potency of 5-HT in the 
mouse aorta.
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However, the lack of functional am-ARs in the am-KO did not significantly affect the 
serotonergic response, suggesting compensation by serotonergic receptors, i.e. S-HTza 
receptors.
Finally in Chapter 4 the role of am-AR activation in NO release was reported as the 
effect of L-NAME on am-KO aortae was significantly different from the effect of L- 
NAME in am-KO aortae. The results confirmed that the am-AR is involved in the 
release of NO and hence vasodilatation of the mouse aorta.
Overall conclusion
The combined results indicate that the am-AR is the sole adrenergic vasoconstrictor in 
the mouse aorta. Not only is the am-AR responsible for mediating adrenergic responses 
it can also be activated by 5-HT and can synergistically interact with the serotonergic 
vasoconstrictor system. Furthermore, the am-AR is not just a vasoconstrictor as it has a 
role in NO dependent vasodilatation. Thus the am-AR. has a complex and varied role in 
modulating the tone of WT mouse aorta.
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